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1
Introduction and scope of the thesis
8From “one size Fits all” to “patient customized” treatment
Anticancer drug development attempts to translate understanding gained from basic research into 
improved clinical practice through cancer drug trials [1]. These trials aim to test new ways of cancer 
treatment. Traditionally, the specific goal of early therapeutic trials is to define the safety, tolerability 
and pharmacological properties (phase I) as well as antitumor efficacy of novel agents (phase II). Later 
stage therapeutic trials attempt to prove that a treatment imparts clinical benefit, usually compared to 
standard treatment (phase III and IV). The latter generally include hundreds to thousands of patients, 
can last several years and be very expensive; the often quoted price to generate one licensed drug is 
US$ 1 billion [2, 3]. Frustratingly, the majority of clinical cancer trials have little impact on either pa-
tient benefit or understanding of cancer biology, raising major concerns about the current anticancer 
drug development process [2, 3]. The overall concern is that it increases the pressure on the pharma-
ceutical industry to generate anticancer drugs with broad applicability in cancer patients and therefore 
large fiscal returns [4]. 
This ‘one size fits all’ approach may not be the best or most efficient way to develop anticancer drugs [2], 
as is evident from the high proportion of negative large randomized trials for common cancers as well 
as the very limited benefits achieved in terms of disease outcome for the small proportion of positive 
trials that lead to drug approval. These trials impart the risk that an active drug for a small subgroup 
is being masked by inactivity in the large population, resulting in disapproval of the drug for all. If the 
trial turns out positive, this will only define the best treatment for the average patient whereas it may 
not be the best treatment on the individual level.
The degree of benefit from a new treatment should preferably be recognized in early phase trials, 
i.e. before large randomized trials are pursued, resulting in a decrease in the proportion of large, late 
stage, negative trials. To do this, a paradigm shift in the process of drug development and response 
evaluation is needed, facilitated by sophisticated markers of treatment benefit, so-called biomarkers. 
Biomarker Facilitated drug evaluation
The discovery of increasingly numbers of novel molecularly targeted anticancer drugs and the many 
possible combinations of these agents necessitates “hypothesis-testing drug evaluation” in selected 
patients. This process starts with in vitro studies identifying a target presumed to be key to tumor sur-
vival. Subsequently, multiple drugs are tested in in vitro and animal models and those that modulate 
the target in a way that results in cytotoxic or cytostatic effects are selected. During this preclinical 
work, hypotheses can be generated on how and to what degree the drug alters the target and down-
stream pathways by using static and dynamic markers that reflect these changes (e.g. phosphorylation 
of proteins, apoptosis, proliferation, perfusion, metabolism). The dose range and schedule that results 
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in optimal target modulation is selected for clinical studies.  
Next, in vivo validation is warranted. Although early clinical trials should still continue to focus on drug 
safety and tolerability in combination with pharmacokinetics (“what the body does to the drug”), 
pharmacodynamics (“what the drug does to the body/tumor”) should be more emphasized before 
large phase III trials are designed and executed. Pharmacodynamics can identify which patients show 
the drug-induced tumor changes that were observed in the preclinical models (hypothesis-testing), 
thereby offering the opportunity to link tumor characteristics with the degree of treatment benefit. 
Eligibility criteria for subsequent phase III trials can then be adjusted to include only those patients 
that are expected to benefit from the treatment.
Because drugs generally trigger a cascade of tumor alterations, the direct target itself (e.g. a tumor 
growth factor) or more downstream effects (e.g. proliferation or cell viability) are available for phar-
macodynamic measurements. Downstream effects are often the result of several upstream effects 
and thus less specific, but have the advantage that unexpected drug effects can be monitored and that 
the net result of interactions between several upstream molecular pathways can be evaluated. 
Biomarker types
Following the definition adopted by the Biomarkers Definitions Workgroup, a biomarker is being de-
fined as “a characteristic that indicates normal biological processes, pathogenic processes, or phar-
macologic responses to therapeutic intervention” [5]. Mechanistic understanding of tumor and drug 
biology can be obtained by biomarkers and their use can speed up drug development resulting in more 
patients being treated with the optimal drug regimen. Each step of drug development requires specific 
biomarker classes. Of note, these categories are not mutually exclusive. 
A pharmacodynamic (PD) biomarker is a dynamic assessment that shows that a biological process has 
occurred or altered in a patient after treatment. 
 • Examples are a change in protein expression or phosphorylation or a decrease in tumor 
 metabolic activity, perfusion or size. 
 • PD biomarkers can be used to confirm the proof of mechanism by identifying the intended 
 change in tumor biology, also called “target modulation”. 
 • PD biomarkers can guide selections of drug dose and regimen for testing in phase   
 II/III studies (i.e. which regimen results in optimal target modulation).
 • In contrast to predictive and prognostic biomarkers, PD biomarkers do not have   
 to relate with patient or treatment outcome. 
A predictive biomarker is a baseline characteristic that categorizes patients by their likelihood to re-
spond to a therapeutic intervention.
 • Examples are genetic alterations that sensitize patients to certain drugs.
 • They may predict a favorable or unfavorable response (i.e. an adverse event). 
A prognostic biomarker is a baseline patient or disease characteristic that informs about the natural 
history of the disorder in that particular patient in the absence of a therapeutic intervention.
Surrogate endpoint biomarkers are a subset of pharmacodynamic biomarkers that relate to patient or 
treatment outcome and are used as a substitute for a clinical efficacy endpoint. 
 • Examples are measurements of tumor size, metabolic activity, cell proliferation, or perfusion. 
 • They are expected to predict clinical benefit or harm (or lack of benefit or harm). 
   
Biomarker development
Like drugs, biomarkers require several phases of development before they can be used for clinical deci-
sion making. This includes technical and methodological validation and clinical qualification. Although 
these steps are uniform for each biomarker (e.g. genomic, immunohistochemical [IHC], protein level, 
receptor expression, or imaging), we will focus on quantitative imaging biomarkers in this thesis.
Ideally, the development of quantitative imaging biomarkers is hypothesis driven. This can be illus-
trated by the use of radiolabeled water (H2
15O), a PET tracer. Drugs have been designed to target tumor 
vasculature, thereby reducing tumor perfusion with the aim to starve the tumor resulting in growth 
arrest. 
H2
15O PET non-invasively measures tumor perfusion and in theory measuring perfusion with H2
15O 
PET allows monitoring drug effects on tumor vasculature. This pharmacodynamic measurement might 
predict patient benefit, qualifying it as a surrogate endpoint biomarker.
After discovery, the biomarker has to be standardized to obtain identical results in different labora-
tories and clinics. This includes standardization of acquisition, reconstruction, data processing and 
data analytical protocols. After standardization, repeatability and reproducibility must be studied to 
discriminate noise from true biological change. Validation is the often used term to describe this pro-
cess. A critical distinction should be made between analytical validation and clinical qualification. Al-
though validation, qualification and evaluation have been used interchangeably in the literature, the 
distinction should be made to properly describe the particular phase the biomarker is transitioning 
through. 
10
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Following analytical validation, a stepwise process of qualification and verification should be followed 
[6-8]. Qualification describes the clinical evaluation process of a biomarker. It ensures that the bio-
marker is used in the correct context and that it reliably performs the job it is intended or expected to 
[9]. That context may be selecting or deselecting people for a clinical trial, monitoring drug-induced 
toxicity, or other purposes. The amount of evidence needed to qualify a biomarker for a given purpose 
is related to the consequences of using the result to make decisions, such as to pursue the develop-
ment of a drug or whether to withhold a drug from individuals in a clinical trial. The use of poorly 
validated and qualified biomarkers will yield misleading results and can lead to subsequent disregard 
of a potentially useful biomarker or an inappropriate decision being made about the drug and patient 
care. Thus the biomarker should be “fit-for-purpose”.
DRug anD bIomaRkeR Co-Development 
When known and measurable using validated and qualified biomarkers, molecular characteristics can 
guide patient stratification in clinical trials. However, most commonly the molecular characteristics 
that drive a patient’s response to treatment are not fully known and might only be discovered dur-
ing the clinical development of drugs. Also, in case the mechanism is known, validated and qualified 
biomarkers are rarely available at the start of the trial. This necessitates co-development trials that 
combine biomarker qualification and drug development [10].     
role                                                                                                    example                                                                                                 
Integral
= used for clinical decisions.
Prospectively defined populations
(selection or stratification factor).
Integrated
= intended to validate hypotheses for                 
establishing further trials, not used for              
clinical decisions in the current trial. 
Pharmacodynamic markers in phase I trials; 
prespecified predictive biomarker analysis in 
phase II or phase III study, not used for eligibility 
criteria or patient management.
Exploratory
Retrospective hypothesis generating biomarker 
identification; pilot studies.
table 1. Biomarker role in clinical trials, depending on the level of qualification.
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Depending on the available evidence of the predictive value of the biomarker under investigation, 
combination trials can be designed. The role of a biomarker in clinical trials can be integral, integrated 
or exploratory (Table 1). An integral role is only justified when the biomarker is already qualified as 
such. Patients that are sensitive to the drug are identified upfront or early after treatment initiation by 
the biomarker and the information is used for stratification, thereby directly influencing trial design. 
Integrated use tests hypotheses on drug action that were raised in preclinical or phase I/II studies. 
This information can be used to initiate subsequent trials with integral use of the biomarker, but the 
biomarker is not used for clinical decision making in the current trial. Exploratory use can generate 
hypotheses on drug effects and how to evaluate these. Biomarkers with an exploratory role should be 
implemented as early as possible during drug development. If explored in preclinical and phase I stud-
ies, they can be validated and qualified simultaneously with drug development in subsequent phase 
II and phase III studies.
rationale For the incorporation oF Functional imaging Biomarkers in this thesis
Response monitoring in advanced non-small-cell lung cancer (NSCLC) is complex. Tumor shrinkage 
usually does not occur until several cycles of chemotherapy and is difficult to evaluate because of in-
ter- and intra-observer variation [11]. With targeted agents, size change can be absent despite survival 
benefit [12-15]. Also, the association between anatomical response and survival is weak at best [16] 
(Figure 1). Early use of the “response evaluation criteria in solid tumors” (RECIST) as surrogate end-
point biomarker might underestimate treatment efficacy because size change is a slow process and 
stable disease reflects a heterogeneous group of patients with both good and bad outcome. There-
fore, alternative response criteria are warranted. 
In this thesis we evaluated combined treatment with bevacizumab (B), an antibody against the vas-
cular endothelial growth factor (VEGF), and erlotinib (E), a tyrosine kinase inhibitor (TKI) against the 
epidermal growth factor receptor (EGFR), aiming to target tumor vasculature and growth signaling 
pathways. Their supposed effects are a decrease in vascular permeability and vascular density, and an 
increase in apoptosis [17, 18]. Positron emission tomography (PET) and dynamic contrast enhanced 
magnetic resonance imaging (DCE-MRI) derived parameters were selected to evaluate target modula-
tion to BE treatment and to qualify the parameters as surrogate endpoint biomarkers.   
Because the antivascular activity of combined EGFR and VEGF treatment might result in a decrease in tumor 
perfusion, H2
15O PET and DCE-MRI were selected as pharmacodynamic biomarkers. They were used side-by-
side because their signals reflect different aspects of tumor vasculature. In contrast to H2
15O, gadolinium-based 
contrast agents are not freely diffusible, but partially leak through the vessel wall into the interstitial space and 
leak more through pathological tumor vessels as a result of greater permeability. Therefore, DCE-MRI derived 
12
    Chapter
                   1Introduction and scope of the thesis
parameters do not selectively reflect tumor perfusion, but rather a combination of perfusion, vessel perme-
ability and vascular surface area. DCE-MRI signal approaches true tumor perfusion in case permeability and 
vessel surface area are not limiting factors for tracer kinetics. However, if so, the signal reflects a combination 
of perfusion, vessel surface area and permeability.
18F-FDG PET was selected to monitor the EGFR signaling pathway. Akt is a downstream protein kinase of the 
EGFR signaling pathway and plays a central role in transducing oncogenic signals from EGFR activation to meta-
bolic as well as cell survival and proliferative effects. It is activated by phosphatidylinositol 3-kinase (PI3 kinase), 
negatively regulated by the dual-specificity phosphatase and tensin homologue (PTEN), and phosphorylates 
mammalian target of rapamycin (mTOR). PI3 kinase–dependent Akt stimulation regulates glucose metabolism 
in response to growth factor stimuli [19]. Therefore, Akt seems to be a key mediator of the establishment and 
maintenance of glycolysis in cancer cells. The hypoxia-inducible factor-1α (HIF-1α) is a downstream mediator 
of Akt that contributes to the regulation of glucose transport and metabolism [20, 21]. As depicted in Figure 2, 
emerging data suggest that targeted as well as classical chemotherapeutic agents directly or indirectly affect 
these signaling pathways, glucose transporters, and metabolic enzymes that control glycolysis. Therefore, glu-
13
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Figure 1. The relation between tumor size change and and the difference in survival for metastatic lung 
cancer. Although the surrogate endpoint is a significant predictor of survival, much less than half the 
variability in the survival difference was explained by the variability in the difference in tumor size [40].
10
5
0
-5
0           5         10         15         20        25         30        35         40        45
Response difference (%)
OS= -0.048+0.090RR
Su
rv
iv
al
 d
iff
er
en
ce
 (m
on
th
)
Lung cancer           R2=0.16; p<0.0001
cose metabolism measured with 18F-FDG PET seems to be an attractive pharmacodynamic biomarker to study 
EGFR targeted therapy. Because activation of EGFR results in accelerated tumor proliferation, the PET prolif-
eration tracer 18F-FLT is another biomarker of interest. Inhibition of the EGFR axis as well as tumor starvation 
(by impairment of perfusion) might result in a decrease in tumor proliferation, measurable with 18F-FLT PET. 
imaging Biomarkers used in this thesis
Ideal biomarkers are accurate, reproducible, minimally invasive, inexpensive, entail negligible or no risk 
when measured and have a minimal drop-out rate. These requirements can be met by non-invasive 
methods like PET and DCE-MRI [22]. The techniques can be repeated several times during treatment 
without interfering with tumor biology and allow to study inter- and intra-lesional heterogeneity. They 
in-vivo measure tumor pharmacokinetics (by labeling drugs) and dynamics (by monitoring biological 
change). A main advantage to alternatives like tumor biopsy is that functional imaging parameters 
reflect tumor biology as a complex of biological processes in both tumor and supporting cells that 
14
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Figure 2. Molecular targets of cytotoxic and cytostatic drugs in the pathways controlling glucose me-
tabolism [42].
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interact with each other. This is an important advantage because clinical failure of drugs that show 
target modulation and antitumor activity in preclinical models are not an exception [4]. Therefore in-
vitro and xenograft results cannot be extrapolated to the clinical setting without in-vivo validation of 
the results (hypothesis-testing drug evaluation).  
Two main categories of imaging biomarkers are distinguished; anatomical and functional. Anatomical 
imaging biomarkers allow uni-, bi-, or three-dimensional tumor size measurements using static tech-
niques. Functional ones combine anatomical with biological information and allow in-vivo dynamic 
studies of tumor characteristics without interfering with it.    
anatomical Imaging biomarkers
Computed Tomography (CT)
Response assessment with CT is based on the response criteria in solid tumors (RECIST). This method 
uses unidimensional measurements of the sum of the longest diameter of selected target lesions. The 
criteria were first published in 2000 by an international collaboration including the European Organi-
sation for Research and Treatment of Cancer, the National Cancer Institute of the United States, and 
the National Cancer Institute of Canada Clinical Trials Group (RECIST v 1.0) [23] and updated in 2009 
(RECIST v 1.1) [24]. Current RECIST guidelines limit size measurements to a maximum of two lesions 
per organ and five in total. Lesions should have a minimal diameter of 1 cm. Response is categorized as 
shown in Table 2. RECIST v 1.1 also includes a functional imaging biomarker to optimize the detection 
of tumor progression; any new lesion present on 18F-FDG PET that is compatible with tumor metastasis 
is regarded as progressive disease.
15
response                                           Definition
Partial response (PR) > 30% reduction in the sum of tumor diameter
Complete response (CR) Total tumor disappearance
Stable disease (SD) 
< 30% decrease and < 20% increase in the sum of tumor 
diameter
Progressive disease (PD)
> 20% increase in the sum of tumor diameter with a minimum 
of 5 mm absolute increase or appearance of any new lesion
table 2. Categories of response, according to RECIST v 1.1.
Functional Imaging biomarkers
Positron Emission Tomography (PET)
PET allows non-invasive measurements of the 3-dimensional distribution of a positron labelled com-
pound within a living subject. Positron emitting radionuclides can be used to synthesize radiophar-
maceuticals that act as substrates for endogenous pathways, thereby enabling the in-vivo tracking of 
biological processes. In the body, the radiopharmaceuticals emit positrons that undergo annihilation 
with nearby electrons, resulting in the release of two photons. These so-called annihilation photons 
leave at an angle of 180 degrees and are detected by coincidence imaging as they strike scintillation 
crystals. The resulting data can be reconstructed to reveal the distribution of the radiotracer within 
the subject. Currently, many positron emitters with different characteristics are available, including 18F, 
15O, 11C, 13N, 124I, 68Ga and 86Y, which can be used to label virtually every chemical compound. With PET, 
visualization of biological processes like tumor metabolism, cellular proliferation, specific cell surface 
receptors, angiogenesis, and tumor hypoxia is possible. 
18F-Fdg
Today, the most widely used PET tracer is 18F-fluorodeoxyglucose (18F-FDG), a glucose analogue that allows 
the quantification of glucose metabolism. Tumor cells exhibit high rates of glycolysis to fulfill their increased 
energy demand. One of the key alterations associated with the high glycolytic rate of cancer cells is in-
creased cellular glucose uptake. The uptake of 18F-FDG is similarly accelerated in tumor cells [25-28].
The most accurate method to analyze tracer kinetics is to quantitatively assess the 18F-FDG uptake rate 
over time. The metabolic rate for glucose is calculated from the time course of radiotracer concentra-
tion in tissue and arterial blood. Dynamic scanning following injection as well as an arterial input func-
tion (AIF) are required. For thoracic studies, the latter can be derived from vascular structures within 
the field of view.
Other methods of kinetic analysis include visual and semi-quantitative assessment of 18F-FDG metabo-
lism. These approaches assume that 18F-FDG uptake is virtually complete and that the dephosphory-
lation rate is negligible. The standardized uptake value (SUV) is a semi-quantitative index of tumor 
uptake normalized to the injected dose and a measure of the total volume of distribution, e.g. body 
weight. 
The SUV is a function of patient size, time interval between injection and scanning (usually 60 min), 
plasma glucose level and image reconstruction settings [29]. SUVs strongly correlate with the meta-
bolic rate of 18F-FDG. Because it does not require dynamic data acquisition and arterial blood sam-
pling, the SUV has frequently been used as a measure of 18F-FDG uptake to assess differences between 
scans. The main disadvantage of SUV, however, is the inherent assumption that plasma clearance is 
16
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always the same. If plasma clearance of 18F-FDG changes as a result of therapy (i.e. due to differences 
in uptake or clearance in other tissues), the relationship between uptake at a certain time and injected 
dose will also change. This cannot be accounted for in the SUV calculation and, consequently, compari-
son of pre- and post-therapy scans might be misleading. This can be tested by validating SUV against 
the metabolic rate in a subset of patients [30].  
Guidelines for 18F-FDG PET response assessment were first published in 1999 by the European Orga-
nization for Research and Treatment of Cancer PET Study Group and recently updated by the group of 
Wahl et al who proposed a new concept of PET response evaluation called “PERCIST” (PET Response 
Criteria in Solid Tumors) that uses a combination of absolute and relative change to detect treatment 
effects [31]. This concept was used as a template to validate and qualify 18F-FDG PET as imaging bio-
marker in this thesis.    
18F-Flt
18F-fluorothymidine (18F-FLT) is a PET tracer reflecting tissue proliferation. FLT is a substrate for thymi-
dine kinase 1 (TK1), which is a key enzyme in the salvage pathway of thymidine DNA synthesis. Several 
studies have shown good correlation between 18F-FLT uptake and other markers of cellular prolifera-
tion, including proliferating cell nuclear antigen, flow cytometry and Ki-67 nuclear staining [32-35]. 
Kinetics are analyzed the same way as for 18F-FDG. Guidelines on 18F-FLT PET response assessment are 
not yet published.
h
2
15o 
Radiolabeled water (H2
15O) allows the quantification of tumor perfusion. The tracer is freely diffusible 
and regional uptake therefore reflects tissue perfusion. One of the hallmarks of cancer is neoangio-
genesis, the sprout of new blood vessels that help to sustain expanding neoplastic growth. Tissue per-
fusion is thought to reflect tumor vascular status and H2
15O PET therefore offers an interesting method 
for the non-invasive evaluation of drugs that target tumor vasculature.  
Kinetic modeling is based on the Fick principle [36] and analyzed according to the Kety-Schmidt model 
[37]. In a dynamic scan, dC
tissue
(t)/dt (the change in tissue concentration of H2
15O at a certain time 
point) is equal to K1 (the plasma to tissue transport rate constant) times Cplasma(t) (the tracer concentra-
tion in plasma at that point in time) minus k2 (the tissue to plasma rate constant) times Ctissue (t) (the 
tracer concentration in tissue at that point in time): 
17
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dCtissue (t)
dt = FCblood (t) "
F
VT
Ctissue (t)! K1Cplasma(t)-k2
The compartment model corresponding to this equation is shown in Figure 3. Dynamic scanning as 
well as an AIF are required. Including a fractional blood volume (V
b
) and the volume of distribution 
(VT), the equation corresponds to:
VT, or distribution volume, describes the tissue to plasma concentration ratio in equilibrium, which 
corresponds to the partition coefficient of water. VT is equal to one if there is full exchange of tracer 
between blood and tissue. A nonlinear least-squares fit of this function to the measured time–activity 
curve in the tissue of interest yields perfusion F and the distribution volume of water VT [38].
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI)
DCE-MRI allows the observation of contrast agent extravasation from the vascular compartment to 
the extravascular extracellular interstitial space (EES), providing parameters reflecting a combination 
of blood flow, vascular surface area and vascular permeability. Sequential magnetic resonance images 
are made before, during, and following the injection of a paramagnetic contrast agent, generally a 
small molecular weight gadolinium (Gd) containing compound such as gadopentetate dimeglumine.  
Kinetic modelling is also based on the Fick principle [36] and analyzed according to the Kety-Schmidt 
18
Ctissue
Cblood
K1
K2
Abbreviations: C
blood
, concentration of tracer in arterial whole blood; C
tissue
, concentration of tracer in tissue; K1, rate constant from 
plasma to tissue; k2, rate constant for tissue clearance.
  
Figure 3. Single–tissue compartment model [41].
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model [37]. In DCE-MRI studies, K1 is a function of blood flow (F), permeability (P), and the vascular 
surface (S) and is called Ktrans. Tofts et al [39] proposed the terms Ktrans, kep, fPV, and ve as outcome pa-
rameters derived from the Kety-Schmidt single–tissue compartment model. The model describes the 
change in contrast agent concentration in the interstitium of the tumor tissue C
tissue
(t), with C
plasma
(t) 
being the concentration of contrast agent in the plasma space of the tumor tissue. Ktrans is the product 
of the endothelial transfer coefficient and surface area, which is the transport rate constant from 
plasma to tumor tissue. kep is the reflux coefficient or the transfer of contrast agent from tissue back to 
the blood. The equation is similar to that of given for PET: 
The two compartments within the tumor are the blood plasma and the EES. fPV is the fraction of plas-
ma volume related to whole tissue volume. ve, which equals K
trans/kep, is a measure for the EES fraction. 
Note that the definitions of F and Ktrans, and VT and ve, are not similar because water is freely diffusible 
in tissue, including cells, whereas Gd is only transferred into the extracellular space.
scope and outline oF the thesis
The aim of the present thesis was to validate and qualify PET and DCE-MRI derived imaging param-
eters in patients with NSCLC that were treated with erlotinib and bevacizumab.
In chapter two we discuss the use of blood flow measurements with H2
15O PET and DCE-MRI in an on-
cological setting. The review was designed to discuss H2
15O PET and DCE-MRI side-by-side to address 
differences and synergistic value of flow measurements with these two techniques. 
In chapter three to five the repeatability of three imaging biomarkers was assessed: H2
15O , 18F-FDG 
and 18F-FLT. The aim of these studies was to provide results that can be used for binary decision making 
in future clinical trials. 
Chapter six and seven describe the results of a multicenter efficacy study of combined BE treatment 
in advanced stage NSCLC. Patients were scanned with CT, 18F-FDG PET, H2
15O PET and DCE-MRI at 
baseline and after three weeks of treatment to evaluate target modulation and to qualify the imaging 
biomarkers during BE treatment. 
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aBstract
Positron emission tomography (PET) with H2
15O and dynamic contrast-enhanced magnetic resonance 
imaging (DCE-MRI) provide noninvasive measurements of tumor blood flow. Both tools offer the abil-
ity to monitor the direct target of antiangiogenic treatment, and their use is increasingly being studied 
in trials evaluating such drugs. Antiangiogenic therapy offers great potential and, to an increasing 
extent, benefit for oncological patients in a variety of palliative and curative settings. Because this 
type of targeted therapy frequently results in consolidation of the tumor mass instead of regression, 
monitoring treatment response with the standard volumetric approach (Response Evaluation Criteria 
in Solid Tumors) leads to underestimation of the response rate. Monitoring direct targets of anticancer 
therapy might be superior to indirect size changes. In addition, measures of tumor blood flow contrib-
ute to a better understanding of tumor biology.
This review shows that DCE-MRI and H2
15O PET provide reliable measures of tumor perfusion, provid-
ed that a certain level of standardization is applied. Heterogeneity in scan acquisition and data analysis 
complicates the interpretation of study results. Also, limitations inherent to both techniques must be 
considered when interpreting DCE-MRI and H2
15O PET results. This review focuses on the technical and 
physiological aspects of both techniques and aims to provide the essential information necessary to 
critically evaluate the use of DCE-MRI and H2
15O PET in an oncological setting. 
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introduction
Angiogenesis, the formation of new blood vessels from the endothelium of pre-existing vasculature, 
plays a central role in tumor growth and metastasis [1].
Once a tumor grows beyond 1–2 mm in size, passive diffusion of nutrients and oxygen is insufficient 
and neovascularization becomes necessary [2]. These newly formed blood vessels are highly abnormal 
and heterogeneous, even in tumors of equal histology and grade [3–5]. Areas of dilated, tortuous, and 
leaky vessels exist together with less abnormal areas [6, 7]. Interstitial hypertension, caused by vascu-
lar hyperpermeability and mechanical stress of lymphatics by tumor cell growth, can lead to blood flow 
stasis or even retrograde flow in tumors [8, 9]. This results in hypoxia and acidosis, which in turn is a 
major cause of resistance to radiation and chemotherapy and associated with a poorer prognosis [10]. 
Recently, drugs have been designed to specifically inhibit angiogenesis. Their effect typically results in 
consolidation of the tumor mass instead of regression.
Therefore, the standard volumetric approach with computed tomography (CT) (Response Evaluation 
Criteria in Solid Tumors) may not be sufficient to assess treatment response. Measuring change in 
tumor blood flow (perfusion) during antiangiogenic therapy might allow for the discrimination of re-
sponders from nonresponders irrespective of volumetric response.
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and positron emission tomog-
raphy using radiolabeled water (H2
15O PET) are sensitive techniques that aim to noninvasively study 
and quantify the physiology of tumor microcirculation. Both techniques are based on the continuous 
acquisition of two-dimensional (2D) or 3D images during the uptake and clearance of an adminis-
tered tracer. DCE-MRI makes use of paramagnetic tracers, mostly consisting of a low-molecular-weight 
gadolinium (Gd)-based agent. PET uses positron-emitting tracers, of which H2
15O can be used to study 
tumor blood flow. Both techniques are now being used in several phase I, II, and III clinical trials 
evaluating tumor vascular response to antiangiogenic drugs. However, acquisition protocols and study 
designs are far from uniform and may affect results. This complicates the comparison of imaging stud-
ies and possibly results in an underestimation of the abilities of DCE-MRI and H2
15O PET. Both PET and 
MRI have specific advantages and disadvantages. Some limitations are inherent to the techniques, but 
others can be overcome by study design. These issues need to be addressed when designing a study 
and must be kept in mind when interpreting the results of such studies.
Mutual understanding between those using H2
15O PET and those using DCE-MRI in oncology is gen-
erally very limited. Both techniques have great potential, but limitations still exist and must not be 
neglected. This is the first review to discuss both H2
15O PET and DCE-MRI in monitoring tumor vascular 
response side-by-side. We focus on the technical and physiological aspects of both techniques and aim 
to supply the reader with essential information necessary to critically evaluate the use of DCE-MRI and 
H2
15O PET in an oncological setting. First, the technical and physiological background of PET and MRI 
are discussed. Then, the methodology of flow measurements with both techniques is presented, and 
their validation and reproducibility are addressed. Finally, the application of DCE-MRI and H2
15O PET 
in monitoring response to anticancer treatment and the methodological considerations influencing 
quantitative measurements of tumor perfusion are discussed.
Blood FloW measurements
background
Technical Background of PET/MRI Signal
There is a fundamental difference between imaging an MRI contrast agent and imaging a PET tracer. 
Paramagnetic contrast agents are not by themselves detectable with MRI, but are visible because they 
shorten T1 and T2 relaxation times of the nearby hydrogen nuclei. In clinical practice, Gd compounds 
are most commonly used. The relation between signal intensity and Gd concentration is complicated. 
Gd concentration cannot be measured directly, because the signal enhancement (T1 relaxation) is a 
characteristic of the tissue being studied. There is no linear relationship between the degree of en-
hancement and the Gd concentration, particularly at high concentrations. Therefore, absolute quan-
tification with DCE-MRI is difficult, and most often the proportional change in signal enhancement 
between the baseline and post-treatment measurements is used. 
In contrast, H2
15O concentration shows a linear relation with signal intensity as measured with PET. 
Therefore, this technique is able to absolutely quantify tumor perfusion.
Physiological Background of PET/MRI Signal
H2
15O is a freely diffusible positron-emitting tracer. Therefore, regional uptake directly and specifically 
reflects tissue perfusion. Gd-based contrast agents are never freely diffusible. Therefore, the degree 
of signal enhancement with DCE-MRI depends on several physiological and physical characteristics, 
including contrast concentration, tissue perfusion, permeability, and volume of the extracellular ex-
travascular space (EES) [11]. Thus, H2
15O PET and DCE-MRI are both able to monitor tumor microvascu-
lature, but the first specifically measures tissue perfusion whereas the latter measures a combination 
of processes, mainly perfusion and permeability.
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modeling Signal Intensity
General Model
PET and DCE-MRI perfusion measurements are both based on the Fick principle (Fick, 1870) and ana-
lyzed according to the Kety-Schmidt model [12], although the nomenclatures used in PET and DCE-
MRI are slightly different. In a dynamic scan, dC
tissue
(t)/dt (the change in tissue concentration of a flow 
tracer or contrast agent at a certain time point) is equal to K1 (the plasma to tissue transport rate 
constant) times C
plasma
(t) (the tracer concentration) minus k2 (the tissue to plasma rate constant) times 
the tracer concentration in tissue at that point in time:
         (1)
The compartment model corresponding to this equation is shown in Figure 1. K1 equals flow F multi-
plied by extraction fraction E, which in its turn is a function of F and the permeability surface product 
PS (the latter only being relevant in the case of nonfreely diffusible tracers):
         (2)
In H2
15O PET studies, K1 is equal to F and thus represents true blood flow, whereas in DCE-MRI studies, 
K1 is a function of blood flow (F), permeability (P), and the vascular surface (S) and is also called K
trans or 
Kps. The term Ktrans is generally used to describe the kinetics of contrast agents with a high PS product, 
thus mainly representing perfusion, whereas Kps is used for contrast agents with a lower PS product 
and thus represents a mixed effect of perfusion and permeability as shown in equation 2 [13, 14]. 
With H2
15O PET, C
plasma 
is effectively equal to C
blood
 because of the rapid exchange between blood cells 
and plasma. With DCE-MRI, C
plasma
 is calculated as C
blood
 divided by one minus the hematocrit, because 
Gd contrast agents are only present in plasma. For both techniques, a large vessel within the imaged 
volume can be used for definition of an image-derived arterial input function (IDIF). In order to use an 
IDIF, a feeding input vessel of substantial size (such as the aorta or left ventricle) must be included in 
the imaged volume, together with the target lesion. With PET, C
blood
 or the arterial input function (AIF) 
can be measured using (continuous) arterial blood sampling during the scan. 
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Figure 1. Single-tissue compartment model.
For a freely diffusible tracer with 100% extraction, such as water in the range of flow values relevant 
for tumor imaging, equation 1 corresponds to:
          (3)
Here, VT is the tissue to plasma concentration ratio in equilibrium, which corresponds to the partition 
coefficient of water. VT is equal to one if there is full exchange of tracer between blood and tissue. The 
solution of this equation, including a fractional blood volume v
b
, is:
  
         (4)
A nonlinear least-squares fit of this function to the measured time–activity curve in the tissue of inter-
est yields the perfusion F and distribution volume of water VT [15]. Therefore, this method also allows 
for the quantification of tissue perfusion when VT does not equal one. 
In the case of MRI, a different nomenclature is used. Low-molecular-weight Gd is not freely diffusible, 
but partially leaks through the vessel wall into the interstitial space and leaks more through pathologi-
cal tumor vessels as a result of greater permeability. DCE-MRI applying Gd contrast agents exploits this 
hyperpermeable nature of tumor vessels. The same kinetic model as above can be applied to fit DCE-
MRI data [16]. Tofts et al [11] proposed the terms Ktrans, kep, fPV, and ve as outcome parameters derived 
from this single–tissue compartment model. The equation is similar to equation 3:
    
         (5)
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This equation describes the change in contrast agent concentration in the interstitium of the tumor 
tissue C
tissue
(t), where C
plasma
(t) is the concentration of contrast agent in the plasma space of the tumor 
tissue. Ktrans is the endothelial transfer coefficient surface area product, which is the transport rate 
constant from plasma to tumor tissue. kep is the reflux coefficient or the transfer of contrast agent from 
tissue back to the blood. The solution of this equation is similar to the solution given for PET:
           (6)
The two compartments within the tumor are the blood plasma and the EES. fPV is the fraction of 
plasma volume related to whole tissue volume. ve, which equals K
trans/kep, is a measure for the EES 
fraction. Note that the definitions of F and Ktrans, and VT and ve, are not similar because water is freely 
diffused in tissue, including cells, whereas Gd is only transferred into the extracellular space. Table 1 
lists all the parameters involved in modeling PET and MRI signaling.
Specific Aspects of H2
15O PET
A dynamic PET scan following a bolus injection of H2
15O consists of a series of consecutive short scans 
(frames), with typical durations starting with 5 seconds per frame and increasing to 30 seconds per 
frame (totaling 10 minutes), and starts simultaneously with the bolus injection. Although frame dura-
Symbol                     Definition                                                                                                 unit
F Perfusion ml . cm-3 min-1
E Extraction unitless
K1 F 
. E, rate constant from plasma to tissue ml . cm-3 min-1
k2 Rate constant for tissue clearance min
-1
VT Distribution volume ml cm
-3 
V
b
, fPV Fractional blood or plasma volume ml cm-3 
Ktrans, Kps Volume transfer constant between plasma and EES min-1
kep Rate constant between EES and plasma min-1
Ve Fractional extravascular, extracellular leakage volume unitless
AUGC Initial area under the Gd concentration curve AU
C
plasma
, AIF Concentration of tracer or Gd contrast agent in arterial plasma AU . ml-1
C
tissue
Concentration of tracer in tissue AU . ml-1
C
blood
Concentration of tracer in arterial whole blood AU . ml-1
Abbreviations: AU, arbitrary units; EES, extracellular extravascular space; Gd, gadolinium; MRI, magnetic reso-
nance imaging; PET, positron emission tomography.
table 1. PET and MRI nomenclature.
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tions shorter than 5 seconds are possible, they would result in very noisy images because of the low 
number of counts per frame and this would not contribute to more reliable flow measurements. The 
amount of injected H2
15O is about 1 GBq and depends on the high count rate capabilities of the scan-
ner. Prior to the emission scan, a short (several minutes) transmission scan using rotating 68Ge rod 
sources, analogous to a CT scan but acquired with 511 keV gamma radiation instead of x-rays, has to be 
performed to correct for photon attenuation in tissue. In the case of combined PET-CT scanners, a low-
dose (20 –50 mAs) CT scan can be used for this purpose. A conventional PET scan after administration 
of 1 GBq H2
15O results in an effective radiation dose of approximately 1 mSv, or about half the average 
annual radiation load per person from the environment [17]. A combined PET-CT scan with 500 MBq 
H2
15O and a 30-mAs low-dose CT of, for example, the thorax results in a higher effective dose of 1.4 
mSv. In the latter case, the lower amount of administered H2
15O is feasible because of the improved 
signal-to-noise ratio of state-of-the-art scanners. The spatial resolution of PET images is on the order 
of 6 mm in all three directions in clinical PET scanners. Because of the short radioactive half-life of 15O 
(2 minutes), a scan can be repeated within 10 minutes of the previous scan, which allows for the mea-
surement of direct short-term therapy effects within one imaging session. Also, a scan can be followed 
by a second scan with a different tracer to study other aspects of tumor biology. Because of the short 
half-life, H2
15O PET studies require the availability of an on-site cyclotron for the production of 15O.
Specific Aspects of DCE-MRI
For DCE-MRI, a clinical MRI scanner can be used with field strength usually in the range of 1–3 Tesla. The 
scanning protocol starts with high-resolution 3D imaging of the tumor and its environment, with both 
T1- and T2-weighted sequences. These images are used to delineate the tumor volume. The protocol con-
tinues with five precontrast T1-weighted measurements with different flip angles to determine the T1 re-
laxation time in the blood and tissue before contrast arrival. This T1 value is required for the model-based 
quantification [16]. Then, the contrast is given by i.v. injection. Upon injection, the dynamic acquisition 
starts using the same 3D T1-weighted pulse sequence and the same slice positions, but with a fixed flip 
angle (e.g. 35 degrees), containing 30–35 scans of about 1 second each. Thus, the temporal resolution is 1 
second. The spatial resolution inplane is about 1.5 x 1.5 mm, and through-plane is about 10 mm. The use 
of thick image planes, however, leads to a degradation of in-plane resolution, depending on heterogene-
ity in the axial direction, because each plane represents an average image of a 10-mm thick volume. For all 
tumors that are subject to respiratory motion, the patient is asked to hold his breath as long as possible. 
Renal clearance of contrast occurs with an elimination phase half-life of 100 minutes [18]. Because of the 
relatively slow clearance of contrast agent, DCE-MRI scans cannot be repeated within the same imaging 
session. Figure 2 shows images of a dynamic MR sequence following a contrast bolus injection. 
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Figure 2. Representative DCE-MR images from a patient with NSCLC. The sequential images show the 
tumor at different time points after contrast bolus. The signal intensity curve over time was measured 
in the tumor, the aorta, and the pulmonary artery (AP).
Despite the many research papers in this field, consensus is lacking on the exact kinetic model to be 
used for DCE-MRI. Therefore, model-free quantification of DCE-MRI data is still widely applied. This 
approach calculates basic properties of the tissue enhancement curve, such as time to onset and peak 
and end, time intervals of rising and transit, amplitude, and the mean and maximum upslope of the 
DCE-MRI tissue enhancement curve. The upslope values can be normalized for the area-under-the-
curve and upslope of the AIF. Another frequently used semiquantitative measurement is the initial 
area under the Gd concentration curve (AUGC).
parametric Images
In principle, it is possible to apply the above equations on a pixel-by-pixel basis to obtain parametric 
images, a graphical representation showing F, VT, K
trans, or ve, for each pixel [19]. Parametric images 
retain the original image resolution, allowing for better assessment of heterogeneity than region of 
interest (ROI)-based methods. Heterogeneity analyses can add to ROI analyses, and DCE-MRI seems 
especially promising because of its high spatial and temporal resolution. Nonlinear least-squares fit-
ting of equations 4 or 6 on a pixel-by-pixel basis is very time-consuming, which is not a limiting factor 
for MRI because of the small number of image planes, but is impractical for the number of voxels of 
about one million in a typical clinical PET image volume. In addition, it yields noisy parametric images. 
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Although a subregion of the total imaged volume can be selected in order to limit the computation 
time, faster methods are available and preferable. Basically, there are two fast options for creating 
parametric images. First, the differential equation 1 can be integrated on both sides, resulting in the 
following equation:
          (7)
When evaluating this equation and plotting, for each frame, the left-hand side of the equation versus 
the integral ratio on the right-hand part, this equation describes a straight line, intercepting the y-axis 
at K1 (F or K
trans) and the x-axis at K1/k2 (VT or ve). Using this linearization, F and VT (or K
trans and ve) can be 
obtained for each pixel using a simple and fast linear least-squares fit [20]. The second option to create 
parametric images is by the use of basis functions:
         
         (8)
A set of basis functions exp(-βit)     Cplasma(t) is created by convolution of the plasma input function with a 
set of single exponential functions, with exponential clearance rate constants βi, for example, between 
0.01 and 1 min-1. For each voxel, the basis function that, multiplied by K1 (F or K
trans), best fits the mea-
sured data is selected. Each of these iterations involves a simple linear fit procedure, which is much 
faster than a nonlinear fit and limits the time necessary to construct parametric images from several 
hours to several minutes. In addition, this method reduces image noise while allowing for inclusion 
of a blood volume compartment and retaining the quantitative accuracy of the resulting parametric 
images. The basis function method also allows for fixation of VT or ve to further reduce noise [19, 21]. 
Figure 3. Coronal images of H2
15O uptake (A), perfusion (B), and, for reference, 18F-3’-deoxy-3’ 
-fluorothymidine (18F-FLT) uptake (C) of a patient with a mediastinal relapse of non-small-cell 
lung cancer. The perfusion image was calculated using the basis function method, with the 
distribution volume VT fixed to 1, and corrected for both arterial and venous blood volume. 
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Figure 3 shows an H2
15O perfusion image calculated using the basis function method, compared with 
typical images of 18F-3’-deoxy-3’-fluorothymidine (18FLT), a proliferation tracer, and images of H2
15O 
radioactivity concentration. Figure 4 shows a DCE-MRI perfusion image calculated by nonlinear least-
squares fits of equation 6 to each pixel’s tissue enhancement curve.
validation and reproduciBility
h
2
15o-pet
Validation
Dynamic H2
15O PET has been well validated in the brain and myocardium [22–27]. Some validation 
studies have been performed in other tissues, including the lung [28, 29], kidney [30], and skeletal 
muscle [31, 32]. To date, no validation studies have been performed in tumors. In theory, the model 
should also fit tumor perfusion measurements because H2
15O is freely diffusible throughout the body 
and the range of reported values (0.15–1.29 mL blood/mL tissue per minute) lies well within the range 
of validated perfusion values [33, 34]. On the other hand, typical vascular abnormalities in tumor tis-
sue (vascular shunts, large vessels situated within a lesion) can result in overestimation of perfusion if 
models are used without correction for these effects [35, 36]. Therefore, validation studies in tumors 
are still needed and awaited.
Reproducibility
In brain and myocardium [37–40], as well as in some other tissues [34, 41, 42], H2
15O PET has been 
shown to be reproducible with within-subject coefficients of variation (wCV) in the range of 9%–14%. 
The reproducibility value (defined as the range within which 95% of measurements fall) was in the 
range of 22%–34%. Two oncological studies have been performed [15, 34]. Although the study groups 
were small, reproducibility results were in the same range as those observed in the brain and myocardi-
um, with wCV of 11% for abdominal tumors [34] and errors up to 10% reported for breast tumors [15]. 
dce-mri
Validation
The first approach for validating DCE-MRI perfusion is to verify whether an MRI-derived parameter 
does indeed deliver absolute perfusion measurements. No such validation study has been performed 
in tumors. In the human myocardium, Ktrans was compared with myocardial perfusion as measured us-
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ing H2
15O PET [43]. There was a strong correlation for dipyridamole-induced flow (r = 0.70; p = .001) 
and a moderate correlation for myocardial perfusion reserve (r = 0.48; p = .04) between MRI and PET. 
In a second approach, it was validated against immunohistochemistry as the gold standard. Correlation 
of DCE-MRI signal enhancement with microvascular density (MVD) was found to be inconsistent [44]. 
One reason for this may be that tissue enhancement is not only determined by MVD but also by the 
status of the capillary–interstitial space barrier (vessel wall permeability), which is not accounted for 
by immunohistochemistry. In breast cancer lesions, tissue expression of vascular endothelial growth 
factor (VEGF) was closely correlated to kep [45]. Because VEGF expression shows a spatial association 
with vessel permeability [46, 47], this finding further supports the theory that enhancement of the 
DCE-MRI signal partially reflects vessel permeability. 
Because DCE-MRI measures a combination of flow and permeability, it is difficult to validate. Attempts 
have shown that signal enhancement reflects vascular status, but validation studies in tumors, as have 
been done for the myocardium, are still awaited.
Reproducibility
Two studies have evaluated reproducibility in an oncological setting. The first evaluated the reproduc-
ibility of quantitative and semiquantitative kinetic parameters in 21 patients with solid tumors [48].
AUGC and ve were found to be reproducible with wCVs of 12% and 9%, respectively.
Ktrans and kep showed greater variability (with wCVs of 29% and 24%, respectively). The latter are more 
sensitive to changes in the AIF, which could explain the lower reproducibility. Comparable results were 
found in a study of 11 patients with advanced cancers [49]. AUGC and Ktrans showed wCVs of 16% and 
19%, respectively. The reproducibility value was 30% for AUGC and 36% for Ktrans. With serial imaging of 
patients, a decrease in Ktrans of > 40%–45% can be addressed as a treatment effect [48–51].
34
Figure 4. T1-weighted magnetic resonance image (left) and dynamic contrast-enhanced magnetic res-
onance imaging Ktrans perfusion image (right), also shown as overlay in the T1 image, of a patient with 
non-small-cell lung cancer, calculated by least-squares fits to equation 6. Ktrans is the volume transfer 
constant between plasma and the extravascular extracellular space.
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monitoring response to anticancer treatment
Predicting response to therapy as early as possible creates the opportunity to customize patient treat-
ment. There is a need for this “customization” because response rates to intensive treatment with 
serious, and sometimes lethal, side effects are often low. To continue treatment with limited or no 
effect only provides the patient with side effects, while depriving the patient of potential benefit from 
other treatment. The ultimate goal is to customize treatment prior to initiation. Encouraging results 
have been published on gene-expression profiling, where correlations between gene expression and 
drug sensitivity were found [52–54]. Some success has been achieved in measuring the expression 
level of tumor markers to which the drug is targeted [55]. However, before these tools can be used 
in a clinical setting, further research is needed. Until then, predicting response early in treatment is 
still a major step forward when compared with size-based response evaluation after several cycles of 
systemic therapy.
monitoring response to antiangiogenic therapy
Several components of tumor vasculature have been targeted by systemic drugs. The main differentia-
tion can be made between antiangiogenic and antivascular drugs. The first inhibit neovascularization. 
The most striking inhibition has been accomplished by targeting VEGF, via either monoclonal antibod-
ies (MAbs) directed against circulating VEGF or by targeting the VEGF receptor (VEGFR) with tyrosine 
kinase inhibitors (TKIs). Bevacizumab (a VEGF MAb) has been shown to decrease tumor perfusion, 
vascular permeability, MVD, interstitial fluid pressure (IFP), and circulating endothelial and progeni-
tor cells [56]. This suggests a direct antivascular effect. Receptor TKIs generally target not only the 
tyrosine kinase of the VEGFR but also the tyrosine kinases of other receptors, such as the platelet-
derived growth factor receptor, fibroblast growth factor receptor, and epidermal growth factor re-
ceptor (EGFR), which suggests additional effects when compared with MAbs. Examples are imatinib, 
sorafenib, and sunitinib. Selective blocking of EGFR is another inhibitory pathway of angiogenesis [57]. 
Examples of EGFR TKIs are erlotinib and gefitinib. Antivascular or vascular disruptive agents (VDAs) 
damage existing blood vessels, aiming at depriving the tumor from oxygen and nutrients. Combret-
astatin, the major VDA under investigation, is able to rapidly shut down blood vessels and can result in 
pronounced tumor necrosis in patients with solid tumors [58, 59]. 
Knowledge of the nature of a drug action, and its influence on PET and MRI derived parameters, can 
aid in choosing the best imaging tool and time interval to monitor response. H2
15O PET measures perfu-
sion and VT. Because water is freely diffusible, a change in vascular permeability cannot be monitored 
accurately, although this could be measured with PET using other tracers such as [68Ga]transferrin or 
[11C]methylalbumin [23, 60]. A decrease in IFP (resulting from a decrease in vascular permeability or 
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lowering of mechanical stress by reducing tumor cell density) results in an increase in perfusion. A 
decrease in MVD results in a decrease in perfusion. VT (the ratio of H2
15O in tissue to that in plasma at 
equilibrium) is expected to be stable with antiangiogenic therapy and to decrease with antivascular 
therapy because of induced necrosis or increased intercapillary distance. 
DCE-MRI–derived Ktrans has several physiological interpretations, depending on the balance between 
capillary permeability and blood flow. In situations in which capillary permeability is very high, the 
flux of contrast agent into the EES is flow limited and Ktrans will approximate tissue perfusion. On the 
other hand, when permeability is low and blood flow is high, Ktrans gives an indication of capillary per-
meability. However Ktrans frequently indicates a combination of flow and capillary permeability [11]. A 
decrease in vascular permeability and/or MVD results in a decrease in Ktrans because of a lower extrac-
tion rate and lower blood vessel surface area, respectively. A decrease in IFP, however,
results in an increase in Ktrans because of lower interstitial resistance. 
As indicated, antiangiogenic therapy promotes several morphological and functional changes in a tu-
mor with sometimes opposite effects on MRI- and PET-derived parameters. The net effect is mea-
sured, and therefore it is of no surprise that the relation between treatment effects and imaging pa-
rameters is not straightforward. In spite of the above limitations, H2
15O PET and DCE-MRI have shown 
their potential in response assessment early in anticancer treatment. In renal cell cancer, paired 18F-
FDG and H2
15O PET scans were performed in five patients before and after SU5416 (a VEGFR TKI) and 
interferon-α. 18FDG and H2
15O PET both showed a decrease in one patient with stable disease, an 
increase in one with progressive disease, and no change in three patients [61]. Razoxane (a cytostatic 
and antiangiogenic agent) was shown to reduce tumor perfusion in patients with advanced renal cell 
cancer [62]. Statistical significance, however, was not reached, and perfusion did not correlate with 
tumor progression, possibly because of the small sample size. Response monitoring to endostatin and 
combretastatin therapy revealed a reduction in tumor perfusion, as measured with H2
15O PET [59, 
63]. Both studies showed a dose-dependent reduction in perfusion, with a nonlinear relation in the 
endostatin study. Combretastatin caused a rapid perfusion reduction in solid tumors after 30 minutes, 
which remained significant after 24 hours. Interestingly VT also was determined, which showed a re-
duction 30 minutes after injection with recovery after 24 hours. This trend might be a result of partial 
reversal of the vascular response, indicating that part of the tissue was targeted but still viable. 
DCE-MRI has been incorporated into several phase I and II trials. PTK/ZK (a VEGFR TKI) has been tested 
in a phase I trial in patients with advanced cancers [50, 51, 64]. DCE-MRI was performed at baseline, 
day 2, and the end of each 28-day cycle. Ktrans decreased in a dose-dependent way. A reduction of > 40% 
in the baseline value at day 2 was predictive of stable disease. In a recent phase II study, patients with 
advanced breast cancer were treated with bevacizumab monotherapy for one cycle, followed by six 
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cycles of bevacizumab, doxorubicin, and docetaxel. Significant reductions in Ktrans, kep, and ve were seen 
after one cycle, which persisted when cytotoxic chemotherapy was added. The decreases in Ktrans, kep, 
and ve were correlated with increased apoptosis and a reduction in VEGFR expression [65]. Several 
targeted agents have been shown to decrease DCE-MRI–derived parameters in a dose-dependent 
manner, making DCE-MRI a useful indicator in drug pharmacology [66, 67]. A recent study of DCE-MRI 
in patients with progressive multiple myeloma treated with thalidomide found amplitude A, which is 
proportional to the relative signal enhancement, to be a good prognostic indicator of progression-free 
survival [68]. 
Most PET and MRI results are derived from small studies. Together with heterogeneity in acquisition 
protocols and study design, these factors might limit their value. Therefore, prospective phase III trials 
with predefined cutoff values for PET and MRI results are awaited.
potential Synergistic value of DCe-mRI and h
2
15o pet
Because PET measures true perfusion and MRI measures a combination of perfusion and vascular 
permeability, the two modalities can complement each other. In theory, both perfusion and perme-
ability can be isolated when F and Ktrans are known. An alternative is the use of a PET tracer such as 
[68Ga]transferrin or [11C]methylalbumin to measure permeability directly. So far, no oncological study 
has been performed that incorporated both DCE-MRI and H2
15O PET.
Combining Information on tumor vasculature and metabolism
Tumor metabolism can be measured with 18F-FDG PET. 18F-FDG uptake is the product of perfusion 
and extraction. It can be hypothesized that poorly perfused and hypometabolic areas reflect necrosis, 
while poorly perfused and hypermetabolic areas reflect hypoxia (because of anaerobic glucose hy-
permetabolism under hypoxic circumstances). It is possible to measure oxygen consumption directly 
using 15O2 and PET. Knowledge of the regional tumor microenvironment can supply relevant informa-
tion on mechanisms of treatment failure, but can also aid in treatment planning (e.g. radiotherapy). 
Recently, the synergistic value of H2
15O PET and 18F-FDG PET was shown in breast cancer, where a 
pretherapeutic low ratio of 18F-FDG uptake to perfusion was the best predictor of complete response 
to neoadjuvant chemotherapy and also predictive of disease-free survival [69]. 18F-FDG metabolism 
and perfusion were positively correlated, although highly variable. Zasadny et al [70] also found a posi-
tive correlation between 18F-FDG metabolism and perfusion, with the additional finding of a higher 
slope of the curve at lower flow rates, possibly indicating hypoxia in areas with low perfusion and high 
metabolism. In contrast, 18F-FDG metabolism was found to be negatively correlated with perfusion in 
non-small-cell lung cancer (NSCLC), liver tumors, and head-and-neck cancer. Perfusion in the latter 
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two was assessed with contrast-enhanced CT [71–73]. In NSCLC and head-and-neck cancer, the ratio 
was found to positively correlate with tumor size, suggesting the presence of hypoxia in larger tumors 
where tumor growth exceeds angiogenesis [71, 73]. In contrast, a high tumor perfusion rate predicted 
poor response to radiotherapy in head-and-neck cancer [74]. This reflects the complexity of tumor bi-
ology. High tumor blood flow does not immediately indicate sufficient oxygenation and thus favorable 
radiotherapy outcome. Hypoxia stimulates angiogenesis via upregulation of specific transcription and 
growth factors, like VEGF [75]. This results in a more complex, but abnormal, chaotic vascular network 
with increased blood flow, but inadequate oxygen and nutrient supply. Thus, hypoxic areas can exist 
irrespective of high blood flow, a finding confirmed in a PET study in brain tumors using fluorine-18 
fluoromisonidazole (a hypoxia tracer) and H2
15O [76].
timing of Response evaluation
Jain [77, 78] introduced the term “normalization” to describe the (transient) reversal of vessel ab-
normalities his group observed after antiangiogenic treatment. The time span of normalization, the 
“normalization window,” describes the period in which abnormal vessels either regress or normalize. 
In this period, the nutrient, drug, and oxygen supply is thought to be improved [77, 78]. Eventually, all 
tumors show resistance, after which vessels become abnormal again. The time span of this window 
is unknown for most drugs and, in addition to drug characteristics, may depend on the tumor type 
and possibly on individual tumor and patient characteristics. Because of these time-dependent tumor 
changes, it seems extremely important to know when to scan in order to adequately measure treat-
ment effect. 
In most protocols, time to response evaluation is based on CT response protocols instead of consid-
erations of tumor biology. This might be one of the reasons why H2
15O PET and DCE-MRI failed to 
demonstrate a correlation with outcome in some trials. 
The reported normalization windows after treatment with VEGF TKIs or MAbs have been heteroge-
neous [79, 80], which makes designing future trials difficult but challenging. Serial measurements can 
aid in the definition of this time window for new drugs [79]. Therefore, if financially and logistically 
possible, serial PET and MRI measurements should be planned for new drug trials in order to assess 
the best time point for response monitoring after antiangiogenic treatment. Although most patients 
in such trials have a limited life expectancy, this strategy can result in a high cumulative radiation dose, 
especially with combined PET-CT scanners.
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methodological considerations — Factors inFluencing Quantitative measurements 
oF tumor perFusion and permeaBility 
aIF Definition
Independently of the parameter used, several considerations have to be made about the ROI and AIF. 
The latter describes the concentration of MRI contrast or PET tracer in plasma over time, which has a 
great influence on measurements of (semi)quantitative parameters. It is generally accepted that the 
AIF varies between patients and between visits within each patient because of variations in cardiac 
output, renal function, and vascular tone. In principle, the AIF should be accurately measured for each 
scan. With PET, accurate measurement of the AIF can be obtained by arterial blood sampling with an 
online system, measuring arterial radioactivity concentration independently of tumor site. Because 
arterial sampling is invasive, an image-derived AIF may be more convenient. However, in many cases 
it is not possible to measure an image-derived AIF because of the absence of a suitable artery within 
the imaging field of view. 
With MRI, image-derived measurement of the AIF is the only option, because measurement of the 
contrast agent concentration by arterial sampling is not possible. AIF measurements have shown that 
DCE-MRI reproducibility is worse with suboptimal AIF definition than with using a standardized AIF 
[49, 81]. In addition, the relation between tracer concentration and signal intensity becomes progres-
sively nonlinear with increasing tracer concentration. This is especially the case in the feeding artery 
during the first passage of the administered bolus. Therefore, it has been proposed that the AIF should 
be measured with a small prebolus, and then the true AIF for the main bolus can be reconstructed 
from this [82]. Several other methods have been developed to meet this problem. Most of them are 
based on reference region models or a functional form of a population-derived AIF [81, 83]. Whichever 
technique is being used, it has a great impact on the results. 
tissue RoI Definition
The tissue ROI should be a well-defined part of the tumor, consistent throughout follow-up and pref-
erably throughout the whole study to avoid sampling errors. This could be the entire tumor or a sub-
region. ROI can be defined on CT, MRI, PET emission, or PET transmission images. DCE-MRI obviously 
uses the high-resolution MR images, but PET has no well-defined anatomic landmarks available. CT 
can be used, but coregistration incorporates spatial error. Integrated PET-CT overcomes much of this 
problem, although respiratory motion still challenges accurate coregistration in the thorax and upper 
39
abdomen. Definition of anatomic ROIs using CT and MRI has its own disadvantages. Metabolically 
inactive areas (reflecting necrosis) are difficult to identify and might be incorporated, causing under-
estimation of the perfusion in viable tumor tissue. In addition, atelectasis and adjacent infectious 
consolidation complicate ROI definition. 
With PET, ROI can be defined either on the H2
15O image or on a subsequently performed PET scan with 
a tissue-accumulating tracer. Because of the limited spatial resolution of PET and the “noisy” data 
produced by a diffusible tracer like H2
15O, ROI definition on an H2
15O PET image is difficult (Figure 3A). 
Peritumoral areas of high flow (resulting from infection or adjacent large vessels) and small or highly 
irregular tumors complicate delineation. Parametric images, depicting flow instead of radioactivity 
concentration, show better tumor-to-background contrast [19], but are still in need of improvement 
(Figures 3B and 4). In the case of heterogeneity, areas of low or absent flow are not accounted for (not 
visible) and only perfused areas are selected. Therefore, the ROIs defined on parametric images proba-
bly do not reflect the true tumor mass. Adding a tissue-accumulating tracer (allowing for better tumor-
to-background contrast, e.g. 18F-FDG or 18F-FLT) to the scan protocol creates the opportunity to define 
an ROI reflecting metabolically active tissue, which can then be copied to the perfusion image (Figure 3). 
Preferably, a 3D ROI is constructed to ensure all tumor tissue is incorporated. When 2D regions are 
used, it is recommended to have a minimum of three sections through the tumor in order to account 
for spatial heterogeneity within a lesion [84]. ROI definition is not easy and straightforward, but should 
be based on the desired information and knowledge of treatment effects, and, most importantly, it 
should be performed in a standardized, reproducible manner [85]. 
organ and tumor position
Quantification of tumor perfusion is more complicated in the lung and upper abdominal lesions. In 
the liver, AIF definition is difficult because of the dual hepatic blood supply (portal vein and hepatic 
artery). The hepatic artery accounts for the greatest part of the blood supply to liver tumors, but the 
portal vein contributes to a small amount in small metastases and at the surface of large metastases 
[86–89]. A model including the dual hepatic blood supply, addressing these issues, has been suggested 
[90, 91]. Tumor motion influences delineation and quantification. Thoracic lesions at the base of the 
lung and close to the thoracic wall, as well as upper abdominal lesions, are most vulnerable to respira-
tory motion [92]. A dynamic DCE-MRI sequence can be performed within a single breathhold, thereby 
avoiding substantial motion error. PET, with its lower temporal resolution, is especially affected. Pul-
monary gated PET, using only the data required during a certain phase of the respiratory motion cycle, 
is a promising tool to compensate for this type of error [93, 94], although difficult to implement for 
dynamic H2
15O scans because of limited count rates.
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Spatial and temporal Resolution
Heterogeneity occurs at the microscopic level. DCE-MRI with its high spatial resolution, typically 1.5 x 
1.5 mm in-plane and 10 mm through-plane, offers detailed pictures, whereas PET has a spatial reso-
lution of  approximately 6 mm, resulting in an averaged perfusion picture [95]. MRI also has better 
temporal resolution, which is on the order of 0.1 seconds for a 2D acquisition and 1 second for a 3D ac-
quisition. This ensures that the upslope of the contrast enhancement can be measured with adequate 
temporal resolution, mostly within one breathhold. This allows for detailed heterogeneity analyses 
that might add to perfusion measures. Tumor vasculature is highly heterogeneous throughout lesions, 
both in place and time. Microvascular blood flow fluctuates markedly within seconds, even without 
treatment [96, 97]. Excellent spatial and temporal resolution only give a quick snapshot and might 
not be representative of the overall vascular status within a given tumor region. Therefore, it can be 
hypothesized that an average picture (time and place) might provide more practical information than 
a detailed one.
partial volume effects
Partial volume effects typically occur in small lesions. This effect refers to two distinct phenomena that 
negatively influence quantitative measurements, image blurring and averaging signal at the voxel level 
[98]. Because of the finite resolution, the activity of a small source is projected as a larger but less ac-
tive source (part of the signal spills out). Averaging at the voxel level occurs with all image modalities 
and is explained by the fact that every image is built up by pixels (2D) or voxels (volumetric pixels, 3D). 
Lesion boundaries do not conform themselves to this tight framework and thus voxels can exhibit both 
tumor and adjacent tissue, resulting in an over- or underestimation of the true pixel/voxel activity.
In this way, spill in can also be explained. Nearby large vessels, obviously with high blood flow, can 
cause spill in of activity that can be accounted for in compartment models (equation 4). In a similar 
way, hypoperfused lesions surrounded by physiologically highly perfused tissue (e.g. liver or spleen) 
are also affected.
Response Definition in Clinical trials
Response evaluation is usually done by calculating the percentage change between baseline and post-
treatment values. This delta function substantially depends on the value of the divisor. With a small 
divisor, a small difference results in an unrealistic response rate. At the other end of the spectrum, a 
response could be missed because of a relatively large divisor. Thus, simply calculating the percentage 
change might not be useful for very small or large tumors. Reproducibility studies can shed light on this 
subject [99]. Quantification is highly dependent on both hardware and software. Image resolution, re-
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construction methods, ROI strategy, and quality control (i.e. calibration) all account for fluctuations in 
results. Differences of up to 40% are described in the literature for standardized uptake values (SUVs) 
with 18F-FDG PET [100]. SUV measurements, however, require crosscalibration of a dose calibrator and 
the PET scanner, whereas flow measurements using H2
15O do not, removing uncertainties resulting 
from calibration errors in the case of flow studies. In general, most errors can be overcome when only 
one scanner is used, together with uniform reconstruction methods and data analysis. However, today 
most clinical studies are multicenter designed. If absolute values are necessary for within-study evalu-
ation and when general recommendations for cutoff values are desired, standardization is required. 
Until that time, it is recommended that at least each patient be scanned on the same scanner pre- and 
post-treatment with equal methods of scan acquisition, data reconstruction, and analysis. In this way, 
the proportional change in flow values can be used safely.
conclusion
DCE-MRI and H2
15O PET are able to reliably measure tumor perfusion, provided that a certain level 
of standardization of both the scan acquisition and data analysis is applied. Their value and poten-
tial have been shown in several phase I, II, and III drug trials. Both tools can be used to (a) assess 
anticancer drug activity early in drug development, (b) evaluate response to anticancer drugs early 
in treatment, and (c) study biological processes in tumors, which increases knowledge on the tumor 
microenvironment and might lead to a better understanding of drug failure patterns. 
There are still some issues that need to be reconsidered to allow for routine clinical use of DCE-MRI 
and H2
15O PET. H2
15O PET studies require the availability of an onsite cyclotron, while DCE-MRI data 
analysis is not straightforward, and can be complex and time-consuming. In addition, the predictive 
value of H2
15O PET and DCE-MRI has to be confirmed in phase III trials with predefined cutoff values for 
response definition before recommendations on clinical use can be made.
However, their noninvasive nature in combination with promising results must be regarded as a stimu-
lus to incorporate DCE-MRI and H2
15O PET in future trials. This will contribute to a better understanding 
of the value of both techniques and might one day serve patients in the clinical setting.
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aBstract
purpose 
PET and 15O-labeled water (H2
15O) can be used to noninvasively monitor tumor perfusion. This allows 
evaluation of the direct target of antiangiogenic drugs, that is, tumor vasculature. Because these drugs 
often result in consolidation rather than regression of the tumor mass, a change in perfusion might be 
a more sensitive way to evaluate response than are indirect size measures on a CT scan. However, to 
use the technique for serial imaging of individual patients, good reproducibility is essential. The pur-
pose of the present study was to evaluate the reproducibility of quantitative H2
15O measurements. 
methods
Nine patients with non-small-cell lung cancer (NSCLC) were scanned twice within 7 d and before any 
therapy. All H2
15O scans were followed by an 18F-fluorothymidine scan to allow for adequate volume-
of-interest (VOI) definition. VOIs were defined using a 3-dimensional threshold technique. Tumor 
perfusion and the volume of distribution (VT) were obtained using a 1-tissue-compartment model in-
cluding an arterial blood volume component and an image-derived input function. The level of agree-
ment between test and retest values was assessed using the intraclass correlation coefficient (ICC) 
and Bland–Altman analyses. Possible dependency on absolute values and lesion size was assessed by 
linear regression. 
Results
All primary tumors and more than 90% of clinically suspected locoregional metastases could be delin-
eated. In total, 14 lesions in 9 patients were analyzed. Tumor perfusion showed excellent reproducibil-
ity, with an ICC of 0.95 and SD of 9%. The VT was only moderately reproducible, with an ICC of 0.52 and 
SD of 16%. No dependency was found on absolute values of perfusion (p = 0.14) and VT (p = 0.15). In 
addition, tumor volume did not influence the reproducibility of perfusion (p = 0.46) and VT (p = 0.25). 
Conclusion
Quantitative measurements of tumor perfusion using H2
15O and PET are reproducible in NSCLC. When 
patients are repeatedly being scanned during therapy, changes of more than 18% in tumor perfusion 
and 32% in VT (> 1.96 x SD) are likely to represent treatment effects. 
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introduction 
Because of the limited effects of cytotoxic chemotherapy, interest is increasing in more specific mo-
lecular targeted therapeutics for cancer treatment. At present, the most promising therapy for non-
small-cell lung cancer (NSCLC) is provided by antivascular or antiangiogenic agents, which target the 
tumor vascular system. In tumor size and the associated standard size–based approach for monitoring 
response (Response Evaluation Criteria in Solid Tumors) [1], the effects of antivascular or antiangio-
genic agents are not as dramatic as those with classic chemotherapeutics, because antiangiogenic 
agents often result in consolidation rather than regression of the tumor mass. Because the effect 
of these agents is not major cell kill, 18F-FDG might not be the ideal tracer for monitoring treatment 
response with PET. H2
15O, on the other hand, offers the opportunity to measure tumor perfusion, re-
flecting vascular status. This method, by allowing for monitoring of the direct target of antiangiogenic 
drugs, may be superior to indirect measures such as tumor size. Early reports (phase I and phase II 
trials) have supported this hypothesis [2–4]. Another advantage of H2
15O is the short half-life of 15O (2 
min), which allows for serial measurements within a single scan session, enabling the evaluation not 
only of long-term effects but also of immediate effects of an intervention. 
To interpret the effects of treatment, however, test–retest variability needs to be known. Although it 
has been determined for H2
15O studies of cerebral and myocardial blood flow [5–7], only little infor-
mation is available for tumor perfusion studies, in which flow might be much more variable [8–10]. 
Therefore, the purpose of the present study was to assess the reproducibility of quantitative tumor 
blood flow measurements in patients with NSCLC using H2
15O and PET.
materials and methods
Eligible patients were prospectively included after informed consent was obtained in accordance with 
approval by the Medical Ethics Committee of VU University Medical Center. Nine patients with ad-
vanced-stage NSCLC were scanned twice within 7 d (mean, 2.4 d) and before any treatment, using an 
ECAT EXACT HR+ scanner (Siemens/CTI). This scanner has an axial field of view of 15 cm, divided into 
63 contiguous planes. On the basis of prior CT data, the patient was positioned supine on the scanner 
bed with the tumor in the center of the axial field of view. All patients received a venous catheter for 
radiotracer injection. Acquisition started with a 10- to 15-min transmission scan to correct for photon 
attenuation [11]. Next, a bolus injection of 1,100 MBq of H2
15O was administered through an injector 
(Medrad International) at 0.8 mL/s, after which the line was flushed with 42 mL of saline (2.0 mL/s). Si-
multaneous with the injection of H2
15O, a dynamic emission scan (in 2-dimensional acquisition mode) 
was started, which lasted 10 min and had variable frame lengths (12 x 5 s, 12 x 10 s, 6 x 20 s, and 10 
x 30 s). After an interval of 10 min to allow for the decay of 15O, a bolus of 370 MBq of 18F-FLT in 5 mL 
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of saline was injected through the same injector at the same speed and with the same flushing proto-
col. Simultaneous with the injection of 18F-FLT, a dynamic emission scan (in 2-dimensional acquisition 
mode) was started. It had a total duration of 60 min and variable frame lengths (6 x 5 s, 6 x 10 s, 3 x 
20 s, 5 x 30 s, 5 x 60 s, 8 x 150 s, and 6 x 300 s). All dynamic scan data were normalized; corrected for 
dead time, decay, scatter, randoms, and photon attenuation; and reconstructed as 128 x 128 matrices 
using filtered backprojection (FBP) with a Hanning filter (cutoff, 0.5 cycle per pixel). This resulted in a 
transaxial spatial resolution of around 7 mm in full width at half maximum.
Image analysis
Volumes of interest (VOIs) were defined separately for each scan using a semiautomatic threshold 
technique (41% of the maximum pixel value with correction for local background) for any lesion with 
adequate focal uptake [12]. VOIs were defined on 18F-FLT images because of their superior contrast 
between tumor and background. To assess whether VOIs could be defined without the use of an 
additional scan, VOIs were also defined on parametric flow images, which were generated using a 
basis-function approach [13]. For 18F-FLT, the last 3 frames of the 18F-FLT sinograms (45–60 min after 
injection) were summed and reconstructed using ordered-subset expectation maximization with 2 
iterations and 16 subsets followed by postsmoothing of the reconstructed image using a gaussian 
filter of 5 mm in full width at half maximum to obtain the same resolution as the one obtained for the 
FBP images. For H2
15O, parametric images were constructed by the use of basis functions (Appendix, 
Eq. 4A). Delineation of lesions with limited tumor-to-background contrast (due to low focal uptake or 
high background activity) is difficult and hampered by observer variation. Therefore, only lesions that 
required minor or no manual delineation were included. In the latter case, background values were 
set to zero for voxels adjacent to the VOI that had physiologically high 18F-FLT uptake (hematopoietic 
bone marrow, liver tissue, and hypervascular areas such as the mediastinum) to prevent inclusion of 
such voxels in the VOI. For VOIs defined on parametric flow images, the same procedure was followed 
for adjacent hypervascular or well-perfused areas. After this procedure, the threshold technique was 
applied, resulting in volumes specifically containing tumor. Tumor VOIs were transferred to FBP-recon-
structed dynamic H2
15O images for generating time–activity curves. An image-derived input function 
(IDIF) was obtained by manually drawing multiple 2-dimensional regions of interest over the aortic 
arch using FBP data [14, 15]. Regions of interest were drawn in the appropriate frame with optimal 
aorta-to-background contrast (first pass of H2
15O bolus) and were then applied to all frames to gener-
ate input time–activity curves. The 18F-FLT scans were obtained to allow for adequate VOI definition. 
The focus of the present study was, however, on the reproducibility of perfusion measurements, and 
therefore, 18F-FLT results will be reported elsewhere.
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Data analysis
Tumor perfusion and volume of distribution (VT) were estimated by fitting tumor time–activity curves 
using standard nonlinear regression techniques and a single-tissue-compartment model together with 
an IDIF and weighting data for acquired counts and frame duration [16]. Both a model with and a 
model without inclusion of an arterial blood volume component (V
A
) were explored. Model equations 
are provided in the Appendix. The presence of V
A
, and the need to include this in the compartment 
model, were assessed by comparing the residual sum of the squares of fits with and without V
A
, using 
Akaike and Schwarz criteria [17–19]. 
If the SE of either fitted perfusion or V
A
 exceeded 25%, the lesion was excluded from further analysis. 
The level of agreement between test and retest values was assessed using the intraclass correlation 
coefficient (ICC) with a 2-way random model with absolute agreement and Bland–Altman analysis 
[20]. In the latter case, the percentage difference (Δ) values between 2 measures was plotted against 
the mean of both measures and the mean threshold-defined volume. In this way, possible dependency 
on both absolute values and tumor size could be visualized. Statistical dependency was analyzed using 
linear regression. Finally, a 1-sample t test was applied to the Δ values to assess systematic bias.
results
All primary lesions and more than 90% of all clinically suspected locoregional metastases could be delineated, 
including mediastinal lymph nodes, using 18F-FLT images for VOI definition. In total, 14 lesions in 9 patients 
were analyzed. One hilar lymph node of 1.8 cm3 was excluded from analysis because of an SE of greater than 
25% (49%) of the estimated perfusion value in 1 of the 2 scans, possibly due to patient movement. 
Only 8 lesions in 8 patients could be defined using VOIs defined on parametric flow images, as a result 
of less contrast. In addition, for this limited number of lesions, reproducibility of perfusion for these 
VOIs was significantly poorer than that for corresponding VOIs defined on 18F-FLT images (data not 
shown). Consequently, in the remainder only results for 18F-FLT–defined VOIs are shown. 
Individual data are presented in Table 1. Median lesion size (threshold volume as defined on the 18F-
FLT images) was 12.9 cm3 (range, 2.0–89.8 cm3), median perfusion was 0.43 mL x min-1 x g-1 (range, 
0.28–0.75 mL x min-1 x g-1), and median VT was 0.79 (range, 0.59–1.13). The single-tissue-compartment 
model including V
A
 provided better fits than did the model without V
A
 in 22 (79%) and 25 (89%) of 28 
lesions, respectively, according to Akaike and Schwarz criteria. Therefore, all analyses were performed 
for data obtained with the model including an arterial blood component. 
Perfusion showed excellent reproducibility, with an ICC of 0.95 (95% confidence interval, 0.86–0.99) 
and SD of 9% for percentage and 0.037 for absolute change. The VT was moderately reproducible, with 
an ICC of 0.52 (95% confidence interval, -0.21 to 0.82) and SD of 16% for percentage and 0.136 for 
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absolute change. These data show that a change of less than 18% in tumor perfusion and 32% in VT 
(< 1.96 x SD) is likely to be due to test–retest variability. 
Both visual assessment of Bland–Altman plots and linear regression analysis showed no dependency 
on the absolute level of perfusion (p = 0.14) and VT (p = 0.15) or on tumor volume as measured with 
PET (perfusion, p = 0.46; VT, p = 0.25) (Figure 1). In addition, no evidence of systematic bias was found 
(p > 0.80 for both). Finally, variability in 18F-FLT–defined VOI size had no significant effect on the repro-
ducibility of perfusion (p = 0.39) or VT (p = 0.16).
discussion
The main finding of the present study is that in patients with NSCLC, tumor blood flow can be mea-
sured reproducibly using H2
15O and PET. When patients are followed over time, a change of more than 
18% in tumor perfusion and more than 32% in VT is likely to represent a biologic effect. No significant 
dependency on absolute values or lesion size was found, which implies that the same threshold can be 
used for all tumor lesions. Only 1 (small) lesion was excluded because of an SE of more than 25% for 
the estimated perfusion value. Because this was the case in only 1 of the 2 scans, patient movement 
seems to be the most likely cause. 
There have been several reports on the reproducibility of H2
15O PET measurements in brain [5, 6] 
and myocardium [7] and some in other nontumor tissues [21, 22]. Although studies show excellent 
reproducibility, these results cannot easily be translated to an oncologic setting because of differences 
table 1. Absolute values of VOI size, perfusion, volume of distribution of water (VT) and arterial blood 
volume fraction (V
A
) for both test and retest scans of all patients.
patient      lesion              voI (cm3) perfusion vt va voI (cm
3) perfusion vt va
1 Primary
Naruke 5
13.1
10.9
0.28
0.28
0.62
0.70
0.06
0.12
14.0
13.6
0.37
0.32
0.59
0.69
0.04
0.11
2 Primary
Naruke 4
12.6
10.0
0.39
0.51
0.95
0.93
0.08
0.16
31.1
11.3
0.38
0.56
0.70
0.81
0.05
0.11
3 Primary  5.9 0.55 0.75 0.10  9.6 0.57 0.66 0.08
4 Primary 29.8 0.63 0.79 0.03 30.6 0.69 0.85 0.07
5 Primary 31.5 0.41 0.98 0.15 42.3 0.37 0.86 0.09
6 Primary
Naruke 4
Naruke 7
6.6
47.0
8.2
0.42
0.42
0.56
0.69
0.76
0.66
0.08
0.07
0.08
 9.1
53.8
  8.1
0.38
0.41
0.49
0.60
0.80
0.86
0.00
0.13
0.01
7 Naruke 7
Naruke 5
3.4
2.0
0.47
0.46
0.90
0.65
0.03
0.18
 3.0
 2.0
0.43
0.45
1.13
0.78
0.11
0.25
8 Primary 82.4 0.41 0.89 0.03 89.8 0.38 0.90 0.03
9 Mediastinal 
mass
58.0 0.74 0.85 0.12 53.5 0.75 0.99 0.08
 Naruke numbers are based on the mediastinal lymph node classification, as described by Naruke et al [32].
test     Retest
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in VOI definition, tissue characteristics, and perhaps most important, heterogeneity, which can be 
substantial in tumors. The latter can cause underestimation of perfusion measurements [23], which 
in turn might result in decreased reproducibility. Two 15O inhalation PET studies have been performed 
to explore reproducibility of perfusion measurements in a limited range of tumors (mainly hepatic le-
sions) within a small number of patients [8, 9]. The dual hepatic blood supply (portal vein and hepatic 
artery) complicates quantification of perfusion in the liver [24]. Consequently, it is difficult to compare 
blood flow measurements in hepatic lesions with those in tumors of other origin. Wells et al [8] ana-
lyzed 7 lesions (6 liver, 1 lung) in 5 patients and found ICCs and SDs of 0.89 and 29% for perfusion and 
0.96 and 12% for VT, respectively. Wilson et al [9] reported on 5 breast tumors in 5 patients and found 
differences of up to ± 10% for perfusion measurements. The relatively low reproducibility of perfusion 
measurements in the study by Wells et al [8] might be because of an inadequate definition of the input 
function, caused by either the dual hepatic input or delay and dispersion of the measured input func-
tion (arterial blood sampling). In contrast to IDIF, arterial blood sampling requires corrections for delay 
and dispersion [9, 25], and this could have affected accuracy [26]. On the other hand, reproducibility of 
VT was excellent, a finding that could not be reproduced in the present study. This might be due to the 
relatively high amount of noise in the tail of IDIF curves as compared with the much smoother input 
curves derived from arterial blood sampling (Figure 2).
Figure 1. Bland–Altman plots for tumor perfusion and VT. Delta is percentage change between test 
and retest scans. Mean VOI size is mean tumor volume of test and retest scans in cubic centimeters. 
Straight lines represent mean values and dotted lines ± 1.96 x SD values.
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Definition of tumor VOI is difficult for H2
15O studies because of low tumor-to-background contrast. 
Many methods have been proposed for VOI definition, including the use of CT [27], H2
15O itself [9], 
18F-FDG [19, 28, 29], or a combination of anatomic (CT or PET transmission) and functional (H2
15O) im-
ages [3, 8, 30] (Figure 3). 
It is likely that the lack of H2
15O test–retest and response monitoring studies is partly because of the 
VOI definition problem. In the present study a threshold technique was applied to a subsequent 18F-
FLT scan. A lower limit of 41% of the maximum pixel value was chosen, because this best reflects true 
tumor volume [12]. That definition of VOI was not restricted to 18F-FLT–abundant voxels within the tu-
mor regions. This could have led to bias, because the relationship between perfusion and proliferation 
in tumors is not known. As a result of the use of a separate 18F-FLT scan for VOI definition, total scan 
duration was 90 min. The addition of an 18F-FLT scan to the acquisition protocol also led to an increase 
in radiation load. The total amount per patient in this study was approximately 20 mSv. Although all 
patients had advanced-stage disease with a limited estimated life expectancy of 8–10 mo [31], limi-
tation of radiation load would become important when patients with early-stage disease are being 
scanned or when better treatment becomes available for those with advanced-stage disease. 
If VOIs could be defined without the use of an 18F-FLT scan, total scan time could be reduced to about 
20 min and radiation dose to approximately 2.5 mSv. Therefore, an additional analysis was performed, 
defining VOIs on parametric flow images. Parametric images rather than summed H2
15O images were 
used, because the latter suffer from contamination of (high) intraarterial signals. Nevertheless, be-
cause of perfusion of the surrounding tissue, 6 of 14 lesions could not be defined using these para-
metric images. In addition, reproducibility was inferior to that for 18F-FLT–defined VOIs (test–retest 
variability 15% for parametric VOIs, compared with 9% for 18F-FLT–defined VOIs). Consequently, this 
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Figure 2. Time–activity curves of arterial input function for 2 different patients demonstrated by IDIF 
(A) and arterial blood sampling (B). IDIF peak is sharper, because it does not suffer from dispersion. 
On the other hand, tail is noisier because of poorer count statistics.
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approach does not seem to be a viable option for routine response-monitoring studies. The use of a 
separate CT scan for VOI definition was not attempted, as even a small misalignment between CT and 
PET scans could result in erroneous flow values, especially for smaller lesions. 
With the introduction of integrated PET-CT, however, it is likely that the CT scan can be used for VOI 
definition, making the additional 18F-FLT scan (or that of another tissue-accumulating tracer) obsolete. 
This would reduce scan time to less than 15 min. radiation dose of H2
15O PET-CT studies would primar-
ily be determined by the CT scan protocol (amount of milliamperes applied and body parts scanned), 
because H2
15O studies themselves only account for a small dose because of the short half-life of 15O. 
Nevertheless, further studies using a PET-CT scanner are required to assess reproducibility for CT-
defined VOI. 
Another reason for the limited number of oncologic H2
15O studies might be the relatively limited avail-
ability of on-site cyclotrons, which are needed because of the short half-life of 15O (2 min). However, 
when both PET-CT and an on-site cyclotron are available, perfusion studies can be performed with 
relative ease for both patient and physician. The production of H2
15O requires minimal staff, scan time 
is short, and, at least for patients with NSCLC, there is no need for arterial cannulation. In addition, the 
present results indicate that tumor perfusion measurements are reproducible.
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Figure 3. CT (A), 18F-FDG PET emission (B), PET transmission (C), and H2
15O PET emission (1–4 min after 
injection) (D) images that can be used for VOI definition. All images are from same patient.
!" #"
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conclusion
With the increasing use of antiangiogenic drugs and other targeted agents, suitable biomarkers are 
desired to evaluate response to such treatment. Biologic imaging offers the unique opportunity to 
noninvasively monitor treatment effects, irrespective of size changes. In this study we have shown that 
tumor perfusion measurements are reproducible in patients with NSCLC using H2
15O PET and an IDIF. 
Our data suggest that future intervention studies should apply a 20% cutoff value to define response 
to treatment.
appendiX
modeling perfusion Data. 
For the present study, perfusion measurements were based on the original tracer kinetic model pro-
posed by Kety [33], using the implementation presented by Hoekstra et al [16]. In brief, in a dynamic 
scan, dCT(t)/dt (the change in tissue concentration) of a tracer at a certain time point is equal to K1 
(the plasma-to-tissue transport rate constant) multiplied by C
P
(t) (the tracer concentration in plasma) 
minus k2 (the tissue-to-plasma rate constant) multiplied by the tracer concentration in tissue (CT) at 
that time point:
        Eq. 1A
Because water is freely diffusible (i.e. extraction is 100%), K1 is equal to perfusion (F). In addition, 
in case of blood flow, the delivery is not determined by the plasma concentration but rather by the 
whole-blood concentration, CB. Thus, for H2
15O, Equation 1A can be rewritten as:
         Eq. 2A
The solution of this equation, including a fractional arterial blood volume (V
A
), is:
         Eq. 3A
A nonlinear, least-squares fit of this function to the measured time–activity curve in the tissue of in-
terest (CT(t)) yields perfusion and VT [9]. If VA is negligible, it can be set to zero before fitting, thereby 
increasing precision of perfusion and VT estimates. 
!
!
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parametric Images. 
Parametric images can be obtained using a basis-function implementation of the same single-tissue-
compartment model:
        Eq. 4A
In this approach, first a set of basis functions exp(_ßit)     CB(t) is created by convolution of the whole-
blood input function with a set of single exponential functions. In the present study, a set of exponen-
tial constants, ßi, was used, ranging from 0.01 to 1 min-1. Next, for each basis function all voxels were 
fitted to Equation 4A using simple linear regression. Finally, for each voxel, the linear fit (i.e. basis 
function) was selected that provided the best fit. Because parametric images were generated only for 
VOI definition, in the present study VT was fixed to 0.75 to reduce noise [13, 19, 21].
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aBstract
purpose  
Positron emission tomography with the glucose analogue 18F-fluorodeoxyglucose (18F-FDG PET) is in-
creasingly used to monitor tumor response to therapy. In order to use quantitative measurements of 
tumor 18F-FDG uptake for assessment of tumor response, the repeatability of this quantitative meta-
bolic imaging method needs to be established. Therefore we determined the repeatability of different 
SUV measurements based on the available data.
methods
A systematic literature search was performed to identify studies addressing 18F-FDG repeatability in 
malignant tumors. The level of agreement between test and retest values of two PET uptake mea-
sures, SUV
max
 and SUV
mean
, was assessed with the coefficient of repeatability using generalized linear 
mixed effects models. In addition the influence of tumor volume on repeatability was assessed. Prin-
cipal component transformation was used to compare the reproducibility of the two different uptake 
measures. 
Results
Five cohorts were identified for this meta-analysis. For SUV
max
 and SUV
mean
, datasets of 86 and 102 pa-
tients were available, respectively. Percentage repeatability is a function of the level of uptake. SUV
mean
 
had the best repeatability characteristics; for serial PET scans, a threshold of a combination of 20% 
as well as 1.2 SUV
mean
 units was most appropriate. After adjusting for uptake rate, tumor volume had 
minimal influence on repeatability. 
Conclusion
SUV
mean
 had better repeatability performance than SUV
max
. Both measures showed poor repeatability 
for lesions with low 18F-FDG uptake. We recommend to evaluate biological effects in PET imaging by re-
porting a combination of minimal relative and absolute changes to account for test-retest variability. 
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introduction
18F-FDG PET has gained an important role in the clinical setting to detect and stage malignancies and 
assess treatment response [1-6]. In the research setting, PET is increasingly being used to study early 
changes of biological effects during and after anticancer treatment [7-10]. The non-invasive nature 
of PET allows multiple serial measurements without interfering with biological processes within the 
tumor and might obviate more invasive procedures, like biopsy. 
Even though PET clinical practice is still dominated by qualitative (visual) image analysis, several po-
tential indications require quantification, e.g.  when prognostic and predictive information is required 
beyond the level of TNM staging. A decrease of 18F-FDG uptake after therapy is associated with favor-
able clinical outcome [1-6, 11] However, to date only qualitative, and not quantitative, PET measures 
have been incorporated in response classification systems for solid tumors and lymphoma [12, 13].
The European Organization for Research and Treatment of Cancer (EORTC) PET study group published 
recommendations, as far back as 1999, for response monitoring using quantitative PET data to pro-
mote consistency in the reporting of studies [14]. The proposed system was based on the results of 
both drug evaluation and a few repeatability studies. 
To discriminate true signal change from noise and to be able to stratify patients based on changes in 
18F-FDG uptake values, the repeatability of the measurement and the error of the determination need 
to be known. The present meta-analysis intends to determine the repeatability of different SUV mea-
surements based on the available data and to evaluate potential sources of heterogeneity.  
 
materials and methods
Study Design
We performed a systematic literature search of Medline and Embase databases to identify studies 
addressing 18F-FDG repeatability in malignant tumors by using the following search terms: positron 
emission tomography, FDG, repeatability and test-retest. Additionally, extensive cross-referencing was 
done, review articles were screened, and experts in the field were consulted. Studies were included 
when the following criteria were met: 1) assessment of repeatability with 18F-FDG PET in malignant tu-
mors; 2) use of standardized uptake values (SUV); 3) uniform acquisition and reconstruction protocols; 
4) application of the same scanner for the test and retest scan for each patient (i.e. no within patient 
scanner variation). 
For dynamic studies, SUVs were calculated using the last frame of the dynamic acquisition. Because 
the method of tumor delineation (e.g. maximum pixel value, or threshold based or fixed diameter 
volume of interest [VOI]) can affect 18F-FDG uptake measures, we attempted to obtain uniformly de-
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fined tumor volumes between studies for each uptake measure. This volume was defined by a 3-di-
mensional threshold based volume (isocontour defined, with a cutoff of 50% of the maximum 18F-FDG 
concentration within the tumor). If we were unable to extract the required data from the original 
publications, authors were asked to provide it or to reanalyse their data with the isocontour technique 
(using in-house developed software provided by us).
Statistical analysis
For both PET uptake measures, SUV
max
 and SUV
mean
, the level of agreement between test and retest 
measurements was assessed using the intraclass correlation coefficient (ICC) calculated using a ran-
dom-effects model with random intercepts for published study, patient and tumor location. Kruskal-
Wallis tests were applied to the uptake measures to assess systematic bias between studies. One 
sample Anderson-Darling tests were used to assess the distribution of the means of the test and retest 
observations. 
variance-mean and variance-volume Relations
To assess repeatability we determined the relation between the mean and variance of the test and 
retest scans, where the variance in the test-retest measurements is assumed solely due to measure-
ment error. To account for differences in this relation between published studies we assessed this 
association using generalized linear mixed effects models (with published study as a random factor) 
and generalized linear models (with published study as a fixed effect). The outcome variable was the 
square of the difference in test-retest measurements with the log transformed test-retest mean as a 
fixed effect. Given the assumption of normality, the square of the difference is chi-square distributed, 
and therefore Gamma error distributions were employed [15]. The log-link function was used to relate 
the estimated variance to the test-retest mean resulting in an allometric mean-variance relation. Dif-
ferences between published studies were assessed using the generalized linear models with published 
study as a fixed effect. The influence of tumor volume on 18F-FDG uptake test-retest repeatability was 
assessed by including the log transformed tumor volumes as fixed effects. To avoid extrapolation, we 
limited the estimated variance-mean associations to values between the 5th smallest and 5th largest 
observed PET measurements values. 
Coefficient of 95% Repeatability
Once the variance-mean relation had been estimated, the relation between the Coefficient of 95% 
Repeatability (CR95) and the mean was calculated as 1.96 times the standard deviation [16, 17]. The 
CR95 is the variation solely due to measurement error. If the difference of two measurements exceeds 
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the CR95, then this difference is 95% likely to be due to a true change in tumor 18F-FDG uptake rate 
and not measurement error. 
Single pet observations
The test-retest CR95 corresponds to a two observation setting, such as serial baseline and post-treat-
ment assessments. In some clinical trials however, a single PET scan result is used, e.g. for patient 
stratification during randomization. The equivalent single observation CR95 can be calculated by divid-
ing the test-retest CR95 by √2 (i.e. half the variance), with the assumption that all measurements are 
performed on the same PET scanner using the same acquisition and reconstruction protocols.
 
Comparison of the Different Quantitative 18F-FDg measures
To compare the repeatability of the two 18F-FDG uptake measurements, a principal component analysis 
was performed using data from the four studies which analysed both PET measures. This resulted in a 
transformation of each of the measures onto the first principal component, and thus allowing their CR95s 
to be compared on the same scale. The significance level of all tests was set at 0.05. The generalized lin-
ear mixed effects models were fitted using the GLIMMIX procedure in SAS (SAS Institute Inc., Cary, NC, 
USA). All other analyses were performed in R v2.9.2 (The R Foundation for Statistical Computing, 2009). 
 
results
Eight repeatability studies were identified [16, 18-24]. One study was excluded due to the use of differ-
ent scanners for the test and retest scan [24]. All authors were contacted to provide patient based data 
on tumor volume, location, and 18F-FDG uptake. The study characteristics are summarized in Table 1. 
Extended analyses of two cohorts were published separately from the original ones; Minn et al [20] 
and Nakamoto et al [22]; Hoekstra et al [18] and Krak et al [19]. Thus, five cohorts were available for 
this meta-analysis. All repeat scans were performed using the same scanner as previously for each 
patient. Three studies used a dynamic scan protocol [16, 18, 20], while the remaining two applied a 
static protocol [21, 23]. All but one [23] were single center studies. Tumor types were gastro-intestinal 
[23], lung [18, 20], and miscellaneous primary, predominantly located in the chest [16, 21]. Two stud-
ies [21, 23] used integrated PET-CT scanners, the others a PET only system. Nahmias et al [21] applied 
a 90 min. time interval between radiotracer injection and scanning, while all other studies applied a 60 
min. time interval. The multicenter study by Velasquez et al [23] reported on two datasets, one before 
and one after quality assurance assessment. The latter dataset was used for the present study. Finally, 
Minn et al [20] excluded lesions with a diameter lower than 2 cm, while the other studies had no clear 
restrictions regarding lesion size.
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Repeatability of Standardized uptake values
SUV
max
. The four available datasets for SUV
max
 [18, 20, 21, 23] included 163 tumor lesions in 86 pa-
tients. The ICC of SUV
max
 was 0.90. The goodness-of-fit tests for normality indicated that SUV
max
 on the 
original scale was significantly different from normal (p < 0.0001). After log-transformation the distri-
bution was normalized (p = 0.37). Figure 1A presents the overall and study-specific relations between 
the mean and the standard deviation (i.e. variance) of the test and retest scans. The difference in 
table 1. Individual study characteristics.
Hoekstra minn nahmias
(50%-iso-
contour)
nahmias
(manual)
velasquez Weber
Patients N 10 10 21 21 45 16
Tumors N 27 10 21 21 105 50
Tumors per patient Median (range) 2 (1 - 7) 1 (1 - 1) 1 (1 - 1) 1 (1 - 1) 3 (1 - 4) 2.5 (1 - 8)
Time* Minutes 60 60 90 90 60 70
Bed position time Minutes Dynamic scan Dynamic scan 3 3 Not available Dynamic scan
Time (days)† Mean (max) 1 (1) 1.8 (7) 2.8 (5) 2.8 (5) 4.1 (7) 3 (10)
Scanner (patients) PET alone 
PET-CT
10
0
10
0
0
2
0
2
7
45
16
3
Location (patients) Thoracical
Abdominal
10
0
10
0
19
2
19
2
0
45
13
3
Tumor volume (cm3) Median 
(range) 
6.2
(0.7 - 111.4)
42.6
(18.6 – 231.0)
4.9 
(1.0 - 79.4)
4.9  
(1.0 - 79.4)
6.4 
(0.4 - 491.4)
5.1
(0.6 - 86.9)
Threshold technique 4x4 voxels around 
the max voxel
50% of the max voxel 
70% of the max voxel 
Manual delineation
X
X
X
X
X
X
SUV
mean
‡
Median 
(range)
5.5
(2.3 - 11.3)
8.1 
(3.9 - 16.4)
6.6
(2.6 - 17.3)
5.1
(1.6 - 17.4)
6.8 
(2.5 - 24.4)
4.5
(1.3 - 10.5)
SUV
max
§
Median 
(range)
8.3 
(3.8 - 18.5)
9.2 
(4.6 - 19.5)
10 
(4.1 - 24.1)
8.9 
(4.0 - 23.8)
7.3
(2.5 - 29.7)
  * Time between 18F-FDG injection and the start of the scan for static scans and total scan time for dynamic scans.
  † Time between the test and retest scan.
  ‡ SUV
mean
 values were lower in the Weber study than in the other four studies (p = 0.0006).
  § SUV
max
 values were lower in the Velasquez study than in the other three studies (p = 0.04). 
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test-retest  variability between studies was not significant (p = 0.25). Test-retest variability in absolute 
terms increases with higher SUV
max
 values (Figures 1A and 1B), while the percentage change decreases 
with higher SUV
max
 values (Figure 1C). As a consequence, it is not possible to generate just one value 
that defines the limits of test-retest variability for the full range of SUV
max
 values. However, this can 
be accounted for by combining an absolute and a percentage change of SUV
max
. From Figure 1C these 
Figure 1. SUV
max
 repeatability. (A) The estimated study-specific standard deviations (coloured dashed 
lines; study as a fixed effect) and the overall standard deviation (black solid line; study as a random 
effect). (B) The test and retest scan values plotted on the original scale. The solid line is the coefficient 
of repeatability (CR95). (C) The relation between the CR95, as percentage change, with the level of 
SUV
max
. The dotted lines indicate the absolute and relative differences, as presented in Table 2.
●
●
●
●●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
● ●
●
●
● ●
●●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
1.0 1.5 2.0 2.5 3.0
−4
−2
0
2
4
Log mean
Te
st
−r
et
es
t s
ca
n
A
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
5 10 15 20
5
10
15
20
Test scan
R
et
es
t s
ca
n
B
●
●
●
●
Hoekstra
Minn
Nahmias (manual)
Velasquez
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
5 10 15 20
0
10
20
30
40
Mean
%
 c
ha
ng
e
C
69
values can be extracted. The required absolute difference is calculated as the relative difference mul-
tiplied by the mean value where the CR95 curve crosses the relative difference value. For SUV
max
, the 
30% relative difference crosses the CR95 at a SUV
max
 value of 6.7. Thus the combination of an absolute 
change in SUV
max
 of more than 2 units (0.3 x 6.7) and a relative change of more than 30% is more than 
95% likely to be true change rather than measurement error for all SUV
max
 values that were encoun-
tered in this study. From the same figure it can be calculated that a change of more than 3.1 units and 
25% relative change also exceeds 95% test-retest variability. The combinations of the required minimal 
absolute and percentage changes that are needed to exceed 95% test-retest variability for the SUV 
parameters are presented in Table 2. 
SUV
mean
. The five available datasets for SUV
mean
 [16, 18, 20, 21, 23] included 213 tumor lesions in 102 
patients. The tumor delineation methods differed between the five available studies. Hoekstra et al [18] 
and Weber et al [16] delineated isocontour defined volumes with a 50% threshold of the maximum vox-
el value. Nahmias et al [21] originally published manually defined volumes, but reanalysed their data on 
our request with the 50% isocontour technique. Velasquez et al [23] used a 70% threshold technique be-
cause it was not possible to define 50% volumes without contaminating the tumor VOI with background 
tissue (due to 18F-FDG uptake heterogeneity and a relatively low tumor-to-background contrast). Minn 
et al [20] delineated tumor volumes as 4x4 voxels around the voxel with maximum 18F-FDG uptake. 
                                                                       Relative difference                       absolute difference
SUV
max
- -
25% 3.1
30% 2.0
SUV
mean
 H, N, M, W, V 20% 1.17
25% 0.96
30% 0.75
SUV
mean
 H, N†, W 20% 0.96
25% 0.78
30% 0.66
  * Thresholds can be extracted from Figures 1-3 as explained for SUV
max
 in the text.
  Differences have to exceed both the relative and absolute thresholds.
  H = Hoekstra et al, N = Nahmias et al manual analysis, N† = Nahmias et al 50% isocontour analysis, M = Minn et al,                             
  V = Velasquez et al, W = Weber et al.
 
table 2.  Required relative and absolute differences to exceed test-retest variability.*
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The ICC of SUV
mean
 was 0.91. The goodness-of-fit tests for normality indicated that SUV
mean
 on the 
original scale was significantly different from normal (p = 0.002). After log-transformation this was 
normalized (p = 0.77). 
Figure 2A presents the overall and study-specific relations between the mean and the standard devia-
tion (i.e. variance) of the test and retest scans. These associations differed significantly across studies 
(p < 0.0001), with the greatest variance observed in the study of Velasquez et al [23] and the lowest in 
the study of Nahmias et al [21] (manual VOI delineation). When only studies applying the 50% isocon-
tour technique were included (Hoekstra et al [18], Weber et al [16], 50% isocontour data of Nahmias 
et al [21]), no difference in test-retest variability was apparent between studies (p = 0.13; Figure 3). 
Figure 2. Same as in Figure 1 for SUV
mean
 measurements.
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
● ● ●
●
●
0.5 1.0 1.5 2.0 2.5 3.0
−4
−2
0
2
4
Log mean
Te
st
−r
et
es
t s
ca
n
A
●
●
●
●
● ●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
2 4 6 8 10 12 14 16
2
4
6
8
10
12
14
16
Test scan
R
et
es
t s
ca
n
B
●
●
●
●
●
Hoekstra
Minn
Nahmias (manual)
Velasquez
Weber
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
● ●
●
●●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●●
●
●
●
● ● ●
●
●
2 4 6 8 10 12 14 16
0
10
20
30
40
Mean
%
 c
ha
ng
e
C
71
In the dataset of Nahmias et al [21], the manual delineation method performed better in terms of 
repeatability than the automated one (p = 0.0001).
Figure 2 for SUV
mean
 shows the same trend as was observed for SUV
max
. The absolute change in test-re-
test variability increases with higher SUV
mean
 values (Figures 2A and 2B), while the percentage change 
decreases with higher SUV
mean
 values (Figure 2C). As a consequence, a combination of an absolute 
and a percentage change is necessary to cover the limits of test-retest variability for the full range of 
SUV
mean
 values. From Figure 2 it can be extracted that the combined change in SUV
mean
 of more than 1.2 
units and 20% exceeds 95% test-retest variability for all SUV
mean
 values that were encountered in this 
study, irrespective of the tumor delineation method (values are presented in Table 2). Homogeneous 
tumor delineation (50% threshold technique) resulted in lower test-retest variability (Figure 3, Table 2). 
 
Figure 3. Same as in Figure 1 for the three studies with SUV
mean
 measurements assessed using 50%-
isocontouring.
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We found no statistically significant difference between studies using static (Nahmias et al [21] and Ve-
lasquez et al [23]) as compared with dynamic PET techniques (Hoekstra et al [18], Minn et al [20] and 
Weber et al [16]) (p = 0.90). The principal component analysis indicated that the test-retest variability 
of SUV
max
 is larger than that of the SUV
mean
 (Figures S1 and S2).  
Single assessment Setting
By definition the CR95 for one observation is smaller than the equivalent two observation value due to 
fewer sources of measurement error. The single assessment CR95s were within 25% change for SUV
max 
and within 20% for SUV
mean
 (Table S1, Figure S2). 
Impact of tumor volume on Repeatability
Tumor volume was moderately correlated with the 18F-FDG uptake level (Table 3, Figure S3A). Howev-
er, uptake level was a better indicator for changes in test-retest variability than tumor volume for both 
parameters (Table 3). Repeatability of SUV
mean
 seems to be relatively unaffected by tumor volume, 
irrespective of the delineation method (Table 3, Figure S3B).  
discussion
This meta-analysis summarizes the published evidence on the repeatability of commonly used quan-
titative 18F-FDG measurements in oncology. Our results apply to the use of PET in serial as well as in 
single assessment settings. Compared to SUV
max
, SUV
mean
 had the better repeatability. 
For both measures, the percentage change in test-retest variability is not constant across the range of 
parameter values and negatively related to the level of 18F-FDG uptake. In a clinical setting, combin-
ing a minimal relative and absolute change is sufficient to define a (biological) effect that cannot be 
explained by measurement error only (see Table 2 for thresholds). In the context of analysing serial 
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table 3. Correlations between 18F-FDG uptake and tumor volume and their influence on test-retest variability.
                                                             
  
Correlations
                              Studies Uptake vs. 
Vol
Uptake        
(alone)
Uptake   
(adj. vol)
Vol    
(alone)
 Vol        
(adj. mean)
SUV
max
H, M, N, V 0.38 < 0.0001 < 0.0001 0.03 0.26
SUV
mean
H, M, N, W, V 0.39 < 0.0001 < 0.0001 0.03 0.71
SUV
mean
H, N*, W 0.45 0.002 0.003 0.32 0.78
  H = Hoekstra et al, N = Nahmias et al (manual analysis), N* = Nahmias et al (50% isocontour analysis), 
  M = Minn et al, V = Velasquez et al, W = Weber et al.
 
log likelihood ratio test p values
18F-FDG uptake changes, the PERCIST response classification system assumes a biological change with 
SUVpeak changes > 30% in combination with 0.8 unit change of absolute SUVpeak [25]. In the present 
meta-analysis, there was insufficient data to explore SUVpeak values. Numerical values of SUVpeak typi-
cally vary between SUV
max
 and SUV
mean
 (if VOI volumes of SUV
mean
 exceed the SUVpeak ones). Figure 4 
corroborates the PERCIST assumption of combining 30% with 0.8 unit SUVpeak (for SUVmean we found 
30% and 0.75). The same Figure shows that, when using SUV
mean
, a minimal relative change of 20% in 
combination with 1.2 unit change will also represent a biological change. 
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Figure 4. Same as Figure 3C, now presenting the cutoff rules at 20% and 30% relative change with 
associated absolute changes for the three studies with SUV
mean
 measurements assessed using 50%-iso-
contouring. The required absolute difference is calculated as the relative difference multiplied by the 
mean value where the CR95 curve crosses the relative difference value. For example, the CR95 equals 
30% at 2.2, hence the associated absolute difference is 0.66 (2.2 x 0.3). Therefore a change of at least 
30% and more than 0.66 units will be less than 5% likely to be due to measurement error in 18F-FDG 
uptake rate. The blue dashed lines represent the areas of combined coverage for each rule.
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The first combination is advantageous for tumors with low uptake values where small differences in 
absolute values correspond to large differences in percentage change. The latter combination is ad-
vantageous for high uptake values where relatively large differences in absolute values correspond to 
relatively small differences in percentage change.  It is probable that for tumors with extremely high 
uptake values, an even smaller relative-change threshold would be appropriate. We are unable to sug-
gest corresponding absolute change values as these uptake values are outside the range of our data.
Alternatively, to select lesions for evaluation with 18F-FDG PET, a minimal SUV could be applied (see 
figures for trade off values). This simplifies the situation by excluding low uptake values with large 
(relative change) test-retest variability, leaving the remaining values with a consistent relative test-
retest change that can be used as a (one-value) cutoff for response assessment. The disadvantage of 
this approach is that increases in 18F-FDG uptake (e.g. due to disease progression) can be measured 
reliably, but decreases to values below the threshold (e.g. due to treatment response) cannot. 
Even though methodologies were not fully consistent throughout the studies, we found no important 
interstudy differences in parameter repeatability. For SUV
max 
no difference was found at all, while for 
SUV
mean
 this was only present when all studies were included, irrespective of the delineation method 
used. This difference was caused by a lower performance of the Velasquez data, and good perfor-
mance of the manually delineated data of Nahmias et al. Velasquez et al [23] applied a multicenter de-
sign with a large number of centers. Also, the patient population was substantially different from that 
of the other studies, because only patients with advanced gastrointestinal malignancies were included 
by Velasquez et al whereas the other studies predominantly evaluated lung lesions (Table 1). Since the 
physiologic 18F-FDG uptake by the liver and gastrointestinal tract is higher and more variable than in 
the lung, this may have challenged tumor delineation. Furthermore, spillover of activity from normal 
organs with variable 18F-FDG uptake (e.g. kidneys, bowel loops) may have affected the test-retest vari-
ability. The authors reported that they were forced to apply a higher threshold of the maximum voxel 
value (70%) to enable tumor tissue discrimination from the normal background. Earlier work from 
our center showed that test-retest variability increases with higher thresholds of the maximum tumor 
volume [19]. Possibly these factors resulted in lower repeatability. 
Therefore we performed a subset analysis of homogeneously delineated lesions using the 50% isocon-
tour technique. This inherently excluded the data of Velasquez et al [23], resulting in interstudy homo-
geneity. Better repeatability was found for this subset as presented in Figure 3 and Table 2. Whether 
the worse repeatability in the overall dataset is due the delineation technique (70% threshold) or the 
location of the lesions (abdominal) remains elusive. Therefore the cutoff values found for the 50% 
threshold subset only hold for 50% isocontoured extra-abdominal lesions, while the overall results can 
be used for all organ sites and histology and irrespective of the SUV
mean
 tumor delineation method.
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Interestingly, the manually delineated data of Nahmias et al performed better than the threshold 
analysis of the same data set. This was also reported earlier by our group [19]. However, both studies 
were single-observer, while the strength of the semi-automated technique is the high intra- and inter-
observer repeatability for lesion delineation. Therefore, superiority can only be evaluated by perform-
ing a head-to-head analysis in a multi-observer setting.
In previous studies it was suggested that repeatability is a function of 18F-FDG uptake value and tumor 
volume. Weber et al [16] reported that the absolute difference between the test and retest values 
remains constant across the range of parameter value, but that the relative change increases with 
decreasing uptake value. Nahmias et al [21] also reported that the absolute difference of the mean up-
take value was constant across the range of SUV
mean
 with increasing relative change for lower SUV
mean
 
values. However, this group reported that for SUV
max
 the absolute difference increased with increasing 
SUV
max
 value, while the relative change remained constant. 
In the pooled dataset of the current study, mean uptake was a better indicator for changes in test-
retest variability than tumor volume (Table 3). SUV repeatability seems to be relatively unaffected by 
VOI size.
We observed a moderately positive correlation between the uptake value and tumor volume (Table 
3, Figure S3A). Hypothetically this can, at least in part, be explained by the “partial volume” phenom-
enon, which results in an underestimation of 18F-FDG uptake in smaller lesions, which in turn results in 
more difficult tumor delineation due to lower tumor-to-background contrast [26]. 
Our results apply to the setting where the same scanner is being used for both the baseline, as well 
as the post-treatment scan with the use of the same acquisition, reconstruction, and data processing 
and analytical protocol. These inclusion criteria were mandatory as variation in these parameters can 
result in parameter differences of up to 50%, only representing noise and not indicative of true biologi-
cal change [27, 28]. Although interstudy differences in image contrast and resolution remained, their 
effects on repeatability are negligible [29]. If this is also true for newer systems with better spatial 
resolution cannot be forecasted based on the current data.     
The study by Kamibayashi [24] was excluded because of the use of a different PET scanner for the test 
and retest scans. In this study, tumor SUV test-retest variability was evaluated in patients that were 
scanned once on a PET only scanner and once on a PET-CT scanner without treatment intervention 
between the two scans. The scanners were from the same vendor and the same acquisition and ana-
lytical protocol was used for both scans. The authors applied a manually drawn 2D ROI for tumor delin-
eation. The standard deviation was only slightly worse than that of the other singlecenter repeatability 
studies and comparable to the multicenter study of Velasquez et al [23] with a SD of 12 ± 10.2% for 
SUV
mean
 and 16.1 ± 10.5% for SUV
max
. This might indicate that different scanners can be used at baseline 
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and post-treatment, provided that standardisation of acquisition, reconstruction, data processing and 
analysis is applied. If this also holds for semi-automatic VOI definition and the use of PET scanners 
from different vendors remains to be further examined.
Although no statistical interstudy difference was present after pooling the data and correcting for VOI 
definition heterogeneity, the cutoff values for definition of test-retest variability should be assessed 
with care because some methodological and patient spectrum heterogeneity between studies pre-
vailed.  
However, we believe that this meta-analysis provides the most critical and robust view at 18F-FDG PET 
repeatability in the oncological setting to date. It enabled the evaluation of dependency on mean 
uptake value and tumor volume, issues that were open for discussion since the publication of Weber’s 
study in 1999 [16]. Ideally, these results should be confirmed prospectively, preferably in a large mul-
ticenter study. Possibly, studies such as the ACRIN (American College of Radiology Imaging Network) 
study 6678 - FDG-PET/CT as a predictive marker of tumor response and patient outcome: Prospective 
Validation  in Non-Small Cell  Lung Carcinoma  -, incorporating a test-retest study evaluating 18F-FDG 
PET-CT with a static protocol at 60 min. post-injection, can provide the opportunity for this.   
conclusion
This meta-analysis shows the repeatability of different 18F-FDG uptake measurements, based on the 
available data. SUV
mean
 performed better than SUV
max
. Importantly, both parameters showed worse 
repeatability for lesions with low 18F-FDG uptake. This can be accounted for by combining relative and 
absolute differences. For SUV
mean
 a 30% and 0.75 unit change or 20% and 1.2 unit change exceeds 95% 
test-retest variability. Homogeneous delineation and exclusion of abdominal lesions improved repeat-
ability. For SUV
max
 the equivalent values are 30% and 2 units change. These cutoff values can serve as a 
guide for future clinical trials. Given the limited data and as some interstudy heterogeneity prevailed, 
our results should preferably be confirmed in a prospective repeatability study, preferentially including 
SUVpeak. For serial (e.g. baseline and post-intervention scan) and single PET measurements, different 
thresholds should be used since each scan is affected by test-retest noise.
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Figure S1. A comparison of published study-specific first principal components (dashed lines) with the 
first principal component calculated from pooled data (black solid line).
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Figure S2. A comparison of CR95s (i.e. mean-variance relations) for SUV
max
 (blue), SUV
mean
 (all data; red) and 
SUV
mean
 (50% isocontour; orange). The scales are matched via the first principal component (Figure S1). 
Solid lines represent the test-retest CR95s, while the dotted lines are the one observation CR95s (i.e. 
variance divided by √2).
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table S1. Required relative and absolute differences to exceed test-retest variability.*
                                                                       Relative difference                       absolute difference
SUV
max
15% 3.2
20% 1.6
25% 0.9
SUV
mean
 H, N, M, W, V 10% 1.21
15% 0.77
20% 0.55
SUV
mean
 H, N†, W 10% 0.93
15% 0.62
20% 0.48
  * Listed are the relative and absolute differences required for a difference to have less than 5% probability of being due to   
    measurement error, when comparing a single PET observation to a fixed value. Differences have to exceed both the relative 
    and absolute thresholds.
Figure S3. SUV
mean
 repeatability with respect to tumor volume. (A) The log of the tumor uptake plotted 
against the log of the tumor volume. (B) The estimated published study-specific standard deviations 
(dashed lines) and the model fit with published study as a random factor (solid line).
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Reproducibility of 18F-FLT PET in tumors
aBstract
purpose 
Positron emission tomography (PET) using 18F-3’-deoxy-3’-fluorothymidine 18F-FLT allows noninvasive 
monitoring of tumor proliferation. For serial imaging in individual patients, good reproducibility is es-
sential. The purpose of the present study was to evaluate the reproducibility of quantitative 18F-FLT 
measurements. 
methods 
Nine patients with non-small-cell lung cancer (NSCLC) and six with head-and-neck cancer (HNC) un-
derwent 18F-FLT PET twice within 7 days prior to therapy. The maximum pixel value (SUV
max
) and a 
threshold defined volume (SUV
41%
) were defined for all delineated lesions. The plasma-to-tumor trans-
fer constant (Ki) was estimated using both Patlak graphical analysis and nonlinear regression (NLR). 
NLR was also used to estimate k
3
, which, at least in theory, selectively reflects thymidine kinase 1 
activity. The level of agreement between test and retest values was assessed using the intraclass cor-
relation coefficient (ICC) and Bland-Altman analysis. 
Results 
All primary tumors and > 90% of clinically suspected locoregional metastases could be delineated. In 
total, 24 lesions were defined. NLR-derived Ki, Patlak-derived Ki, SUV41% and SUVmax showed excellent 
reproducibility with ICCs of 0.92, 0.95, 0.98 and 0.93, and SDs of 16%, 12%, 7% and 11%, respectively. 
Reproducibility was poor for k
3
 with an ICC of 0.43 and SD of 38%. 
Conclusion 
Quantitative 18F-FLT measurements are reproducible in both NSCLC and HNC patients. When monitor-
ing response in individual patients, changes of more than 15% in SUV
41%
, 20–25% in SUV
max
 and Patlak-
derived Ki, and 32% in NLR3k-derived Ki are likely to represent treatment effects.
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introduction
18F-3’-deoxy-3’-fluorothymidine 18F-FLT has been proposed as a positron emission tomography (PET) 
tracer of proliferation. FLT is a substrate for thymidine kinase 1 (TK1), which is a key enzyme in the 
salvage pathway of thymidine DNA synthesis. Several studies have shown good correlations between 
18F-FLT uptake and other markers of cellular proliferation, including proliferating cell nuclear antigen, 
flow cytometry and Ki-67 nuclear staining [1–5]. 
In most tumors 18F-FLT uptake is lower than 18F-FDG uptake [6]. In addition, its biodistribution and 
metabolic profile are not ideal [7]. Consequently, 18F-FDG remains the method of choice for diagnosing 
and staging of tumors. It has been suggested that 18F-FLT may have additional value in combination 
with 18F-FDG because the combination has been reported to result in fewer false-positive findings [8, 
9], but results have not been consistent [2, 10, 11]. 
Based on its TK1-related signal, 18F-FLT PET has been proposed as a biomarker for predicting (early) re-
sponse to systemic or locoregional treatment [12–14]. Recent studies have shown that 18F-FLT PET can 
predict response to therapy as early as 1 week after treatment [15], and a decrease in 18F-FLT uptake 
seems to be correlated with prolonged overall survival [16, 17]. 
In addition, 18F-FLT might also be a specific tracer for monitoring the effects of agents targeting thy-
midylate synthase (TS), an enzyme that plays a central role in the de novo pathway of DNA synthesis. 
Downregulation of this pathway results in an upregulation of the salvage pathway and thus of 18F-FLT 
uptake. Recent results have indicated that anti-TS effects can be monitored as soon as 2 hours after 
administration [18]. 
To evaluate response in individual patients, reproducibility of the parameter of interest needs to be 
known. The purpose of the present study was to determine reproducibility of quantitative 18F-FLT 
measurements in a prospective study of patients with non-small-cell lung cancer (NSCLC) or head-
and-neck cancer (HNC).
materials and methods
Eligible patients were included prospectively after providing written informed consent in accordance 
with institutional review board approval. In total, nine patients with NSCLC and six with HNC were 
scanned twice within 7 days (mean 1.9 days, median 1 day) prior to any therapy using an ECAT EX-
ACT HR+ scanner (Siemens/CTI, Knoxville, TN). This scanner has an axial field of view (FOV) of 15 cm, 
divided into 63 contiguous planes. Each patient was positioned supine on the scanner bed with the 
primary tumor in the centre of the axial FOV. The primary tumor and all other evaluable lesions in 
the FOV were analysed. A venous catheter was placed in all patients, which was used for injection of 
18F-FLT and venous blood sampling [19]. In addition, in HNC patients an arterial catheter was placed in 
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the radial artery for arterial blood sampling. Each acquisition started with a 10 to 15-min transmission 
scan in order to acquire a fixed number of 85 million counts [20], which was used for attenuation cor-
rection of the subsequent emission scan. This was followed by a bolus injection of 370 MBq 18F-FLT in 
5 mL saline through an injector (Medrad International, Maastricht, The Netherlands) at 0.8 mL/s, after 
which the line was flushed with 42 mL saline (2.0 mL/s). Simultaneously with the injection of 18F-FLT, a 
dynamic emission scan (in 2-D acquisition mode) was started with a total duration of 60 min and with 
variable frame lengths (6 x 5 s, 6 x 10 s, 3 x 20 s, 5 x 30 s, 5 x 60 s, 8 x 150 s, and 6 x 300 s). All dynamic 
scan data were corrected for dead time, decay, scatter, randoms and photon attenuation, and were 
reconstructed as 128 x 128 matrices using filtered back projection (FBP) with a Hanning filter (cutoff, 
0.5 cycles per pixel). This resulted in a transaxial spatial resolution of around 7 mm full-width at half-
maximum (FWHM). As FBP reconstructed images suffer from streak artefacts, volume of interest (VOI) 
definition may be inaccurate, especially in lesions with low tumor-to-background contrast [21, 22]. 
Therefore, for VOI definition purposes only, the last three frames of the sinograms (45–60 min after 
injection) were summed and reconstructed using ordered-subset expectation maximization (OSEM) 
with two iterations and 16 subsets followed by postsmoothing of the reconstructed images using a 
5-mm FWHM gaussian filter to obtain the same resolution as for the FBP images [21]. 
In the HNC patients, arterial 18F concentrations were monitored continuously using a fully automated 
blood sampling device (Veenstra Instruments, Joure, The Netherlands) [23]. The withdrawal rate was 5 
mL/min during the first 10 min and 2.5 mL/min thereafter. In all patients, venous blood samples were 
drawn at 5, 10, 20, 30, 40 and 60 min after injection to correct for plasma/whole blood ratios and 
plasma metabolite fractions, and as a quality control procedure for defining an image-derived input 
function (IDIF) for NSCLC patients as described for 18F-FDG [24]. To avoid contamination, 3–5 mL blood 
was withdrawn prior to each sample and the line was flushed with 1.5 mL saline after sampling, as 
described previously [19]. 
Venous blood samples were analysed using solid-phase extraction chromatography for separation of 
18F-FLT from 18F-FLT-glucuronide. For this procedure 0.3 mL plasma was dissolved in 2 mL water. This 
solution was placed onto a SepPak Vac 6cc (1 g) C18 cartridge (Waters Corporation, Milford, MA). The 
eluate was collected, after which the cartridge was rinsed with 5 mL water to collect the polar me-
tabolites, being primarily 18F-FLT-glucuronide. The cartridge was then rinsed with 5 mL 96% ethanol to 
collect the parent compound. All fractions and the cartridge were counted using a Wallac 1480 Wizard 
well counter (Perkin-Elmer Life Science, Zaventem, Belgium), and the percentage parent within each 
plasma sample calculated. Metabolite data were interpolated by fitting to an exponential function. 
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Image analysis
The maximum pixel value within the tumor and a threshold defined volume (41% of the maximum 
pixel value with correction for local background) were defined semiautomatically for any lesion with 
adequate focal uptake [25, 26]. Boundaries of lesions without adequate tumor-to-background con-
trast (low focal uptake and/or high level of background) are difficult to define and, consequently, de-
lineation is hampered by increased observer variation. Therefore, only lesions which required no or 
only minor manual delineation were included. In the latter case background values were set to zero 
for voxels directly adjacent to the VOI that had a physiologically high radiotracer concentration (hyper-
vascular areas, haematopoietic bone marrow and liver). After this procedure the threshold technique 
was applied, resulting in volumes specifically containing tumor. Tumor VOIs were defined on OSEM 
reconstructed images and transferred to FBP reconstructed dynamic images, thereby generating time-
activity curves (TACs). An input function was obtained by continuous arterial blood sampling in HNC 
patients and derived from the dynamic FBP images in NSCLC patients. IDIFs were defined by multiple 
manually drawn 2-D regions of interest (ROIs) over the aortic arch (elliptical ROI, 8 × 30 mm) and as-
cending aorta (spherical ROI, 15 mm) [27]. Again, ROIs were then projected onto all frames to generate 
input TACs.
Data analysis
Full kinetic analysis to derive values of the individual rate constants and Ki, the plasma-to-tumor trans-
fer constant, was performed for threshold defined VOIs using the following methods: (1) Patlak graphi-
cal analysis (time interval 10–60 min after injection; Ki only) [28] and (2) nonlinear regression (NLR) 
using the standard two-tissue compartment model with both three (NLR3k) and four (NLR4k) rate 
constants and an additional blood volume parameter (V
b
). In both cases, the metabolite-corrected 
plasma curve was used as input function. The presence of a fourth rate constant (representing de-
phosphorylation of phosphorylated 18F-FLT) and the need to include this in the model were assessed 
by comparing fits with and without a k
4
 parameter using Akaike [29] and Schwarz [30] criteria. 
Kinetic analysis of regional tissue TACs was performed using dedicated software developed within 
Matlab (The Mathworks, Natick, MA). In general, fits are rejected when the (fitted) standard error of 
any parameter exceeds 25%. This was, however, never the case in the present study. In addition, the 
goodness of fit was checked visually for all TACs. SUV was derived for both the maximum pixel value 
(SUV
max
) and the threshold defined VOI (SUV
41%
) for the time intervals 40–60 min and 50–60 min af-
ter injection (with multiple correction factors [31]). The level of agreement between test and retest 
values was assessed using the intraclass correlation coefficient (ICC) with a two-way random model 
with absolute agreement, and Bland-Altman analysis [32]. In the latter case, the percentage difference 
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in values (Δ) between two measures was plotted against (1) the mean of both measures and (2) the 
mean threshold defined volume. In this way, possible dependency on both absolute 18F-FLT uptake 
and tumor size could be evaluated. Additionally, dependency was statistically analysed using linear 
regression. Finally, a one-sample t test was applied to the Δ values to assess systematic bias and the 
parameter values of both test and retest scans were compared using the Wilcoxon signed ranks test 
to evaluate the distribution.
results
All primary tumors and more than 90% of clinically suspected locoregional metastases could be de-
lineated. In total, 24 lesions (15 NSCLC and 9 HNC) were defined. A small subset of lesions (5/24) 
required manual intervention during delineation (Figure 1). Full kinetic analysis was possible for 23 
lesions; blood analyses failed in one patient. The median lesion size (threshold defined PET volume) 
was 8.2 cm3 (range 1.7–86.1 cm3), the median NLR3k-derived Ki was 0.047 mL·min
−1·mL−1 (range 0.021–
0.120 mL·min−1·mL−1), the median Patlak-derived Ki was 0.037 mL·min
−1·mL−1 (range 0.017–0.074 
mL·min−1·mL−1), the median SUV
41%
 was 3.3 (range 1.3–6.4) and the median SUV
max
 was 4.8 (range 2.4–
9.3). The 3k model provided better fits than the 4k model in 26 (57%) and 28 (61%) of 46 measured 
lesions according to Akaike and Schwarz criteria, respectively. In other words, the majority of the data 
were best fitted with the 3k model. Visual check of the TACs revealed good fits for all lesions. 
Descriptive statistics for all parameters of 18F-FLT kinetics for both test and retest scans, as well as p 
values for the Wilcoxon signed ranks test, are presented in Table 1. No systematic bias (one-sample t 
test: SUV
41%
, p = 0.98; Patlak Ki, p = 0.25), or a significant difference in the distribution of paired differ-
ences (Wilcoxon signed ranks test; p > 0.08 for all) was found. The threshold VOI definition technique 
resulted in consistent volumes for most tumors throughout both scans. The median change in tumor 
volume between test and retest scans was 10%. Only the delineation of one lesion resulted in an ex-
Figure 1. Two coronal 18F-FLT images of tumor lesions that required manual intervention: a. lesion in 
right upper lobe close to costal bone, b. large intrapulmonary lesion with inferior part close to right 
diaphragm.
a b
! !
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ceptional difference in volume of 150% between the two scans. This was probably due to inaccurate 
definition of the maximum pixel value, possibly caused by patient motion in one or both scans. 
Only very small variations were found between different SUV
41%
 normalization methods (body weight, 
body surface area and lean body mass) and time intervals (40–60 min and 50–60 min after injection) 
with ICCs ranging from 0.97 to 0.98. Therefore, the SUV results are presented for only one correction 
method (body weight) and a single time interval (40–60 min after injection). NLR3k-derived Ki, Patlak-
derived Ki, SUV41% and SUVmax showed excellent reproducibility with ICCs of 0.92, 0.95, 0.98 and 0.93, 
and SDs of 16%, 12%, 7% and 11%, respectively (Table 2). In contrast, NLR3k-derived k
3
, which, at least 
in theory, selectively reflects TK1 activity, showed poor reproducibility with an ICC of 0.43 and an SD 
of 38%. As expected from Akaike and Schwarz analyses, inclusion of a fourth rate constant resulted in 
decreased reproducibility with an ICC of 0.75 and an SD of 25% for NLR4k-derived Ki, and an ICC of 0.33 
and an SD of 70% for NLR4k-derived k
3
 (Table 2). 
These data show that, when monitoring therapy effects, changes of less than 32% in NLR3k-derived Ki, 
24% in Patlak-derived Ki, 14% in SUV41% and 22% in SUVmax (< 1.96 × SD) cannot be distinguished from 
normal test–retest variability. 
table 1. Descriptive statistics of mean and median values, standard deviation and range for all para-
meters of 18F-FLT kinetics of both scans.
parameter       mean      median sd Range
no of 
measurements mean median sd Range
no of 
measurements
p value (Wil-
coxon signed 
ranks test)
NLR3k Ki 0.048 0.042 0.021 0.022 – 0.120 24 0.047 0.042 0.018 0.021 – 0.101 23 0.73
NLR3k K1 0.177 0.139 0.128 0.076 – 0.608 24 0.159 0.142 0.076 0.087 – 0.393 23 0.86
NLR3k k2 0.118 0.109 0.067 0.030 – 0.360 24 0.102 0.087 0.052 0.041 – 0.257 23 0.65
NLR3k k
3
0.047 0.044 0.019 0.017 – 0.104 24 0.043 0.042 0.015 0.020 – 0.079 23 0.33
NLR3k V
b
0.153 0.109 0.143 0.013 – 0.608 24 0.123 0.114 0.100 0.001 – 0.394 23 0.17
Patlak Ki
a 0.038 0.036 0.013 0.019 – 0.072 24 0.039 0.037 0.015 0.017 – 0.074 23 0.32
SUV
41%
b 3.35 3.28 1.11 1.42 – 6.42 24 3.35 3.20 1.12 1.34 – 6.23 24 0.79
SUV
max
b 5.17 5.14 1.63 2.66 – 9.32 24 5.04 4.78 1.66 2.40 – 9.22 24 0.17
VOI sizec 16.5 8.4 20.1 1.6 – 82.4 24 18.5 9.4 21.8 1.8 – 89.8 24 0.08
 a Patlak analysis was performed using the time interval 10–60 min after injection.
 b SUV values presented were corrected for body weight and measured between 40 and 60 min after injection.
 c VOI size is tumor volume in cubic centimetres, defined by a 41% threshold technique as described in the text.
test scan               Retest scan
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Subgroup analysis for NSCLC and HNC patients showed similar results for Patlak-derived Ki and an even 
better SD result for NLR3k-derived Ki in NSCLC patients as compared to HNC patients, suggesting no 
error due to the use of an IDIF (Table 2). 
Bland-Altman plots of SUV
41%
 and Patlak-derived Ki showed no dependency on absolute 
18F-FLT uptake, 
but a trend of reduced reproducibility for smaller lesions (Figure 2). This trend, however, was not sta-
tistically significant (SUV
41%
, p = 0.35; Patlak Ki, p = 0.51).
discussion
Our results show that quantitative 18F-FLT measurements are reproducible in both NSCLC and HNC 
patients. When serial measurements in patients are performed, changes of more than 15% in SUV
41%
, 
20–25% in Patlak-derived Ki and SUVmax, and 30–35% in NLR3k-derived Ki are likely to represent biologi-
cal effects. In addition, no significant dependency between absolute 18F-FLT uptake and lesion size was 
found, implying that the same threshold can be used for all tumor lesions. Although one tumor lesion 
showed a change of 150% in tumor volume between the two scans, the threshold technique resulted 
in reproducible tumor volumes for all other lesions. 
Akaike and Schwarz analyses showed that for most tumor lesions data were best fitted with the 3k 
model, indicating that 18F-FLT phophorylation was irreversible, at least within the time frame of the 
measurements. Therefore, the fourth rate constant should be set to zero. In a recent study it was 
table 2. Reproducibility results of simplified and full kinetic analyses of 18F-FLT uptake.
                                      patients                                              ICC (95% CI) SD % change SD abs. change
NLR3k Ki All 0.92 (0.83–0.97) 16% 0.008
NLR3k k
3
All 0.43 (0.30–0.71) 38% 0.019
NLR4k Ki All 0.75 (0.49–0.88) 25% 0.016
NLR4k k
3
All 0.33 (-0.95–0.65) 70% 0.073
Patlak Ki All 0.95 (0.89–0.98) 12% 0.004
SUV
41%
All 0.98 (0.95–0.99) 7% 0.2
SUV
max
All 0.93 (0.85–0.97) 11% 0.6
NLR3k Ki NSCLC 0.92 (0.78–0.98) 11% 0.004
Patlak Ki NSCLC 0.92 (0.75–0.97) 12% 0.004
NLR3k Ki HNC 0.92 (0.72–0.98) 22% 0.011
Patlak Ki HNC 0.96 (0.85–0.99) 12% 0.005
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shown that significant dephosphorylation starts at ± 50 min after injection and that k
4
 can reliably be 
estimated with a scan time of 120 min [33]. Furthermore, a strong correlation was found between 
NLR3k Ki derived from a 60-min scan and NLR4k Ki derived from a 120-min scan [33]. A scan protocol 
of 120 min, however, is too long for routine (serial) clinical studies, especially in critically ill patients. 
In addition, the risk of movement artefacts increases with longer scan times. Our results indicate that 
with a scan time of 60 min, a fourth rate constant can be neglected. 
To the best of our knowledge, reproducibility of 18F-FLT measurements in malignant tumors has only 
been assessed in eight patients (nine lesions) with breast cancer [15] and in six patients with NSCLC 
[34]. Shields et al [34] evaluated an unknown number of lesions in six patients using SUV
max
 and SU-
V
mean
 (50% threshold technique) and carried out full kinetic analyses (NLR with unknown number of 
rate constants and Patlak) with the use of an IDIF. Unfortunately, full details of their study (e.g. the 
number of rate constants in the NLR analyses, location and number of lesions, whether mean or me-
dian for absolute difference of test and retest scans) were not reported. Nevertheless, reproducibility 
results were comparable with the present results (around 20% test–retest variability in SUV and ki-
netic parameters). 
Figure 2. Bland-Altman plots for SUV
41%
 and Patlak Ki (circles NSCLC lesions, triangles NHC lesions, 
delta values percentage change between test and retest scans, SUV
41%
 and SUV
max
 for the time interval 
40–60 min after injection and corrected for body weight, Patlak Patlak-derived Ki, mean PET volume 
mean threshold defined volume of the test and retest scan in cm3, straight lines mean values, dotted 
lines ± 1.96 x SD).
 
a b 
c d 
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Results in breast cancer [15] are also consistent with the present results with reported ICCs of 0.99 
and 0.97, and SDs of 11% and 15% for SUV and Patlak Ki, respectively. Differences in study design and 
methods, however, make it difficult to perform a direct comparison. The absence of IDIF analyses, the 
relatively low number of lesions included with no locoregional (lymph node) metastases, and the very 
high tumor-to-background ratio in the breast (due to low uptake of 18F-FLT in fatty tissue) [35, 36] imply 
that results for breast tumors do not necessarily hold for tumors of other origins (with lower tumor-
to-background ratio). In the present study IDIF was used for NSCLC lesions, thereby greatly simplifying 
the acquisition protocol for thoracic tumors. Clearly, this is much more convenient for patients and 
better suited for routine clinical use. Subgroup analyses for NLR3k and Patlak-derived Ki did not reveal 
inferior results for NSCLC as compared to HNC, where arterial blood sampling was performed, suggest-
ing that the use of an IDIF does not significantly contribute to test–retest variability. 
In the present analyses, locoregional lymph nodes were also included, and thereby all possible sce-
narios encountered in clinical trials were evaluated. In addition, this provided a means for evaluating 
possible dependency on absolute 18F-FLT value and tumor size. 
SUV
max
 is the most frequently used (semi)quantitative measure in clinical PET studies due to its ease 
of definition and low observer variation. Nevertheless, results indicate that better reproducibility can 
be achieved by using threshold defined SUV
41%
. Although pulmonary lesions are not easy to delineate 
due to physiologically high uptake in surrounding mediastinum, liver, vertebrae and costal bones, re-
producibility was not reduced, indicating that the applied threshold technique is reliable. 
Since radiotracer uptake depends on perfusion and extraction, SUV and Ki are not specific measure-
ments of TK1 activity. 18F-FLT uptake mainly depends on the extracellular ATP concentration, which 
has greatest impact on the turnover of 18F-FLT due to induction of a change in structure of TK1 from a 
dimer to a tetramer, which has about a 20-fold greater effect on the turnover of the tracer [37]. How-
ever, previous data have shown that 18F-FLT uptake may also depend on perfusion (blood flow) rather 
than on TK1 activity [38]. Therefore, at least in theory, k
3
 appears to be the parameter of interest for 
studying TK1 activity. Unfortunately, NLR3k-derived k
3
 showed poor reproducibility. However, both Ki 
and SUV have shown good correlations with other proliferation markers, with Ki having the strongest 
correlation [4, 15, 33]. The present results indicate that both Ki and SUV are reproducible. 
Since Ki has the best correlation with other proliferation markers, dynamic scanning should, whenever 
possible, be applied in response monitoring studies. If static scans are acquired, however, the present 
results support the use of a threshold defined VOI instead of the maximum pixel value. In the present 
study only therapy-naive tumors were analysed. It should be kept in mind, however, that an interven-
tion may affect the various rate constants in a different manner. For example, a certain therapy could 
result in a reduction in delivery (K1) with only a minor change in TK1 activity (k3). In that case, both Ki 
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and SUV would decrease more than the actual decrease in proliferation rate. In addition, SUV and Ki 
might not be similarly affected. 
conclusion
Our results show that both simplified and full kinetic analyses of 18F-FLT data have excellent reproduc-
ibility in NSCLC and HNC patients. Furthermore, the data support the use of an IDIF for kinetic analyses 
of intrathoracic lesions. Future response monitoring studies, correlating 18F-FLT response with patho-
logical and clinical outcome, should be performed to assess which 18F-FLT parameter is best for predict-
ing response to therapy.
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Erlotinib and bevacizumab in NSCLC
aBstract
purpose
Both bevacizumab and erlotinib have clinical activity in non-small-cell lung cancer (NSCLC). Preclinical 
data suggest synergistic activity.
patients and methods
Chemonaive patients with stage IIIb or IV non-squamous NSCLC were treated with bevacizumab 15 
mg/kg every 3 weeks and erlotinib 150 mg daily until progression. Primary end point was nonprogres-
sion rate (NPR) at 6 weeks. Tumor response was measured with computed tomography, 2-[fluorine-18]
fluoro-2-deoxy-D-glucose (18F-FDG PET) and dynamic contrast-enhanced magnetic resonance imaging 
(DCE-MRI). KRAS and EGFR mutations were assessed in tumor samples.
Results
Forty-seven patients were included. Median follow-up was 15.2 months. NPR at 6 weeks was 75%. 
Median progression-free survival (PFS) was 3.8 [95% confidence interval (CI) 2.3–5.4] months and 
median overall survival (OS) was 6.9 (95% CI 5.5–8.4) months. Toxicity was mainly mild. The presence 
of KRAS (n = 10) or EGFR mutations (n = 5) did not influence outcome. After 3 weeks of treatment, 
> 20% decrease in standard uptake value as measured with positron emission tomography predicted 
for longer PFS (9.7 versus 2.8 months; p = 0.01) and > 40% decrease in Ktrans as assessed by DCE-MRI 
did not predict for longer PFS.
Conclusions
First-line treatment with bevacizumab and erlotinib in stage IIIb/IV NSCLC resulted in an NPR of 75%. 
OS was however disappointing. Early response evaluation with 18F-FDG PET is the best predictive test 
for PFS. 
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introduction
The prognosis for patients with advanced non-small-cell lung cancer (NSCLC) remains poor. Platinum-
based combination chemotherapy has reached an efficacy plateau from which it will not ascend by 
its own [1]. For several reasons, the combination of bevacizumab and erlotinib is of interest in NSCLC. 
First, preclinical and clinical data indicate that antivascular endothelial growth factor (VEGF) and anti-
epidermal growth factor receptor (EGFR) therapies have at least an additive antitumor effect [2, 3]. 
Secondly, the combination has proven to be well tolerated even when both are administered at their 
recommended phase II dose [4]. Finally, both erlotinib as single agent and bevacizumab in combi-
nation with cytotoxic chemotherapy are of proven benefit in the clinical management of advanced 
NSCLC [4–6]. 
Objective response rates (ORRs), as determined by RECIST, obtained in phase II studies define whether 
a drug is moved toward phase III testing [7]. In contrast to traditional anticancer agents, the effects 
of these agents, especially bevacizumab, are cytostatic rather than cytotoxic [8–10]. Therefore, deter-
mining the activity of both agents by anatomical criteria alone probably underestimates their activity. 
The 2-[fluorine-18]fluoro-2-deoxy-D-glucose (18F-FDG PET) studies may find evidence of anti-neoplas-
tic activity within a week after initiation of treatment before changes in tumor volume can be detected 
[11]. Effects of drugs on tumor (micro)vasculature may be determined by dynamic contrast-enhanced 
magnetic resonance imaging (DCE-MRI) [12, 13]. 
The aim of this study was to evaluate the efficacy of erlotinib and bevacizumab in first-line treat-
ment of advanced NSCLC as determined by the non-progression rate (NPR) at 6 weeks. Secondary end 
points included ORR, safety, overall survival (OS) and progression-free survival (PFS) and the relation 
of molecular imaging-derived parameters with PFS and response.
patients and methods
patient eligibility
Key eligibility criteria were stage IIIB (pleural effusion) or IV non-squamous NSCLC; no prior antitumor 
therapy; measurable disease (RECIST); Eastern Cooperative Oncology Group performance status (PS) 
of two or less and adequate hematologic, renal and hepatic function. 
Key exclusion criteria were evidence of tumor invading major blood vessels; presence of a cavitating 
lesion; major surgical procedure, open biopsy, significant injury or radiotherapy within 28 days; serious 
non-healing wound or ulcer; active peptic ulcer disease; evidence of bleeding diathesis, coagulopathy 
or history of ≥ grade 2 hemoptysis; proteinuria ≥ 2+; brain metastasis or spinal cord compression un-
less previously treated with evidence of stable disease (SD) for > 2 months; treatment with anticoagu-
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lants for therapeutic purposes; ongoing treatment with aspirin (> 325 mg/day) or other medications 
known to predispose to gastrointestinal ulceration and any uneven systemic disease. 
Written informed consent was obtained from all patients before inclusion.
Study Design and treatment
The study is a non-randomized phase II study, carried out at three university medical centers in The 
Netherlands. The study was approved by the institutional medical ethics review board of each partici-
pating center. 
Patients were treated with bevacizumab 15 mg/kg as an i.v. infusion every 3 weeks and erlotinib 150 
mg orally daily. No dose reductions of bevacizumab were allowed. Dose reductions of erlotinib were 
according to the label. Patients remained on treatment until disease progression, unacceptable toxic-
ity and/or patient refusal. In case of documented tumor progression, patients received further treat-
ment as per investigator’s decision.
Study assessments
Toxicity was scored every 3 weeks during treatment according to the common toxicity criteria adverse 
events version 3.0. Tumor response was measured with computed tomography (CT) (RECIST) every 6 
weeks until disease progression. Objective responses were confirmed after at least 4 weeks.
exploratory end points
Imaging with CT, DCE-MRI and 18F-FDG PET was carried out at baseline and after 3 weeks of treatment 
(just before bevacizumab infusion). Size was measured with CT and response defined by RECIST 1.0, 
tumor metabolism (SUV) with 18F-FDG PET and a combined measure of perfusion and permeability (the 
endothelial transfer constant, Ktrans) with DCE-MRI. Dynamic 18F-FDG PET studies were carried out selec-
tively at VU University Medical Center, whereas the other centers applied a static whole body 18F-FDG PET 
protocol. (For imaging acquisition: see supplementary material available in Annals of Oncology online.)
tissue biomarkers
Mutation analysis of EGFR (exon 19-21) and KRAS (exon 1) was carried out on extracted tumor DNA. 
Formalin-fixed and paraffin-embedded tumor tissue sections were manually microdissected, and to-
tal genomic DNA was isolated using QIAamp DNA extraction kits (Qiagen, Venlo, The Netherlands). 
Nested polymerase chain reaction sequencing was carried out using the BigDye Terminator v 3.1 Cycle 
Sequencing Kit (Applied Biosystems, Foster City, CA), and the ABI PRISM 310 Genetic Analyzer (Applied 
Biosystems) [14].
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Statistical Considerations and analytical plan
The primary end point of the study was NPR (RECIST) at 6 weeks. This end point was used previously 
and it was shown that it is predictive for clinical benefit [15, 16]. To be able to discontinue the trial 
early if treatment showed insufficient activity, a two-stage design was implemented (Simon’s optimal 
design; p0 = 40%, p1 = 60%, alpha = 0.05, beta = 0.20). A total of 46 patients would be entered and the 
treatment was declared to have sufficient activity to deserve further evaluation if at least 24 patients 
did not progress. A first analysis was made after 16 patients were included; if nine or more patients of 
them progressed within 6 weeks, the study would be stopped. Patients without post baseline tumor 
assessments were regarded as progressive. The analysis for the primary efficacy end points was based 
upon all registered subjects who received at least one dose of study treatment. 
PFS was defined as the time from the start of the treatment to the date of the first documented pro-
gression in terms of RECIST or the date of death. OS was determined from the date of the start of the 
treatment to the date of death irrespective of the cause of death. Patients who had not progressed or 
died at the time of the analysis were censored at the date of last contact. The Kaplan–Meier method 
was used to plot PFS and OS. Predefined cutoff points were used and curves compared by log-rank 
testing. 
Imaging results are presented as percentage change from the baseline value. Predefined cut points for 
imaging studies were based on reproducibility data. A 20% cut point was used for positron emission 
tomography (PET) (i.e. values outside 1.96 x standard deviation) [17], while a 40% cut point was used 
for DCE-MRI-derived Ktrans [18, 19]. 
Statistical analyses were carried out using SPSS (version 15.0; SPSS Inc., Chicago, IL). Results are presented 
with 95% confidence intervals (CIs) and p values. A p value of < 0.05 was considered to be significant.
results
patient Characteristics
From January 2006 till March 2007, 50 patients were registered; 47 patients received at least one dose 
of study treatment. Three patients were ineligible after inclusion but before start of treatment (one 
pulmonary embolism, one tumor involvement of large blood vessel, one trachea–esophageal fistula). 
Patient characteristics are provided in Table 1. 
As at the time of analysis, 11 patients were alive, 3 patients were on treatment; 35 patients stopped 
treatment due to progressive disease (PD), 5 due to toxicity, 2 because of surgical intervention and 2 
patients died before progression was estimated. Patients received a median of four cycles of bevaci-
zumab (range 1–21). Median follow-up for all patients was 15.2 months.
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efficacy
Of the first 16 patients, 11 were non-progressive at 6 weeks. Therefore, the study continued for further 
accrual. For all patients at 6 weeks, 35 of 47 patients (75%) showed no progression. Twelve patients 
(25%) fulfilled the criteria of an objective response with one complete response (CR). Progression was 
more frequently observed in patients without rash (50% of patients without rash versus 15% with any 
grade of rash, Pearson Χ2 6.78; p = 0.012); no correlation was found with gender, PS or smoking history. 
At progression, 27 patients received further chemotherapeutic treatment with a platinum doublet. 
Twenty patients received palliative care only of which six at their own request (one patient underwent 
complementary treatment). The major clinical characteristic that determined whether or not patients 
received further chemotherapy was clinical deterioration due to the progression; nine patients died 
within 1 month after progression.
Secondary end points
Median PFS was 3.8 (95% CI 2.3–5.4) months. No significant differences were observed between males 
and females or (former) smokers and never smokers. Neither rash nor development of hypertension 
was related to PFS, but patients that developed proteinuria had a significant longer PFS (5.7, 95% CI 
table 1. Patient characteristics: total patient population and patients in imaging study.
Characteristics                                                  no. of patients 
                                                                             (n = 47)                                                                                  
no. of patients in imaging study 
(n = 40)
Age, years 
   Median
   Range
59
34-40
58
34-78
Sex
   Male/female 23/24 18/22
ECOG performance status
   0
   1
   2
22
19
6
19
17
4
Stage
   IIIb
   IV
11
36
9
31
Histology
   Adeno
   Other
31
16
28
12
Smoking status
   Never
   Former
   Current
8
23
16
7
21
12
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1.3–10.2, months versus 2.3, 95% CI 0.4–4.2, months; p = 0.04). Median OS was 6.9 (95% CI 5.5–8.4) 
months, with 11 patients censored. No survival difference was observed between females and males, 
patients with versus without rash, ever smokers versus never smokers and between patients with PS 
0–1 or 2. Median duration of tumor response was 10.9 (95% CI 5.0–16.8) months.
Safety
Toxicity was mainly as expected (Table 2). But two patients discontinued treatment because of toxicity 
that was not prespecified as per protocol. One patient developed sudden increase of liver enzymes, 
thrombocytopenic purpura and renal function disturbances, mimicking the renal thrombotic mi-
croangiopathy syndrome caused by bevacizumab [20]. Ultimately, the patient died at home at day 16. 
Autopsy was not carried out. One patient had a sigmoid perforation that was successfully treated by sur-
gery. The resection specimen showed no tumor on microscopic examination. No severe bleeding episodes 
were observed. Three grade 3/4 thromboembolic events were encountered, one pulmonary embolism 
and one cerebrovascular accident. The latter patient was on study for 8 months and had as best response 
SD. The CT scan of the brain at the time of the cerebrovascular accident did not reveal brain metastasis.
Category                                                            adverse event                                                                               all grades grade 3/4
Cardiac Hypertension 8 1
Constitutional Myalgia 6 -
Dermatology Dry skin
Pruritus
Rash-acneiform
Rash-desquamation
14
7
29
5
-
-
11
-
Gastrointestinal Bilirubine
Diarrhea
GGT
GI-perforation
Mucositis
Nausea
12
27
1
1
8
6
2
2
1
1
-
-
Hemorrhage All
Nose
Pulmonary
13
6
2
0
-
-
Metabolic/laboratory Increased ASAT/ALAT
Hyperbilirubinemia
Increased GGT
Increased LDH
Proteinuria
Thrombocytopenia
16
12
1
1
23
1
3
2
1
1
-
1
Vascular Thrombosis
Pulmonary embolism
Cerebrovascular accident
5
1
1
3
1
1
table 2. Related adverse events occurring in > 10% of CTC grade 3/4 patients or having CTC grade 3/4.
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exploratory end points
imaging. Patients were included for imaging evaluation when at least CT and 18F-FDG PET were avail-
able at baseline and after 3 weeks of treatment. Forty patients were found eligible (Figure 1). The 
baseline characteristics of the patients selected for imaging evaluation were comparable to the inten-
tion-to-treat group as depicted in Table 1. Figure 2 shows an example of response assessment by the 
three imaging modalities. Nine of the 40 patients had a CR or partial response (PR) as best response 
according to RECIST. After 3 weeks of treatment, five of these nine patients were classified as respond-
er by CT scan (RECIST) and six of nine by 18F-FDG PET. DCE-MRI was available for 26 of the 40 patients. 
Six of these 26 patients had a CR or PR as best response according to RECIST, and with DCE-MRI two of 
six patients were identified at week 3. 
At week 3, both SUV and Ktrans values decreased but this was not significant [mean SUV and Ktrans de-
crease 5.1% [interquartile range (IQR) -17% to +12%; p = 0.19] and 15.1% (IQR -57% to -3%; p = 0.19), 
respectively]. 
Figure 1. Flowchart of all patients. Transparent boxes provide information on scan failure. Results of 
baseline and week 3 can be found in the shaded white/gray and even gray boxes, respectively.
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Figure 2. Representative image of baseline (A–C) and post-treatment (D–F) 2-[fluorine-18]fluoro-2-de-
oxy-D-glucose positron emission tomography (A, D), dynamic contrast-enhanced magnetic resonance 
imaging (B, E) and computed tomography (C, F) images showing a decrease in 2-fluoro-2-deoxy-D- glu-
cose uptake, tumor perfusion and size after 3 weeks of treatment.
a B c
d e F
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Patients with a metabolic response (SUV decrease > 20%) at week 3 had longer PFS (9.7, 95% CI 1.8–
17.6, months) than those without (2.8, 95% CI 2.0–3.5, months; p = 0.01) (Table 3 and Figure 3). A 
response as assessed by DCE-MRI at week 3 (Ktrans decrease > 40%) did not predict for longer PFS (26 
patients; 4.3, 95% CI 3.5–5.1, months versus 2.7, 95% CI 0–9.1, months; p = 0.63). Although patients 
with a response on CT at week 3 had a longer PFS, this was not significant (4.6, 95% CI 1.3–7.9, months 
versus 2.9, 95% CI 1.3–4.5, months; p = 0.08) (Figure 3). 
tissue biomarkers. Sufficient paraffin-embedded tumor material was available for EGFR (exons 19–21) 
(n = 24) and KRAS mutation (n = 27) analysis. Five EGFR mutations were detected: four in exon 20 and 
one in exon 21. None of these mutations were known to be predictive for response to erlotinib. In 10 
of 27 patients, a KRAS mutation was detected. No differences in ORR, or PFS, were observed between 
wild-type patients and those with a mutation in either EGFR or KRAS (Table 4).
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                                                          pet 
                                                          responder 
                                                          
                                                          n
pet non-
responder
n
HR, (95% CI) p value
7 33 0.27 (0.01–0.78), p = 0.002
Female 4/3 14/19 0.15 (0.02–1.14)
WHO PS 0 3 16 0.41 (0.09–1.84), NS
Adeno/BAC 5 23 0.27 (0.08–0.93), p = 0.04
Never smokers 3 4 0.01 (<0.0001–37), NS
CR/PR 6 3 0.58 (0.11–2.93), NS
Rash 7 23 0.28 (0.1–0.084), p = 0.02
Hypertension 1 4 0.02 (<0.0001–200), NS
Proteinuria 3 16 0.65 (0.15–2.86), NS
 18F-FDG PET, 2-[fluorine-18]fluoro-2-deoxy-D-glucose; PET, positron emission tomography; HR, hazard ratio; CI, confidence interval; 
 WHO, World Health Organization; PS, performance status; NS, not significant; CR, complete response; PR, partial response; BAC, 
 bronchoalveolar carcinoma.
table 3. Response assessment by 18F-FDG PET and clinical characteristics.
n    n
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Figure 3. Kaplan–Meier curves [progression-freesurvival (PFS)] stratified for response after 3 weeks of 
treatment according to computed tomography (CT) (A), 2-[fluorine-18]fluoro-2-deoxy-D-glucose posi-
tron emission tomography (B) and dynamic contrast-enhanced magnetic resonance imaging (C).
a.
C.
b.
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discussion
This is the first study reporting on the activity of the combination of erlotinib and bevacizumab in 
chemonaive patients with advanced NSCLC. The rationale for the clinical evaluation of this combina-
tion in NSCLC is provided by the antitumor activity of dual blockade of the VEGF and EGFR pathway 
both in vitro and in vivo. The primary end point, an NPR of 75%, was met. At the time of design of this 
study, several considerations led to the choice of this primary end point. First, a study investigating the 
efficacy of single-agent erlotinib employed a similar primary end point and demonstrated the feasibil-
ity of our approach [16]. Instead of the NPR at 8 weeks, the NPR at 6 weeks was chosen for the present 
study because of the three-weekly administration of bevacizumab. Secondly, large cooperative phase 
III trials investigating different cytotoxic regimen all report a PD rate in the order of 20%, suggesting 
that an NPR of 75% is a reasonable primary end point for biological treatment [21]. In addition, as 
these agents are believed to be cytostatic rather than cytotoxic, ORR may be a less suitable end point 
for phase II studies with these agents [15]. Two studies evaluated erlotinib–bevacizumab in random-
ized phase II trials in the relapse setting of NSCLC and observed median times to progression of 4.4 
and 3.4 months, respectively [22, 23]. These figures are not different from our results and from that 
obtained in the latest phase III studies in NSCLC in the first-line setting using cytotoxic chemotherapy 
alone [1, 5, 24]. But recent phase III trials in comparable patient groups as our study, i.e. untreated 
non-squamous NSCLC, showed increased PFS (5.3–6.7 months) and OS (11.9–13.6 months) when 
these patients were treated with bevacizumab- or pemetrexed-containing chemotherapy [5, 6, 24]. 
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KRAS
    Mutant
    Wild type
9
14
1
3
1a
3
6
10
3
4
2.3 (2.0–2.6) 
4.0 (2.6–5.4),
p = 0.46
EGFR
    Muntant
    Wild type
5
19
0
4
0
4
4
14
1
5
4.0 (1.1–7.0)
3.9 (1.9–5.8),
p = 0.88
  aOne patient (female, adenocarcinoma, current smoker) with KRAS mutation developed a PR on bevacizumab and erlotinib.     
  NSCLC, non-small-cell lung cancer; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free 
  survival; CI, confidence interval.
table 4. Mutation analysis.
Former/                  never                          pR                   SD                pD                   median, months (95% CI), 
current                                                                                                                              p value
                                                          
  Smoking history (n)                                         Response (n)                                 pFS                                                    
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Although the combination of bevacizumab with erlotinib did significantly improve PFS when compared 
with erlotinib and placebo in a phase III study in pretreated NSCLC patients, this was not translated 
in a survival benefit [23]. Recent data show that adding erlotinib to bevacizumab in the maintenance 
treatment of advanced NSCLC significantly prolongs PFS when compared with placebo [25]. The ORR 
of 24.5% was not different from that what can be obtained with classical chemotherapy. Disappoint-
ingly however, in the study reported here, median OS was 6.9 months only. This disturbing figure calls 
into question the so-called ‘window of opportunity studies’ of novel agents in untreated patients with 
advanced NSCLC. Noteworthy is the fact that only half of the patients received further platinum-based 
chemotherapy upon progression of disease. This was mainly due to deterioration of PS due to disease 
progression and patient refusal. Although disappointing, this is comparable to recent maintenance 
trials in which 50%–60% of patients receive second-line chemotherapy [26–28]. Careful selection of 
patients, possibly by biomarkers [29] and PS [16], for entry into this type of study is mandatory as are 
early stopping criteria (e.g. molecular imaging). 
None of the 27 patients where tissue was available had ‘classical’ EGFR mutations that would have pre-
dicted for response to erlotinib alone. The relatively high number of exon 20 mutations in this study is 
likely to be a chance phenomenon as the mutation frequency of >200 samples tested with the same, 
internationally accepted, method in our laboratory is in line with previous reported data (E. Thunnis-
sen, D. Heideman, unpublished data). In the relapse setting, ORRs of 13%–17% are reported for this 
combination in unselected patients [22, 23], higher than may be expected with single-agent erlotinib 
[4]. The Iressa Pan-Asia Study (IPASS) study reported a 1.1% ORR in chemonaive, EGFR mutation-
negative, advanced NSCLC patients when treated with single-agent gefitinib [30] and showed that only 
patients with activating EGFR mutations benefit from first-line treatment with EGFR tyrosine-kinase 
inhibitor (TKI). All patients in the IPASS study were selected on clinical characteristics and it was clearly 
shown that when mutation status is not known or when EGFR is wild type, patients should be offered 
standard chemotherapy instead of first-line EGFR TKI as median PFS was only 2 months for EGFR wild-
type patients treated with gefitinib. Therefore, one may assume that dual inhibition of the EGFR and 
VEGF pathway exerts an antitumor effect in EGFR mutation-negative patients and this strategy may 
be applicable to a broader population of patients compared with EGFR TKIs alone. Remarkably, one 
PR was obtained in a patient harboring a KRAS mutation. Objective responses in patients with KRAS-
mutated tumors upon treatment with EGFR TKIs alone are rare [31] and this finding illustrates the 
complexity of the effect size of mutations in different pathways on tumor response. These data sug-
gest that simultaneous inhibition of both the EGFR and the VEGF pathway might overcome primary 
resistance to EGFR inhibitors. A hypothesis that is supported by recent results obtained in an in vitro 
model [32]. 
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A phase I/II study of bevacizumab–erlotinib showed that these agents can each be administered at 
their phase III dose and schedule [33]. Toxicity in our study was mainly as expected, but some serious 
adverse events occurred. One patient developed a colon perforation during treatment and another 
developed a thrombotic microangiopathy syndrome. Ten patients experienced grades 3–4 thrombotic 
events, including three pulmonary embolisms and one cerebro vascular accident. Other than these, 
the rate of grades 3–4 toxicity was < 5%. These results are comparable with other studies that evalu-
ated the bevacizumab and erlotinib combination in NSCLC [22, 33]. Rash was the predominant form of 
toxicity and correlated with PFS and OS, although not significantly. 
In this study, efforts were made to correlate molecular imaging with clinical outcome. In phase II stud-
ies using cytotoxic chemotherapy, response rate as determined by anatomical criteria, i.e. RECIST, is 
frequently used as the primary end point. Anatomical imaging has been subject to criticism among 
others by a recent review that showed that < 50% of the difference in survival in 191 phase III stud-
ies conducted in NSCLC could be explained by variability in response rate [34]. We and others have 
shown that clinical outcome to chemotherapy can be predicted early [35] and more robust by using 
response monitoring consisting of serial 18F-FDG PET scanning [36]. Indeed, in this study we were able 
to show that response to targeted treatment as assessed by serial 18F-FDG PET scanning early during 
treatment was significantly associated with PFS, whereas tumor response as assessed by CT was not. 
In particular, the finding that response assessment by 18F-FDG PET scanning at 3 weeks is predictive for 
PFS, even in patients with clinical good prognostic characteristics, is of importance as this opens the 
possibility to halt experimental treatment in the window of opportunity studies in chemonaive NSCLC 
patients early in order not to jeopardize survival by ineffective treatment. CT, in contrast, showed SD 
at week 3 for 45% of patients with PR/CR as their best CT response, reflecting the underestimation of 
treatment effects at early response assessments. Second, three patients with PR at 18F-FDG PET and 
SD at CT had a median PFS of 9.7 months, suggesting that 18F-FDG PET is more discriminative. Antian-
giogenic agents such as bevacizumab are thought to exert their antitumor effects by normalization of 
tumor vasculature, inhibition of lymphangiogenesis and reduction of intratumoral interstitial pressure, 
thereby allowing for improved delivery of therapeutics [37]. Several of these consequences of anti-
angiogenic treatment may be monitored with currently available techniques such as DCE-MRI. This is 
the first report in lung cancer showing that most tumors have a decrease in Ktrans value after 3 weeks of 
treatment, indicating an effect on the tumor vasculature. A similar finding was reported by Willet et al 
in a study in 12 patients with rectal carcinoma treated with bevacizumab preoperatively [9]. However, 
in our study a decrease in Ktrans was not predictive for prolonged PFS. 
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In conclusion, in this phase II study in chemonaive advanced NSCLC, we observed a 75% NPR at 6 
weeks following treatment with a combination of bevacizumab and erlotinib. In contrast, OS was dis-
appointing and some serious toxic effects occurred. Tumor effects with these biologicals are readily 
measurable with PET.
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Imaging during antiangiogenic therapy
aBstract
purpose
With antiangiogenic agents, tumor shrinkage may be absent, despite survival benefit. The present 
study assessed the predictive value of molecular imaging for the identification of survival benefit dur-
ing antiangiogenic treatment with bevacizumab and erlotinib in patients with advanced non-small-cell 
lung cancer. 
methods 
Patients were evaluated using an imaging protocol including CT, 18F-FDG PET, H2
15O PET, and dynamic 
contrast-enhanced MRI to derive measurements on tumor size, glucose metabolism, perfusion, and 
microvascular permeability. The percentage change in imaging parameters after 3 wk of treatment as 
compared with baseline was calculated and correlated with progression-free survival (PFS). 
Results
Forty-four patients were included, and 40 underwent CT and 18F-FDG PET at both time points. Com-
plete datasets, containing all imaging modalities, were available for 14 patients. Bevacizumab and 
erlotinib treatment resulted in decreased metabolism, perfusion, and tumor size. A decrease in stan-
dardized uptake value or tumor perfusion of more than 20% at week 3 was associated with longer PFS 
(9.7 vs. 2.8 mo, p = 0.01, and 12.5 vs. 2.9 mo, p = 0.009, respectively). Whole-tumor Ktrans (the endothe-
lial transfer constant) was not associated with PFS, but patients with an increase of more than 15% in 
the SD of tumor Ktrans values—that is, an increase in regions with low or high Ktrans values—after 3 wk 
had shorter PFS (2.3 vs. 7.0 mo, p = 0.008). A partial response, according to the response evaluation 
criteria in solid tumors (RECIST), at week 3 was also associated with prolonged PFS (4.6 vs. 2.9 mo, p = 
0.017). However, 40% of patients with a partial response as their best RECIST response still had stable 
disease at week 3. In these cases tumor perfusion was already decreased and Ktrans heterogeneity 
showed no increase, indicating that the latter parameters seem to be more discriminative than RECIST 
at the 3-wk time point. 
Conclusion
PET and dynamic contrast-enhanced MRI were able to identify patients who benefit from bevacizum-
ab and erlotinib treatment. Molecular imaging seems to allow earlier response evaluation than CT.
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introduction
Response monitoring in advanced non-small-cell lung cancer (NSCLC) is complex. Tumor shrinkage 
usually does not occur until several cycles of chemotherapy and is difficult to evaluate because of 
inter- and intraobserver variation [1]. With targeted agents, volumetric change might not happen at 
all, despite survival benefit [2–5]. Also, the association between response and survival is weak at best 
[6]. Therefore, alternative criteria for response assessment are warranted. Monitoring tumor biology 
during therapy offers an interesting alternative and might add to size-based criteria. 
PET and dynamic contrast-enhanced (DCE) MRI allow for the noninvasive quantification of aspects of 
tumor biology, depending on tracer characteristics [7]. 18F-FDG, the most frequently and widely used 
tracer in the clinical setting, enables the quantification of glucose metabolism. Tumor perfusion can 
be measured with the short-lived PET tracer H2
15O (radiolabeled water), which is a freely diffusible and 
accurate perfusion tracer. DCE-MRI uses a paramagnetic gadolinium-based contrast agent to measure 
tumor perfusion by a combination of microvascular flow, permeability, and surface area. Particularly 
DCE-MRI, and to a lesser extent H2
15O PET, have been studied in clinical trials evaluating antiangiogenic 
drugs [8–10], but few included patients with NSCLC. 
The drug combination used in the present study, bevacizumab and erlotinib (BE), targets the vascular 
network of tumors. Erlotinib inhibits the function of the epidermal growth factor receptor, and beva-
cizumab targets circulating vascular endothelial growth factor. Their supposed effects are a decrease 
in vascular permeability, microvascular density, and cell density [11, 12]. These effects may eventually 
result in tumor necrosis. This ultimate goal would result in a decrease in tumor size (measured by CT). 
However, antiangiogenic drug therapy often results in consolidation rather than mass regression. De-
spite the absence of size change, such therapy could result in decreased glucose metabolism because 
of lower 18F-FDG availability (by antivascular effects) or a lower metabolic rate of glucose in tumor 
tissue. More subtle effects on tumor perfusion and permeability can be visualized with H2
15O PET and 
DCE-MRI. 
The aim of the present study was to assess the predictive value of DCE-MRI– and PET-derived biomark-
ers during antiangiogenic treatment in patients with NSCLC. The combined use of DCE-MRI, H2
15O PET, 
and 18F-FDG PET in this study offers the opportunity to evaluate the individual parameters side by 
side.
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materials and methods
Study Design and eligibility Criteria
All subjects included in a prospective multicenter phase II trial evaluating the efficacy of BE treat-
ment in chemonaïve patients with advanced NSCLC were studied using an extensive imaging protocol 
including CT, DCE-MRI, H2
15O PET, and 18F-FDG PET. Patients were included when at least 2 imaging 
studies (including CT) were available at baseline. The protocol was approved by the institutional medi-
cal ethics review board of each participating center. Written informed consent was obtained from 
all patients. Inclusion criteria were histo- or cytologically documented stage IIIB (malignant pleural 
effusion) or IV nonsquamous NSCLC; no prior systemic therapy; measurable disease, as defined by 
the response evaluation criteria in solid tumors (RECIST); and an Eastern Cooperative Oncology Group 
performance status of 0–2. Major exclusion criteria were evidence of the tumor invading major blood 
vessels; the presence of a cavitating lesion; radiotherapy within 28 d before registration; evidence of 
bleeding diathesis, coagulopathy, or history of grade 2 or greater hemoptysis; and brain metastasis or 
spinal cord compression, unless previously treated, with evidence of stable disease for at least 2 mo. 
Study treatment
Patients were treated with bevacizumab (15 mg/kg) as an intravenous infusion every 3 wk and er-
lotinib (150 mg orally) daily. No dose reductions were made for bevacizumab. In the case of severe 
side effects, the dose of erlotinib was reduced according to the label. Patients remained on treatment 
until disease progression, unacceptable toxicity, or patient refusal. In the case of documented tumor 
progression (as assessed by RECIST), patients received further treatment as per investigator decision. 
Study medication and imaging were discontinued in these cases.
Imaging Schedule and parameters
Imaging with CT, DCE-MRI, H2
15O PET, and 18F-FDG PET was performed at baseline and after 3 wk of 
treatment (just before bevacizumab infusion) to derive measures on tumor size, vascular permeability, 
perfusion, and metabolism. Additional CT scans were made every 6 wk from baseline until disease pro-
gression. Size was measured with CT and response defined by RECIST. Perfusion (F) was determined 
with H2
15O PET; glucose metabolism (metabolic rate of glucose [MRglu] and the standardized uptake 
value [SUV]) with 18F-FDG PET; and a combined measure of microvascular flow, permeability, and sur-
face area (the endothelial transfer constant [Ktrans]) with DCE-MRI. 
Dynamic 18F-FDG and H2
15O PET studies were performed selectively at 1 center, whereas the other 
centers applied a static whole-body 18F-FDG PET protocol without perfusion measurements. CT and 
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DCE-MRI were available for all centers. 
Imaging acquisition
PET was performed with 4 scanners: 2 Siemens ECAT EXACT HR+ scanners, 1 Philips Gemini TF-64 PET/
CT scanner, and 1 Siemens Biograph bismuth germanate PET/CT scanner. Dynamic scans were ob-
tained on a single Siemens ECAT EXACT HR+ scanner and static ones on the other systems. All patients 
were asked to fast for 6 h before scanning. Patients received a venous injection of 18F-FDG (179–458 
MBq), depending on individual patient and scanner characteristics. 
Dynamic acquisition started with a 10- to 15-min transmission scan to correct for photon attenuation 
[13]. After a bolus injection of H2
15O (1,100 MBq), a dynamic emission scan (in 2-dimensional acquisi-
tion mode; total duration, 10 min) was started. After an interval of 10 min to allow for decay of H2
15O, a 
bolus injection of 18F-FDG (370 MBq) was administered, and a dynamic emission scan (2-dimensional; 
total duration, 60 min) was started. Data were reconstructed as 128 x 128 matrices using filtered back-
projection with a Hanning filter (cutoff, 0.5 cycle/pixel). For volume-of-interest (VOI) definition purpos-
es, the last 3 frames of the 18F-FDG sinograms (45–60 min after injection) were summed. This summed 
frame was reconstructed using ordered-subset expectation maximization (OSEM) with 2 iterations and 
16 subsets, followed by postsmoothing of the reconstructed image using a gaussian filter (5 mm in full 
width at half maximum) to obtain the same resolution as for the filtered backprojection images. 
Static acquisition was performed with the following settings: Siemens HR+: 2-dimensional mode, 4-min 
emission and 3-min transmission per bed position, and OSEM reconstruction (2 iterations, 16 subsets); 
Philips Gemini: 3-dimensional mode, 135-s emission per bed position, and time-of-flight OSEM recon-
struction using default settings; and Siemens Biograph: 3-dimensional mode, 5-min emission per bed 
position, and Fourier rebinning plus OSEM reconstruction (4 iterations, 8 subsets). All appropriate 
corrections for normalization, dead time, random coincidences, scatter, and attenuation were applied. 
Attenuation correction for the PET/CT systems was based on a low-dose CT scan acquired during tidal 
breathing and on transmission scans with rotating 68Ge rod sources for the Siemens HR+ system. All 
reconstructions resulted in an image resolution of 7 mm at the center of the field of view (FOV). 
DCE-MRI was performed on three 1.5-T clinical MRI systems: 2 Siemens Sonata systems and an Intera 
Philips system. All DCE-MR images were acquired in a transverse plane (5 slices; slice thickness, 10 
mm), with the patient using a breath-hold technique. The acquisition protocol included 5 precon-
trast T1-weighted (3-dimensional spoiled gradient-echo sequences) measurements with different flip 
angles (35°, 25°, 15°, 10°, 8°, 4°, and 2°) to determine the T1 relaxation time in the blood and tissue 
before contrast arrival. Next, gadolinium–diethylenetriaminepentaacetic acid (0.1 mmol/kg of body 
weight) (Magnevist, 0.5 mol/L; Bayer Schering Pharma) was intravenously injected (3.0 mL/s) and 
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flushed with 15 mL of saline. This injection was followed by the DCE series, using the same sequence 
as the 5 precontrast T1-weighted measurements but with a flip angle of 35°, containing 30–35 scans 
of 2 s each. Images were acquired with the following parameters: first Siemens scanner: repetition 
time/echo time, 2.84/1 ms; FOV, 350 mm; and matrix, 263 x 350, and second Siemens scanner: rep-
etition time/echo time, 2.05/0.75 ms; FOV, 350 mm; and matrix, 160 x 256. For the Philips scanner, 
parameters were repetition time/echo time, 4.5/2 ms; FOV, 350 mm; and matrix, 144 x 256. A fast data 
acquisition period (interscan interval, 2 s) was started before the bolus arrival, with the patient under 
breath-hold instructions to minimize motion artifacts during the first passage of the contrast agent.
Data processing
During the study, clinicians were unaware of the imaging results, and those who analyzed the images 
were unaware of clinical outcome and the alternative modalities (except for appropriate FOV position-
ing of initial PET using the baseline CT). 
pet 
Patients were evaluable only when all scans were obtained on the same scanner, with a consistent 
protocol with respect to injected 18F-FDG dose, interval from injection to scanning, and acquisition set-
tings (i.e. exclusion of within-patient variability) [14]. Because individual medical centers used differ-
ent PET scanners, only the relative change of imaging parameters was used. In this way, heterogeneity 
due to the use of multiple scanners was nearly eliminated [15]. All images were converted to ECAT 7 
format and analyzed using software developed in-house. Threshold-defined VOIs of the primary tu-
mor (41% of the maximum pixel value, with correction for physiologic uptake in the local background) 
were defined semiautomatically [15, 16]. For dynamic scans, the 18F-FDG tumor VOIs were applied to 
both 18F-FDG and H2
15O dynamic data to generate time–activity curves. An image-derived input func-
tion was created by multiple 2-dimensional regions of interest (ROIs) manually drawn over the aortic 
arch and ascending aorta. Three venous blood samples were taken as a quality control for the image-
derived input function [17]. ROIs were then applied to all frames to generate an input time–activity 
curve. Full kinetic analysis to derive values of the MRglu was performed using a 3-compartment model 
and Patlak graphical analysis [18]. For all scans, simplified semiquantitative measures were derived 
by calculating the mean SUV for primary tumor VOIs (50–60 min after injection for dynamic scans 
and 80 min after injection for static ones) and corrected for lean body mass. The correlation between 
simplified (SUV) and full kinetic (MRglu) analysis was explored to validate the use of SUV during this 
intervention [19]. Mean SUV was chosen above maximum because of superior reproducibility [20] and 
because it allowed the validation of SUV against MRglu, which cannot be done for a single voxel. 
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Tumor perfusion was estimated using dynamic H2
15O data and a 1-tissue-compartment model, consid-
ering an arterial blood volume component, and an image-derived input function [21, 22]. 
dce-mri
A single central slice containing the primary tumor was selected, and an ROI was manually drawn around 
the whole tumor. Before an ROI was drawn, the unenhanced and enhanced images were both viewed 
so that nontumor tissue and large vessels were avoided. Care was taken to ensure that tumor ROIs of 
subsequent scans were drawn at the same anatomic position. To obtain an arterial input function in 
every patient, an ROI was manually drawn in a major blood vessel using 1 transverse plane in the peak 
arterial enhancement phase of imaging. Unfortunately, it appeared impossible to derive an adequate 
arterial input function in every patient, mainly because of the anatomic location of some tumors, the 
absence of a large vessel in the field of view, and strong inflow (signal saturation) effects. Therefore, 
a standardized arterial input function was used [23]. All DCE-MRI data were analyzed with software 
developed in-house. A pharmacokinetic 2-compartment bidirectional exchange model was used to de-
termine Ktrans [24, 25]. Pharmacokinetic analysis was done on a pixel-per-pixel basis. Ktrans values of indi-
vidual pixels were collected and tabulated in a Ktrans pixel histogram. The SD was calculated, representing 
the heterogeneity of tumor Ktrans distribution (Ktrans SD) [25–27]. Analysis was performed after ruling out 
zero values of Ktrans to exclude nonperfused regions, for which the pharmacokinetic model is not valid.
Statistical analysis
To investigate the agreement of SUV and MRglu measurements at baseline and after 3 wk of treatment, 
the r2 value was calculated together with the slope of the standardized values of the difference of both 
paired measurements. The 95% confidence interval (CI) of the slope was obtained using the adjusted 
bootstrap percentile method. Baseline patient characteristics were compared with ANOVA for con-
tinuous variables and with the Fisher exact and Χ2 tests where appropriate for qualitative variables. 
The predictive value of CT-, DCE-MRI–, and PET-derived measures for PFS was assessed using the per-
centage change from the baseline value (Δ value). PFS was defined as the time from start of treatment 
to the date of first documented disease progression in terms of RECIST or the date of death. Patients 
who had not progressed or died at the time of analysis were censored at the date of last contact. 
Predefined cutoff points were used and curves were compared by log rank testing. On the basis of 
reproducibility data, a 20% cutoff point was used for PET (i.e. values outside 1.96 x SD) [16, 28]. For 
DCE-MRI, a 40% cutoff point was used for Ktrans and 15% for Ktrans SD [10, 29]. Statistical analyses were 
performed using SPSS (version 15.0; SPSS Inc.). Results are presented with hazard ratios (HRs), includ-
ing 95% CIs and p values. A p value of less than 0.05 was considered to be significant.
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results
Forty-seven patients were enrolled from 3 centers in The Netherlands. One patient received thoracic 
radiotherapy, but this was 6 Gy before inclusion. Three patients were excluded because no PET and 
MRI scans were available, resulting in the inclusion of 44 patients (Figure 1). 
Individual patient results are presented in a supplemental table, available in Journal of Nuclear Medi-
cine online. As indicated in Figure 1, complete imaging datasets were available for 14 patients, mainly 
because of the single-center availability of H2
15O PET and, to a lesser extent, technical failures of DCE-
MRI. At the time of analysis, 35 patients (80%) had died and 41 (93%) showed disease progression. 
Median follow-up was 15.6 mo. An example of an imaging profile for a patient with a response on all 
modalities is shown in Figure 2. 
47 patients
14 with all data available at both baseline and week 3
2 progressed
1 withdrawal from imaging
1 unable to lie still because of pain
1 with no 18F-FDG uptake in tumor
21/44 H215O PET
19/44 H215O PET
23 with no access to on-
site cyclotron
2 progressed
2 progressed
4 with technical failure 
otherwise
1 scanned on 2 different 
scanners
43/44 18F-FDG PET
2 progressed
1 with patient movement
40/44 18F-FDG PET 42/44 CT
44/44 CT
27/44 DCE MRI
33/44 DCE MRI
1 with breathing motion
5 with no tumor delineation
5 with technical failure 
otherwise
No failure
Figure 1. Flow chart of patients. Transparent boxes provide information on scan failure. Baseline and 
week 3 time points can be found in hatched boxes and shaded boxes, respectively.
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predictive value of Ct
The mean change in the sum of diameters for all target lesions after 3 wk of treatment was a decrease 
of 8% (interquartile range [IQR], -22% to 4%). After 3 wk, RECIST results were as follows: complete 
response (CR), 0 (0%); partial response (PR), 6 (14%); stable disease, 31 (74%); and progressive disease 
(PD), 5 (12%). At week 6, 3 patients changed from stable disease to PR (7%) and 5 from stable disease 
to PD (12%). Best overall response rates at the time of analysis were CR, 1 (2%); PR, 9 (21%); stable 
disease, 22 (50%); and PD, 12 (27%). Forty percent of patients with PR as their best response on CT had 
stable disease at week 3. Patients with PR at week 3 had a median PFS of 4.6 mo as compared with 2.9 
mo for all other patients (HR, 0.39; 95% CI, 0.18–0.84; p = 0.017) (Figure 3A). 
pet: validation of Suv against mR
glu
 
The results of 17 patients were available at both baseline and after 3 wk. At both time points, there 
was a strong correlation between SUV and MRglu (r
2 = 0.96). The slope of the actual regression line was 
0.98, with a CI (bootstrapped, n = 1,000) of 0.82%–1.05%, indicating that SUV can be safely used as an 
alternative for the fully quantitative Patlak-derived MRglu during BE treatment.
predictive value of glucose metabolism (18F-FDg pet) 
Forty patients were scanned both at baseline and after 3 wk. Mean SUV decreased by 5% (IQR, -16% 
to 12%). The median PFS for patients with a metabolic response (SUV decrease > 20%) at week 3 was 
9.7 mo as compared with 2.8 for other patients (HR, 0.38; 95% CI, 0.18–0.79; p = 0.01) (Figure 3B). 
Direct comparison of 18F-FDG PET with CT was available for 40 patients. Although a response according 
Figure 2. Baseline (top) and week 3 (bottom) scans of patient with a response on all modalities: 
CT (A), 18F-FDG PET (B), H2
15O PET (C), and DCE-MRI (D).
a B c d
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to RECIST was predictive for longer PFS (4.6 vs. 2.9 mo), this was no longer significant (HR, 0.47; 95% 
CI, 0.2–1.1; p = 0.08). 
All patients with PR as their best RECIST score were scanned with 18F-FDG PET, and 7 of 10 showed a 
significant reduction in tumor metabolism, including 2 patients with stable disease at their week 3 CT 
scan. 
Correlation of Suv and ReCISt Response at Week 3
Discrepancy was seen in both directions, but there were no patients with PD using 1 imaging modality 
and PR with the other. Three of 7 patients with PR using 18F-FDG PET showed stable disease at CT. Me-
dian PFS for these patients was 9.7 mo. One patient showed a PR according to RECIST and the absence 
of a significant metabolic response and had a PFS of 4.6 mo. Remarkably, not all patients with PR using 
both modalities (n = 4) performed well. Two patients had a relatively short PFS (2.7 and 3.1 mo), as 
compared with 12 and 14.7 mo for the other 2 patients. One had progression due to brain metastases 
and the other due to pleural effusion with malignant characteristics. 
c
Figure 3. Kaplan–Meier curves (PFS) stratified for response after 3 wk of treatment according to CT (A), 
18F-FDG PET (B), H2
15O PET (C), and DCE-MRI (D).
a B
d
! !
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predictive value of perfusion (H
2
15o pet) 
Tumor blood flow was measured for 19 patients both at baseline and after 3 wk. Mean blood flow 
decreased by 11% (IQR, -20% to -1%). Patient characteristics were not statistically different from the 
entire cohort (data not shown, p > 0.34). Patients with a greater than 20% decrease in tumor perfusion 
had a median PFS of 12.5 mo, as compared with 2.9 mo for the others (HR, 0.25; 95% CI, 0.09–0.70; p 
= 0.009) (Figure 3C). Direct comparison of H2
15O PET with CT showed that patients with PR on CT had 
longer PFS (median, 5.8 vs. 4.1 mo), but this lost significance (HR, 0.31; 95% CI, 0.04–2.49; p = 0.59). 
Five of 10 patients with PR as their best RECIST score were scanned with H2
15O PET, and all showed a 
significant flow reduction, including 3 patients with stable disease at their week 3 CT scan.
predictive value of DCe-mRI
Twenty-eight patients were scanned both at baseline and after 3 wk. Mean Ktrans decreased by 17% 
(IQR, -55% to -7%). Patient characteristics were not statistically different from the entire cohort (data 
not shown, p > 0.52). Ktrans was not associated with PFS (40% cutoff point, log rank, p = 0.39). Histogram 
analysis of tumor Ktrans on a pixel-per-pixel basis by Ktrans SD showed that an increase of 15% in intratu-
mor heterogeneity was predictive for treatment failure (median PFS, 2.3 vs. 7.0 mo; HR, 4.4; 95% CI, 
1.5–13.3; p = 0.008) (Figure 3D). Direct comparison with CT revealed that CT was not discriminative 
in this subset (median PFS, 4.6 vs. 4.2 mo; HR, 0.43; 95% CI, 0.16–1.16; p = 0.1). Seven of 10 patients 
with PR as their best RECIST score were scanned with DCE-MRI, and none showed an increase in Ktrans 
SD, including 3 patients with stable disease at their week 3 CT scan.
Figure 4. Scatter plot of correlation between ∆ Ktrans and ∆ F.
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Correlative Studies
Although both Ktrans and F decreased during treatment, there was no correlation between the change in 
both parameters (Figure 4). Also, tumor blood flow was not correlated to glucose metabolism at base-
line and after 3 wk of treatment, although a nonsignificant trend toward a positive correlation was ob-
served after 3 wk (Figure 5). Three patients had a low MRglu-to-F ratio after 3 wk of treatment, of which 
2 already had a low baseline MRglu-to-F ratio (Figure 5). However, PFS for these patients was heteroge-
neous (range, 2.9–6.9 mo), such that no prognostic value could be attributed to this phenomenon.
discussion
This study shows that molecular imaging allows early response evaluation and seems superior to static 
imaging with CT in patients with NSCLC treated with combined anti–epidermal growth factor recep-
tor and vascular endothelial growth factor therapy. Size-based response criteria are known for their 
inconsistent relation with PFS [2]. With targeted therapy, tumor consolidation might also represent 
therapeutic efficacy, resulting in prolonged survival [3–5]. However, early after treatment initiation, 
patients with tumor consolidation form a heterogeneous group because both tumor shrinkage and 
growth are relatively slow processes. As a result, response and progression can be underestimated 
when tumor size is used as an early predictive marker. In this study, we explored molecular imag-
ing techniques and used prospectively defined cutoff values that were based on reproducibility data. 
Figure 5. Scatter plot of correlation between PET-derived tumor perfusion and metabolism at base-
line (A) and after 3 wk of treatment (B). Three data points in B with low MRglu:F ratio are marked as 
triangles.
a B
! !
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The latter allow the identification of any biologic effect due to the therapeutic intervention that is 
outside the area of test–retest variability. 
Regardless of whether tumor size changed after 3 wk, patients with a more than 20% reduction in 
tumor glucose metabolism had a favorable PFS time. These data suggest that response may occur in 
patients with stable disease at CT and that 18F-FDG PET is able to identify these patients. We used SUV 
for all patients and validated it against the fully quantitative Patlak method in a subpopulation [19]. 
The data do not show a significant effect of BE treatment on the pharmacokinetics of 18F-FDG PET, 
and therefore SUV can be safely used as a substitute for the more advanced Patlak method during BE 
treatment in NSCLC. 
Today, most trials rely on size criteria (RECIST) to base decisions on whether to discontinue drug ther-
apy. However, it can be questioned whether this approach is applicable for trials with targeted agents, 
looking at our and others’ results [2]. Early discontinuation of ineffective therapy can prevent harm-
ful adverse events. In addition, patients can deteriorate soon after treatment failure, depriving them 
of potentially beneficial second-line therapy. Therefore, there is a need for more accurate response 
evaluation early in the course of treatment. In our study, all imaging modalities were able to show lon-
ger PFS for responders than for nonresponders after 1 BE cycle, but head-to-head comparison favored 
molecular imaging. 
Four of 10 patients with PR or CR as their best RECIST result had stable disease at week 3. H2
15O PET 
was performed in half these patients, and all showed a major flow reduction, irrespective of size 
change. DCE-MRI was performed in most cases [7/10], and an increase in Ktrans SD, associated with 
treatment failure, was not seen. SUV decreased in all but 3 patients. One patient had a borderline-
insignificant SUV decrease, whereas 2 others had a 10% decrease and relatively low baseline uptake 
(SUV, 2.9 and 3.0). These 2 patients had stable disease according to RECIST at week 3. Tumor perfu-
sion, however, was strongly reduced in these patients, indicating that blood flow might be a sensitive 
response predictor. 
Blood flow measurements were performed in a subpopulation in this study. A decrease of 20% in 
tumor perfusion was associated with longer PFS (Figure 3C). Even though DCE-MRI–derived Ktrans was 
not predictive of PFS, the pixel-by-pixel histogram analysis of tumor Ktrans suggested that the absence 
of an increase in intratumor Ktrans heterogeneity after 3 wk was associated with a therapy benefit. An 
increase in heterogeneity indicates a less even distribution of gadolinium contrast extravasation into 
the extravascular extracellular space, reflecting a pathologic vessel bed with areas of leaky vessels and 
increased perfusion and areas with severe hypoperfusion and thus absence of normalization. 
The potential of combining data on perfusion and metabolism has been evaluated by Mankoff et al 
[30] and Tseng et al [31] in patients with breast cancer. They observed that glucose metabolism and 
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perfusion exhibit a weak positive correlation at baseline, which increases after (conventional) chemo-
therapy. In addition, patients with high pretherapy MRglu relative to perfusion (MRglu-to-F ratio) were 
more likely to experience therapy resistance and relapse. We did not observe this in our dataset. A 
low MRglu:F ratio is caused by a tumor that has low metabolic activity or is highly vascularized. Anti–
vascular endothelial growth factor treatment may result in a decrease in microvessel density, vascular 
permeability, and interstitial fluid pressure [32]—that is, a combination of an overall reduction in tu-
mor perfusion and normalization of the remaining vessel bed—resulting in less hypoxia in remaining 
tumor tissue. Our results support this hypothesis to some extent because overall tumor blood flow 
and Ktrans decreased, reflecting a reduction in microvascular flow, permeability, and/or surface area. 
Ktrans SD showed that an increase in pathologic vessel bed was associated with worse outcome in terms 
of PFS. Similar results were obtained in rectal cancer 12 d after bevacizumab monotherapy [33]. 
Our study is the first, to our knowledge, to examine the correlation of blood flow measurement be-
tween DCE-MRI and PET during targeted anticancer therapy. Although both Ktrans and F decreased 
during treatment, reflecting a reduction in blood flow and/or vessel permeability, no correlation was 
found (Figure 4), possibly reflecting the different nature of the signals. Although F is a selective mea-
sure of blood flow, Ktrans is influenced by microvascular flow, permeability, and surface area. At baseline, 
the extravasation of gadolinium contrast agent is not restricted by the permeability of the numerous 
leaky blood vessels but is primarily flowdriven. After therapy, the extravasation of gadolinium becomes 
more restricted by the normalized vessel permeability and surface area. This varying pathophysiologic 
meaning of Ktrans at baseline and after therapy might explain the difference in Δ F and Δ Ktrans. Another 
explanation could be the semiquantitative nature of the DCE-MRI technique due to the nonlinear rela-
tionship between the degree of signal enhancement and gadolinium concentration. 
conclusion
This study explored the opportunities of molecular imaging as an early response-evaluation tool. The 
results show that SUV, F, and Ktrans SD all predict for PFS benefit at a significant level and that these 
parameters seem to perform better than RECIST, whereas mean Ktrans did not. The study included rela-
tively few patients, and few were eligible for head-to-head comparison of all techniques (only 14 
patients were scanned using all imaging modalities at both baseline and after 3 wk, reflecting the 
intensity of the protocol). Nevertheless, these results should stimulate similar trials, in part to inves-
tigate mechanisms of action by integrating data from different imaging modalities (with PET/MRI as 
the logical modality, provided that such a device would not compromise the quantitative potential of 
either technique) and in part to explore whether molecular imaging improves patient management or 
go-no-go decision making in drug development.
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the use oF imaging Biomarkers to evaluate vascular modulation
In chapter two we discussed the literature with respect to tumor perfusion measurements with PET 
and DCE-MRI. Antiangiogenic agents are thought to alter tumor vasculature by normalizing vessel 
structure, inhibition of lymphangiogenesis and reduction of tumor interstitial pressure [1]. Several of 
these consequences of antiangiogenic treatment can be monitored with imaging techniques. DCE-
MRI and H2
15O PET measure the endothelial transfer coefficient and tumor perfusion, respectively. 
Accuracy studies for vascular measurements with PET have not been performed in tumors, mainly 
because typical characteristics of tumor vasculature like heterogeneity in afferent and efferent ves-
sels and perfusion inhomogeneity are difficult to model. However, the one-compartment model has 
been validated for perfusion measurements in other tissues like myocardium and brain [2-8]. Although 
perfusion inhomogeneity introduces bias in regional perfusion calculations, measurements of average 
tumor perfusion are expected to be accurate because the model is still linear in the range of observed 
tumor perfusion values.  
For DCE-MRI, accuracy is more difficult to determine because the signal reflects both perfusion and 
permeability. However, data supports the theory that enhancement of the MRI signal reflects vessel 
permeability and tumor perfusion [9-11]. 
Although validation is limited for both techniques, they reflect changes of tumor vasculature and are 
the most sophisticated way to non-invasively study tumor vasculature until more validated methods 
become available. 
The different nature of their signal offers interesting opportunities when both techniques are used 
side-by-side. H2
15O PET specifically measures tumor perfusion due to the free distribution of water, 
while DCE-MRI measures a combination of vessel permeability, surface area and perfusion because 
gadolinium is not freely diffusible. Therefore, the two modalities can complement each other. In the-
ory, both perfusion and permeability can be isolated when perfusion (F) and the endothelial transfer 
coefficient (Ktrans) are known. 
validation oF pet imaging Biomarkers
The results obtained in chapter two in combination with the biological background of combined EGFR 
and VEGF treatment lead to the design of validation and qualification studies aiming to detect target 
modulation and to produce surrogate endpoint biomarkers. First we focussed on validation of the 
imaging biomarkers of interest, and in particular on repeatability. 
In chapter three the repeatability of H2
15O, a marker of perfusion, was evaluated. The study was per-
formed using a PET only system with a 10-15 min. transmission scan followed by a dynamic emission 
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scan. Volumes of interest (VOIs) were defined on subsequently derived 18F-FLT images because of 
superior contrast between tumor and background. When patients are followed over time, changes of 
more than 18% in F and more than 32% in the volume of distribution (VT) are likely to represent a true 
change, rather than measurement error. 
In chapter four, 18F-FDG, a marker of glucose metabolism, was evaluated. A meta-analysis of the published 
data was performed to evaluate the pooled test-retest variability. Recently, Wahl et al introduced the term 
PERCIST [12] as a PET counterpart of the CT biomarker RECIST which is a FDA approved surrogate endpoint 
biomarker. Validation of the PERCIST concept was mandatory before the qualification process could be 
initiated and the present meta-analysis aimed to do so. In accordance with the study of Wahl et al, per-
centage repeatability was found to be a function of the level of uptake. For serial PET scans, a threshold of 
a combination of 20% as well as 1.2 SUV
mean
 units was found to be more than 95% likely to be a true change 
of glucose metabolism, rather than measurement error. After adjusting for uptake rate, tumor volume had 
only minimal effect on repeatability. Compared to SUV
max
, SUV
mean
 showed better repeatability.
In chapter five the repeatability of 18F-FLT, a marker of tissue proliferation, was evaluated. When patients 
are followed over time, changes of more than 15% in SUV
mean
 and 20–25% in Ki and SUVmax are likely to 
represent a change in tumor proliferation, rather than measurement error. 18F-FLT is being trapped in the 
cell due to phosphorylation by thymidine kinase 1. Theoretically, k
3
 is the most specific parameter to study 
TK1 activity and probably best linked to proliferation, because SUV and Ki are also subject to perfusion and 
extraction. Unfortunately, k
3
 showed poor repeatability. However, Ki and SUV were found to be accurate 
markers of proliferation in validation studies using histological proliferation markers like Ki-67 [13-15].
QualiFication oF h
2
15o and 18F-FDg pet DeRIveD ImagIng bIomaRkeRS
Next we designed a clinical phase II trial where NSCLC patients were treated with BE. Regarding PET, 
three tracers were available to evaluate target modulation. The short radioactive half-life of 15O (2 
min) allows a scan to be followed by a second scan with a different tracer to study additional aspects 
of tumor biology. However, the longer half-life of 18F does not allow a sequential scan with a different 
18F tracer within the same imaging session. Therefore either 18F-FDG or 18F-FLT had to be selected. 
Both glucose metabolism and cellular proliferation are downstream effects of the EGFR pathway, as 
discussed in the introduction. The detailed information of the connection between the EGFR pathway 
and glucose metabolism favored 18F-FDG. Recently the superiority of 18F-FDG (compared to 18F-FLT) 
as surrogate endpoint biomarker was shown in a comparative response monitoring study in NSCLC 
patients treated with an EGFR TKI [16].
Because H2
15O and 18F-FDG were not qualified for integral use (i.e. for clinical decision making, see 
Table 1 in chapter 1), the biomarkers were not used to influence trial design, but as pharmacodynamic 
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measurements to study target modulation and explored as surrogate endpoint biomarkers.
Chapter six and seven describe the results of a clinical phase II study where a group of chemotherapy-
naive patients with stage IV non-squamous NSCLC were treated with BE until disease progression 
(assessed with RECIST). The value of imaging biomarkers to predict progression-free survival (PFS) was 
explored using predefined cutoff values. 
The primary end point, a non-progression rate (NPR) of 75% after six weeks of treatment, was met. 
The objective response rate (ORR) of 25% was not different from that what can be obtained with 
cytotoxic chemotherapy. Disappointingly however, median overall survival (OS) was only 6.9 (95% CI 
5.5–8.4) months. Importantly only half of the patients received second-line platinum-based chemo-
therapy upon disease progression. This was mainly due to patient refusal and deterioration of physical 
performance due to disease progression, indicating that early use of sensitive biomarkers is essential 
for optimal patient treatment. 
In patients with longer PFS than the mean, F, Ktrans, and SUV decreased by a mean of 20% (IQR -48% to 
+1%), 17% (IQR -61% to -10%) and 17% (IQR -39% to +2%), respectively, indicating vascular and meta-
bolic change. In contrast, mean F and SUV did not change in patients with lower PFS than the mean; -3% 
(IQR -15% to -4%) and 6% (IQR -2% to +22%), respectively. Mean Ktrans, however, decreased irrespective 
of PFS benefit (-17%, IQR -49% to +10%). This contrast between F and Ktrans might be explained by a de-
crease in vessel permeability and/or surface area which does not translate into a PFS benefit. However, 
tumor Ktrans is a difficult parameter to interpret. At baseline, the extravasation of contrast agent is not 
restricted by the permeability of the numerous leaky blood vessels and is primarily flow driven. After 
therapy, the extravasation becomes more restricted by the normalized vessels. This variable pathophysi-
ologic character of Ktrans might explain the difference in Δ perfusion and Δ Ktrans. Other explanations could 
be error in Ktrans measurements due to the semi-quantitative nature of the DCE-MRI technique (caused 
by the nonlinear relationship between the degree of signal enhancement and gadolinium concentra-
tion) or the use of a population-based AIF (due to failure of patient-based AIF measurements).   
To qualify the imaging parameters as surrogate endpoint biomarkers, we evaluated their predictive 
value for PFS after three weeks of treatment. With RECIST, 14% of the patients had a PR at week 3 
and 78% had SD, while these numbers were 26% and 63% for tumor perfusion, 18% and 68% for SUV 
and 43% and 43% for Ktrans, respectively, using predefined cutoff values. Although a partial response 
(according to RECIST) at week 3 was associated with prolonged PFS (4.6 months for responders vs. 2.9 
months for all other patients; HR 0.39; 95% CI 0.18–0.84; p = 0.017), 40% of patients that had a PR/CR 
somewhere during the course of treatment still had stable disease at the 3-week time point. This cor-
roborates previous observations that size based response criteria have low discriminative value early 
in the course of treatment. In these patients tumor perfusion was already decreased and Ktrans hetero-
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geneity showed no increase. The results indicate that the latter parameters are more discriminative 
than RECIST at the 3-week time point. Regardless of tumor size change, patients that had a metabolic 
response (SUV decrease > 20%) after three weeks had longer PFS (9.7, 95% CI 1.8–17.6, months) than 
those without (2.8, 95% CI 2.0–3.5, months; HR 0.38; 95% CI 0.18–0.79; p = 0.01). 
Although the change in Ktrans indicated vascular modulation, the parameter could not be qualified as a 
surrogate endpoint biomarker because it was not related to PFS (p = 0.39). Exploratory pixel-by-pixel 
analysis of Ktrans showed that patients with an increase of more than 15% in the standard deviation of 
tumor Ktrans (Ktrans heterogeneity), i.e. an increase in regions with low or high Ktrans values, after three 
weeks had shorter PFS (2.3 vs. 7.0 months; HR 4.4; 95% CI 1.5–13.3; p = 0.008). 
An increase in Ktrans heterogeneity indicates a less even distribution of gadolinium contrast extravasa-
tion into the EES, reflecting a pathologic vessel bed with areas of leaky vessels and increased perfusion 
and areas with severe hypoperfusion, both pathological and thus absence of vascular normalization. 
Although promising, Ktrans heterogeneity analysis has yet to be validated and qualified. The cutoff value 
of 15% to define a relevant change was most discriminative, but whether this holds for future studies 
remains speculative.
A greater than 20% decrease in tumor perfusion, as measured with PET, was also associated with PFS ben-
efit; 12.5 months vs. 2.9 months for patients without a decrease (HR 0.25; 95% CI 0.09–0.70; p = 0.009). 
Although both Ktrans and F decreased during treatment, indicating a reduction in perfusion and vessel 
permeability, no clear correlation was found between them, possibly reflecting the different nature of 
the signals, or because of the already mentioned difficulty of quantitative Ktrans measurements due to 
signal saturation and the use of a population based AIF. This could well explain why Ktrans heterogeneity 
was more discriminative than mean Ktrans. Δ (mean) Ktrans requires the absolute value of the week 3 scan 
to be compared with that of baseline, while Ktrans heterogeneity is a reflection of the heterogeneity 
within the tumor and is a measure of the distribution of values within the tumor at a single time-point 
and thus expected to be less dependent on error in AIF measurement and absolute signal value. The 
signal intensity of pixels is being compared to the signal intensity of the other pixels in the tumor 
within the same scan. 
Although tumor perfusion was not related to glucose metabolism at baseline and after three weeks 
of treatment, a non-significant positive relation was observed after three weeks, possibly reflecting a 
combination of an overall reduction in tumor perfusion together with normalization of the remaining 
vessel bed. 
In conclusion, this thesis shows that PET derived parameters of glucose metabolism, proliferation and 
perfusion are repeatable. DCE-MRI derived Ktrans heterogeneity and PET derived measurements of tu-
mor perfusion and glucose metabolism were qualified as surrogate endpoint biomarkers.  
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Future perspectives 
At present, several studies with targeted agents are actively recruiting unselected cohorts of patients 
(www.clinicaltrials.gov). This strategy does not only cause harm by denying patients the best treatment on 
the individual level, but can actually negatively influence their survival. This was recently demonstrated in 
a trial evaluating combined treatment targeting c-MET and EGFR. Although patients with high MET expres-
sion benefited from the addition of a monoclonal antibody (MAb) against MET to an EGFR TKI, patients 
with low MET expression experienced decreased survival when a MET MAb was added [17]. This illustrates 
the importance of continuous comparison of emerging data with preclinical results. Biomarkers can aid 
this process by reflecting target modulation and by relating this to patient outcome. Considering individual 
pros and cons of the different biomarkers, the solution might be to regard them as additive or even syn-
ergistic, rather than competitive. Tumor biopsy is an excellent method to screen multiple pathways and 
receptor mutation and expression profiles within a single tumor sample, impossible to obtain by imaging 
alone. Exploratory tissue analyses have been shown to generate predictive biomarkers that can be used 
for patient stratification (e.g. EGFR mutation status). Recently, our group developed and validated a non-
invasive pharmacokinetic imaging biomarker to assess EGFR mutation status by radiolabeling erlotinib, 
an EGFR TKI. Validation was done by comparing 11C-erlotinib kinetics with EGFR mutation status in tumor 
biopsy samples and subsequent qualification as predictive biomarker was done by relating the results to 
patient outcome [18]. In this example, an invasive method was used to discover the target that predicts for 
treatment benefit. Next, it was used as a platform to validate the non-invasive biomarker 11C-erlotinib. 
Although baseline biomarkers can be highly predictive of patient outcome to therapy, this is unfortu-
nately not the case for all patients, despite biomarker homogeneity at baseline. Tumor-host interac-
tions and additional therapeutic strategies (e.g. radiotherapy or adding a second drug) can modify the 
clinical response. Therefore, a read-out of response during treatment, preferably as soon as possible, 
is essential to detect treatment failure before clinical deterioration occurs, limiting further treatment 
options. Conceptually, imaging can perform this job. Early stopping rules can be applied when change 
in tumor biology is absent, thereby adding valuable information to baseline predictive biomarkers. Re-
petitive biopsy forms an alternative, but clinical feasibility is hampered by its invasive character. Also, 
in contrast to imaging, this method does not allow to assess intra- and inter-lesional heterogeneity.
Recently, the Radiological Society of North America (RSNA) initiated QIBA (Quantitative Imag-
ing Biomarkers Alliance) to advance quantitative imaging and the use of imaging biomarkers in 
clinical trials and clinical practice by engaging researchers, healthcare professionals and industry 
(http://qibawiki.rsna.org). Committees for DCE-MRI, 18F-FDG PET and volumetric CT were formed to 
define basic standards and quality control measures that should ensure consistent, reliable and fit-for-
purpose quantitative biomarkers. Because of the potential of biomarkers to improve drug develop-
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ment and patient outcome on the individual level, QIBA aims to speed up qualification and to receive 
FDA approval for integral use of the biomarkers. 
There are several sophisticated trial designs that facilitate this process by combining drug develop-
ment with biomarker qualification in early phase studies (Figure 1) [19]. The results obtained from 
these studies can be used to adjust eligibility criteria for subsequent phase III trials to include only 
those patients that are likely to benefit from treatment.
In this thesis, PET and DCE-MRI derived biomarkers were used in an integrated manner (see Table 1 in 
chapter 1 for definition). Compared to perfusion measurements with PET and DCE-MRI, 18F-FDG SUV 
was associated with better clinical feasibility and a lower drop-out rate. Although the primary end-
point (NPR of 75%) was met in this study, PFS was disappointing when compared to that of standard 
treatment. However, the subgroup of patients with a decrease in 18F-FDG SUV experienced longer PFS, 
qualifying it as a surrogate endpoint biomarker. Several other trials showed similar results of 18F-FDG 
SUV performance during EGFR TKI treatment [16, 20, 21]. However, none of these trials used the 
biomarker integrally (i.e. discontinuation of treatment when a decrease in 18F-FDG SUV was absent) 
and stopping rules were still based on RECIST (i.e. discontinuation of treatment in case of progressive 
disease). In theory, even patients with progressive disease on CT can benefit from treatment, as has 
been shown for gastrointestinal stroma tumors (GIST) where patients with PD on CT and a decrease in 
18F-FDG SUV responded favorably to drug therapy with imatinib [22]. 
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a. Adaptive parallel design [32, 33]. Two two-stage phase II trials are conducted in parallel; one in the biomarker positive group 
(expected to benefit more from treatment) and one in the biomarker negative group of patients. After the first stage, the trial may 
continue in all patients or only in the biomarker positive group. 
b. Tandem two-step design [33, 34]. All patients are entered in the first stage, regardless of the biomarker result. If the number of 
clinical responses that are observed in the first stage is large enough, the study proceeds to the second stage in the overall population. 
If the number of responses observed in the first stage is insufficient, the study accrues only patients in the subgroup predicted by 
the biomarker to be responders, and study termination is governed by a standard optimal two-stage phase II trial design in that 
subgroup of patients.
Figure 1. Examples of phase II biomarker and drug co-development [19].
a. b.
Biomarker
Biomarker - Stage I
Stage I
Stage II if active
Stop if inactive
Biomarker +
Stage II if active
Stop if inactive
Stage I
Stage II if active
Biomarker
Stop
Stage II
Biomarker -
Biomarker +
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This warrants a study with integral use of 18F-FDG SUV. The same eligibility criteria can be applied. Based 
on the results of Zander et al [16], metabolic response can be assessed with a 18F-FDG PET scan after 
one week of treatment. Only patients that show a decrease in 18F-FDG SUV will continue treatment and 
PFS will be the primary endpoint. Of note, an increase in the summed size of target lesions of > 20% in 
combination with a decrease in 18F-FDG SUV should not be regarded as progressive disease. Patients 
without a decrease in 18F-FDG SUV after one week should be switched to alternative treatment. 
Recent data show that resistance to EGFR TKIs might be reversed by hydroxychloroquine (HCQ), an 
antimalaria and antirheumatic drug, thereby (re)sensitizing tumor cells to EGFR TKIs. This encouraged 
us to initiate a trial to explore the efficacy of this combination together with validation of 18F-FDG SUV 
as surrogate endpoint biomarker for clinical benefit (Figure 2). Eligibility criteria will be based on previ-
ous treatment and EGFR mutation status, a baseline predictive biomarker. A tandem two-step design 
will be used with PFS as primary endpoint. All patients are entered in the first stage of a two-stage 
Simon’s design phase II study, regardless of the 18F-FDG SUV result after one week (Figure 2A). If PFS 
is comparable to that of standard treatment, the study proceeds to the second stage in all patients. If 
PFS is disappointing, a second two-stage Simon’s design phase II study will accrue patients that show 
a decrease in 18F-FDG SUV after one week of treatment (Figure 2B).
Figure 2. Tandem two-step design, modified for a trial evaluating drug efficacy of erlotinib and HCQ 
treatment, together with qualification of 18F-FDG SUV as surrogate endpoint biomarker for PFS benefit.
A. First step
B. Second step
140
Eligible patients for 
erlotinib and HCQ 
treatment
Start treatment
Adequate PFS 
benefit
Inadequate PFS 
benefit
Continue drug trial
Stop drug trial in the 
general study 
population
Stage I of a two-stage Simon’s design trial Stage II
Eligible patients for 
erlotinib and HCQ 
treatment
Start treatment
Discontinue 
treatment
Continue treatment
Lack of 18F-FDG 
SUV decrease
Decrease in 18F-
FDG SUV
Adequate PFS 
benefit
Inadequate PFS 
benefit
Continue drug trial
Drug combination is 
abandoned
Stage I of a two-stage Simon’s design trial Stage II
Discussion and future perspectives
    Chapter
                   8
In recent years, interesting progress has been made in scanner hardware and tracer development, 
providing new and potentially better parameters (Box 1). Several tracers are already available or are 
currently being developed that study numerous aspects of tumor biology and allow to evaluate target 
modulation to several classes of drugs. For example, PET-MRI combines two established techniques in 
one scanner (analogous to PET-CT). 
The CT technique allows to perform volumetric analysis, a more sophisticated way to evaluate tumor 
size that might be more sensitive than the unidimensional RECIST method. Validation studies have 
been performed for volumetric analysis and the method shows better repeatability than RECIST. Quali-
fication studies are currently being performed to evaluate its performance against RECIST. 
Other techniques like diffusion weighted MRI (DW-MRI) and magnetic resonance spectroscopy (MRS) 
are of great interest and potential, but still lack appropriate validation and qualification. However, 
definition of basic standards and uniform application of these biomarkers in dedicated trials should 
reveal their value on short notice. 
To conclude, it is the hope that this and future research on biomarker and drug development will lead 
to better treatment for cancer patients by selecting the best drug on the individual level and by apply-
ing early stopping rules based on changes in tumor biology, resulting in better survival.
box 1. New developments in imaging biomarkers.
Integrated pet-mRI is a promising technique that performs sequential studies with PET and DCE-MRI 
within one imaging session and allows combination studies with minimal spatial mismatch. 
The MR technique can also be used to study other biological processes than perfusion and permeability 
by magnetic resonance spectroscopy (MRS) and diffusion weighted MRI (DW-MRI). 
mrs relies on the fact that nuclei resonate at slightly different frequencies depending on the surrounding 
molecular environment. This allows to evaluate the molecular component of tissues. Several nuclei can 
be monitored (e.g. 1H, 13C, 14N, 19F, 23Na, 31P). The technique detects molecules containing the se-
lected atom. Although it allows to detect several metabolites in one single measurement, limiting factors 
are sensitivity and resolution and the technique requires further development before biomarkers can be 
qualified for clinical use in oncology [23]. 
dW-mri measures the mobility of water within tissues. The basic biological premise for the use of DW-
MRI in cancer is that malignant tissues are generally more cellular and have more high-water content 
than normal tissue, both of which lead to high signal intensity. There are a number of features that af-
fect tissue water diffusivity, including tissue perfusion, cell density and distribution, integrity of cellular 
membranes, and tissue organization. Signal change thus depends on complex interplay between several 
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biological processes in response to therapy. Validation on the biological (what aspects of tumor biology 
are reflected in the parameter) and analytical level (standardization and repeatability) needs to be opti-
malised before these biomarkers can be used in clinical trials.
CT still has many advantages when compared to newer imaging techniques like MRI and PET. It is widely 
available, relatively inexpensive, quick, and requires little time for data analysis and a minimum amount 
of personnel. 
Ct volumetric analysis might overcome some of the disadvantages of unidimensional size measure-
ments, because ill-defined and irregular lesions are subject to interobserver variation [24] and size 
change can be asymmetric. Volumetric analysis is associated with better repeatability than unidimen-
sional analysis [25, 26] and response assessment by CT volumetry seems to be more discriminative [25-
29]. However, despite the potential to complement or even replace RECIST, the superior value of this 
technique as surrogate endpoint for patient outcome in clinical practice remains to be proven [30]. The 
additional discriminative level is generally small and unidimensional measurement still represents an 
adequate alternative with the advantage of better clinical work flow [25]. 
As with MRI, CT can also be used to measure tumor perfusion by studying tracer (contrast) kinetics, 
a technique called dynamic contrast-enhanced computed tomography (DCE-CT). Kinetic modelling is 
similar to that of DCE-MRI. Sequential images are made before, during, and following the injection of a 
contrast agent. The extravasation of contrast agent from the vascular compartment to the extravascular 
extracellular interstitial space provides information on blood flow, blood volume and microvascular per-
meability. In potential, the technique offers an interesting alternative to PET perfusion studies because 
of the wide availability of CT scanners and the need for an on-site cyclotron to perform PET perfusion 
studies due to the short half-life of H2
15O (2 min). Although a comparison study of DCE-CT and H2
15O PET 
showed a moderate correlation for tumor perfusion using a static PET technique [31] providing limited 
validation, robust validation and clinical qualification using basic standards and quality control measures 
are still awaited for DCE-CT.
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achtergrond
Longkanker is een ziekte die moeilijk is te behandelen. Veelal zijn er uitzaaiingen naar andere organen 
op het moment van diagnose en kan genezing niet meer worden bereikt. In dat geval wordt chemo-
therapie gegeven om de ziekte af te remmen met als doel levensverlenging en klachtenvermindering. 
Omdat de winst beperkt is, wordt met wetenschappelijk onderzoek gezocht naar nieuwe medicijnen 
die effectiever zijn dan de bestaande. 
Tumoren bestaan uit een complex netwerk van kwaadaardige cellen en ondersteunende structuren 
zoals bloedvaten en bindweefsel waar op microscopisch niveau vele processen tegelijkertijd plaats 
vinden die de tumor in staat stellen te groeien en zijn destructieve werk uit te voeren. Het profiel van 
deze processen verschilt tussen typen kanker (bijvoorbeeld tussen borstkanker en longkanker) en de 
chemotherapeutische behandeling gericht tegen deze processen is dan ook afhankelijk van het type 
kanker. Recent onderzoek laat zien dat zelfs binnen hetzelfde type kanker dit profiel verschillend kan 
zijn. Dit betekent dat patiënt A met longkanker het beste behandeld kan worden met chemothera-
pie X, terwijl patiënt B met longkanker het beste behandeld kan worden met chemotherapie Y. Om 
erachter te komen welke behandeling het meest effectief is op individueel niveau, dient de behande-
lend specialist voorafgaand aan en tijdens de behandeling op de hoogte te zijn van het tumorprofiel. 
Onderzoeken die gericht zijn op het vinden van specifieke kenmerken in het tumorprofiel noemen we 
“biomarkers”. Door de informatie van deze biomarkers te relateren aan de prognose van een patiënt, 
de respons op behandeling, of het overlevingsvoordeel na behandeling krijgen zij een voorspellend 
vermogen en ontstaan respectievelijk prognostische, voorspellende en surrogaat eindpunt biomark-
ers. Daarnaast kunnen biomarkers inzicht bieden over het werkingsmechanisme van de behandeling. 
Dit worden farmacodynamische biomarkers genoemd en geven aan of een biologisch proces heeft 
plaatsgevonden of is veranderd door behandeling. Belangrijk is om biomarker informatie zo vroeg 
mogelijk te verkrijgen, het liefst voor aanvang van de behandeling, om langdurige therapie met niet of 
onvoldoende werkzame medicatie te voorkomen. Dit laatste is namelijk geassocieerd met onnodige 
bijwerkingen en achteruitgang in conditie waardoor patiënten niet meer in aanmerking komen voor 
een andere behandeling en daardoor korter leven.
De behandelend specialist heeft meerdere onderzoeken tot zijn beschikking die als biomarker kun-
nen fungeren. Voorbeelden zijn tumorpunctie, bloedonderzoek en beeldvormend onderzoek. De ide-
ale biomarker is een onderzoek dat accuraat, reproduceerbaar, makkelijk uitvoerbaar en toepasbaar, 
minimaal invasief, veilig en goedkoop is. Beeldvormend onderzoek is hiervoor uitermate geschikt. Dit 
type onderzoek kan meerdere malen worden herhaald zonder al te grote belasting voor de patiënt, 
mede omdat het een niet-invasief onderzoek is (in tegenstelling tot bijvoorbeeld herhaalde puncties). 
Daarnaast maakt beeldvormend onderzoek het mogelijk meerdere tumorlaesies tegelijkertijd te anal-
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yseren, waardoor gekeken kan worden naar heterogeniteit van het tumorprofiel binnen de patiënt. 
De huidige standaard voor beeldvormend onderzoek is de CT scan, een techniek die de tumor diam-
eter in beeld brengt. Aan dit onderzoek kleven meerdere bezwaren. Afname en toename van tumor 
diameter is een relatief langzaam proces waardoor het niet als vroege biomarker kan worden ingezet. 
Daarnaast heeft het een geringe relatie met (progressie-vrije) overleving. Omdat veel nieuwe behan-
delingen resulteren in stabilisatie van tumor diameter en niet zozeer in afname, is tumor diameter een 
minder gevoelige maat voor therapie evaluatie. 
Een alternatief is positron emissie tomografie (PET). PET scanners detecteren het verval van radioac-
tieve stoffen (tracers). Door een stof te volgen in het lichaam die belangrijk is voor de tumor kan inzicht 
worden verkregen in het tumorprofiel. Het is een dynamische techniek die kijkt naar het gedrag van 
de tumor (hoe gaat de tumor met een stof om en hoe verandert dit door behandeling) in tegenstell-
ing tot de statische CT techniek die enkel kijkt naar tumor diameter. Als bekend is dat een bepaalde 
stof (als voorbeeld nemen we glucose) cruciaal is voor tumorgroei en een behandeling is gevonden 
die de toevoer of het metabolisme van deze stof (glucose) blokkeert, kan deze stof fungeren als een 
goede PET biomarker. Voor aanvang van behandeling kan een scan worden gemaakt. Tumoren die 
veel glucose opnemen zullen waarschijnlijk goed reageren op de behandeling, terwijl tumoren met 
weinig glucose opname minder afhankelijk zijn van de brandstof voor groei en waarschijnlijk minder 
baat zullen hebben van het medicament. Een scan tijdens behandeling laat zien of glucose opname en 
metabolisme ook echt afnemen. Misschien zijn er wel meerdere mechanismen voor glucose opname 
en metabolisme en blokkeert het medicament net het verkeerde mechanisme bij sommige patiënten. 
Hier kan dan weer nieuw onderzoek naar verricht worden om te kijken of voor deze patiënten een 
nieuw medicijn is te ontwikkelen. 
Een tweede alternatief voor CT is “dynamic contrast-enhanced magnetic resonance imaging” (DCE-
MRI). Dit is een dynamische MRI techniek waarbij de structuur en functie van bloedvaten kunnen 
worden beoordeeld door de passage van een contrastmiddel met hele kleine deeltjes daarin te volgen 
door het tumor vaatnetwerk. Met DCE-MRI kunnen de doorbloeding, het bloedvolume en de mate 
van lekkage van het vaatnetwerk in een tumor worden berekend.
Net als geneesmiddelen moeten ook biomarkers ontwikkeld en getest worden voordat zij toegepast 
kunnen worden in de behandeling van patiënten. Dit gebeurt door validatie en kwalificatie. Validatie 
is onderzoek naar de accuraatheid (meet de biomarker wat het beoogt te meten en is deze met-
ing gevoelig en specifiek?) en de reproduceerbaarheid. Kwalificatie omschrijft het onderzoek naar de 
voorspellende waarde. De eisen waaraan een biomarker moet voldoen dient overeen te komen met 
de mate van invloed op de behandeling van een patiënt. Wanneer een biomarker directe invloed heeft 
op de behandelstrategie moet worden voldaan aan de hoogste kwaliteitseisen.
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Het doel van dit proefschrift is om PET biomarkers te valideren en te kwalificeren als surrogaat eind-
punt biomarkers voor de respons op een specifieke kanker behandeling. Deze behandeling is gericht 
tegen de bloedvaten van tumoren waardoor de tumor minder bloed en dus minder zuurstof en voed-
ingsstoffen krijgt. Geneesmiddelen in deze klasse worden antiangiogenese middelen genoemd. Ze zijn 
werkzaam door vaatnieuwvorming tegen te gaan en het bestaande vaatnetwerk te normaliseren. Dit 
laatste is zinvol omdat bloedvaten in een tumor erg poreus zijn waardoor de druk in een tumor hoog 
is en chemotherapie moeilijk in de tumor doordringt. 
tumor doorBloeding meten met pet en mri
In hoofdstuk twee wordt de meting van tumordoorbloeding met PET en MRI besproken aan de hand 
van de bestaande literatuur. Hoewel beide scanmethoden informatie geven over tumor doorbloeding, 
is de aard van het signaal verschillend. PET maakt gebruik van radioactief water wat vrij kan bewegen 
door het lichaam en de tumor. MRI maakt gebruik van Gadolinium, een contrastmiddel dat niet vrij 
door de vaatwand kan bewegen en dus afhankelijk is van de mate van poreusheid (permeabiliteit) van 
bloedvaten. Hierdoor meet PET specifiek de doorbloeding in een tumor, terwijl MRI een combinatie 
van doorbloeding, vaatwand oppervlak en permeabiliteit meet. Deze resultante wordt de endotheliale 
transfer constante (Ktrans) genoemd. 
Hoofdstuk twee laat zien dat PET en MRI betrouwbaar de tumordoorbloeding en de endotheliale 
transfer constante meten, op voorhand dat een zekere mate van standaardisatie in de meetmeth-
ode en data analyse wordt toegepast. Beide scanmethoden zijn in staat om therapie effecten van 
angiogenese remmers te detecteren. De verschillende aard van het MRI en PET signaal maakt hun 
informatie uniek waardoor deze elkaar kunnen aanvullen. In theorie kan de permeabiliteit over het 
tumorvaatoppervlak worden geïsoleerd uit het Ktrans signaal door deze te corrigeren voor de doorblo-
eding, gemeten met PET. 
validatie van pet Biomarkers
De behandeling die onderzocht wordt op werkzaamheid in dit proefschrift is deels gericht tegen een 
groeifactor voor bloedvaten (vasculaire endotheliale groei factor, VEGF) en deels tegen een specifiek 
groeiproces in de tumor dat geactiveerd wordt door activatie van een receptor op tumorcellen (de 
epidermale groei factor receptor, EGFR). Om het effect van deze therapie zo vroeg mogelijk te kun-
nen detecteren kwamen drie PET biomarkers (H2
15O, 18F-FLT, 18F-FDG) en één MRI biomarker (Ktrans) in 
aanmerking. 
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Reproduceerbaarheid
Hoofdstuk 3 tot en met 5 beschrijven  studies die de reproduceerbaarheid van de drie PET biomarkers 
onderzoeken. Deze studies laten zien dat alle onderzochte PET tracers een goede reproduceerbaar-
heid hebben. 
In hoofdstuk drie wordt de reproduceerbaarheid van 18F-FDG, een marker van glucose metabolisme, 
besproken. Een meta-analyse (gezamenlijke analyse van data uit meerdere studies) werd verricht om 
te kijken naar de samengestelde test-retest variabiliteit. De opname werd gekwantificeerd door ge-
bruik te maken van de “standardized uptake value” (SUV). De SUV kan bepaald worden voor een deel 
van de tumor of voor de hele tumor. Als alleen het meest actieve deel van de tumor wordt bekeken 
wordt deze maat de SUV
max
 genoemd, terwijl SUV
mean
 het gemiddelde glucose metabolisme voor de 
hele tumor reflecteert. 
Vergeleken met SUV
max
 is SUV
mean
 beter reproduceerbaar. De test-retest variabiliteit was afhankelijk 
van de mate van 18F-FDG opname. Tumoren met geringe opname hebben een slechtere reproduceer-
baarheid. Tumor volume heeft slechts een verwaarloosbare invloed op de reproduceerbaard van SUV. 
Als twee PET scans met elkaar worden vergeleken geeft een verschil van minimaal 20% en 1.2 SUV
mean
 
units een werkelijk verschil aan in glucose metabolisme. Kleinere verschillen kunnen het gevolg zijn 
van meetfouten.
In hoofdstuk vier wordt de reproduceerbaarheid van H2
15O, een marker van doorbloeding, besproken. 
Omdat het contrast van doorbloedingsplaatjes met PET laag is werd met de patiënt in exact dezelfde 
positie, een aanvullend plaatje gemaakt met 18F-FLT. Op dit laatste plaatje konden de plek en de gren-
zen van de tumor goed worden beoordeeld. Voor dit volume werd de gemiddelde doorbloeding ber-
ekend aan de hand van de H2
15O data. 
Als twee PET scans met elkaar worden vergeleken geeft een verschil van minimaal 18% een werkeli-
jk verschil aan in tumordoorbloeding. Ook werd gekeken naar het verdelingsvolume van water (VT), 
waarbij een toename of afname van 32% of meer de test-retest variabiliteit overstijgt. 
In hoofdstuk vijf wordt de reproduceerbaarheid van 18F-FLT, een marker van cel proliferatie, bespro-
ken. De mate van tracer opname (en dus cel proliferatie) werd, net als bij 18F-FDG, weergegeven met 
SUV. Daarnaast werd met een geavanceerde scantechniek ook in detail gekeken naar de verschillende 
constanten van opname, metabolisme en uitscheiding van de tracer door de tumor. 
Als twee PET scans met elkaar worden vergeleken dan geeft een verschil van minimaal 15% in SUV
mean
 
en 20-25% in SUV
max
 en Ki (de bloed plasma naar tumor transfer constante) een werkelijk verschil aan 
in tumorproliferatie. 
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kWaliFicatie van h
2
15o en 18F-FDg pet bIomaRkeRS
Na de validatiestudies werd een klinische studie geïnitieerd met als doel de PET tracers te kwalificeren 
als vroege voorspellende biomarkers voor een langere progressie-vrije overleving (PFS) na behandel-
ing. Hiervoor werden patiënten met niet-kleincellig longkanker behandeld met een combinatie van 
twee middelen gericht tegen EGFR en VEGF. 
Drie tracers kwamen in aanmerking voor biomarker kwalificatie; 18F-FDG, H2
15O en 18F-FLT. De korte 
radioactieve halfwaardetijd van 15O (2 minuten) maakt het mogelijk om aansluitend aan een H2
15O 
scan, een aanvullende scan met een andere tracer te maken om aanvullende metingen te verrichten 
aan het tumorprofiel. De lange halfwaardetijd van 18F maakt een aanvullende scan met een 18F tracer 
binnen één sessie onmogelijk. Daarom moest een keuze worden gemaakt tussen 18F-FDG en 18F-FLT. 
Vanwege de gedetailleerde kennis over de connectie tussen de EGFR cascade en glucose metabolisme 
werd gekozen voor 18F-FDG. 
Hoofdstuk zes en zeven beschrijven de resultaten van een klinische studie waarin een groep patiënten 
met uitgezaaid longkanker werden behandeld met bevacizumab (anti-VEGF) en erlotinib (anti-EGFR) 
tot progressie van ziekte (tumorgroei op een CT scan). 
De voorspellende waarde van doorbloeding en glucose metabolisme metingen voor PFS zijn geëval-
ueerd met PET en MRI. 
De mediane progressie-vrije en overall overleving in deze studie waren respectievelijk 3 en 6,9 maan-
den. Bij patiënten met een langer dan gemiddelde PFS nam de tumordoorbloeding met gemiddeld 
20% af en Ktrans en SUV met gemiddeld 17%. Dit betekent dat de behandeling bij patiënten met een 
progressie-vrij overlevingsvoordeel heeft geresulteerd in afname van tumordoorbloeding en glucose 
metabolisme. Afname in tumordoorbloeding en SUV was niet zichtbaar bij patiënten zonder pro-
gressie-vrij overlevingsvoordeel. Tumor Ktrans liet een daling zien die onafhankelijk was van PFS. 
Om de metingen te kwalificeren als surrogaat eindpunt biomarkers, hebben we de verandering in 
tumor diameter, doorbloeding, Ktrans en glucose metabolisme na drie weken therapie gerelateerd aan 
de PFS. Afname in tumor diameter, doorbloeding, Ktrans en SUV werd gezien in respectievelijk 14%, 
26%, 18% en 43% van de patiënten. Afname van tumor diameter na drie weken was geassocieerd 
met ziektevrij overlevingsvoordeel (4,6 maanden vs. 2,9 maanden voor patiënten zonder afname van 
tumor diameter). Echter, 40% van de patiënten die later in het behandeltraject een afname in tumor 
diameter lieten zien, hadden nog geen afname na drie weken. Deze uitkomst komt overeen met resul-
taten uit eerdere studies waaruit blijkt dat verandering in tumor diameter een relatief traag proces is 
en kort na aanvang van behandeling een matige voorspeller is van PFS. 
In patiënten met stabiele tumor diameter na drie weken was de tumordoorbloeding wel afgenomen 
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en de heterogeniteit van Ktrans niet toegenomen na drie weken, wat laat zien dat deze parameters een 
beter onderscheidend vermogen hebben. Een toename in tumordoorbloeding van 20% of meer was 
geassocieerd met een PFS voordeel (12,5 vs. 2,9 maanden voor patiënten zonder afname in tumor-
doorbloeding). 
Hoewel de afname in Ktrans laat zien dat de biomarker in staat is om een verandering in het tumor 
vaatnetwerk te meten, kon de parameter niet gekwalificeerd worden als voorspellende biomarker 
door het ontbreken van een relatie met PFS. Exploratieve analyse van Ktrans heterogeniteit binnen de 
tumor liet echter zien dat een toename van 15% of meer in de standaard deviatie van tumor Ktrans (een 
toename van gebieden met hoge en lage Ktrans waarden) na drie weken geassocieerd was met lagere 
PFS (2,3 vs. 7,0 maanden). 
Een toename in Ktrans heterogeniteit betekent grote verschillen in de endotheliale transfer constante 
binnen de tumor en dus grote wisselingen in tumor doorbloeding en/of vaatwand permeabiliteit en 
oppervlakte; kenmerken van een pathologisch vaatbed met gebieden met verhoogde vaatwand per-
meabiliteit en/of doorbloeding en gebieden met sterk verminderde doorbloeding en/of vaatwand 
permeabiliteit en oppervlakte. 
Hoewel, Ktrans heterogeniteit veelbelovend lijkt te zijn, is de parameter nog niet afdoende gevalideerd 
en gekwalificeerd. In deze studie bleek een afkapwaarde van 15% voorspellend te zijn voor PFS 
voordeel, maar of dit stand houdt in toekomstige studies en of dit de test-retest variabiliteit overstijgt 
blijft speculatief op dit moment.
Onafhankelijk van de verandering in tumor diameter hadden patiënten met een afname in tumor 
glucose metabolisme van 20% of meer na drie weken een PFS voordeel (9,7 vs. 2,8 maanden voor 
patiënten zonder afname in glucose metabolisme). 
Concluderend hebben we in deze dissertatie laten zien dat PET biomarkers voor tumor glucose me-
tabolisme, proliferatie en doorbloeding reproduceerbaar zijn. Ktrans heterogeniteit (gemeten met MRI) 
en tumordoorbloeding en glucose metabolisme (gemeten met PET) konden worden gekwalificeerd 
als surrogaat eindpunt biomarkers voor gecombineerde VEGF en EGFR behandeling in patiënten met 
niet-kleincellig longkanker. 
toekomst
Momenteel worden veel studies verricht met nieuwe medicijnen in ongeselecteerde patiëntgroepen 
waarbij enkel wordt gekeken naar het tumortype en niet naar het tumorprofiel. Deze strategie benadeelt 
patiënten door hen op individueel niveau de beste therapie te onthouden. Vaak geeft de behandeling 
gemiddeld voor de hele groep een klein overlevingsvoordeel, maar is de spreiding op individueel gebied 
groot. Er zijn patiënten die enkel bijwerkingen ondervinden terwijl anderen er juist veel baat van hebben. 
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Doordat biomarkers in staat zijn een schifting te maken tussen deze groepen kunnen zij van groot 
belang zijn bij de ontwikkeling van medicijnen en de behandeling van patiënten. Reeds in een vroeg 
stadium van medicijnontwikkeling (tijdens cel- en dierproeven) kunnen zij aantonen of een medici-
jn in staat is het tumorprofiel te veranderen. In kleine klinische studies kan het biomarker resultaat 
worden gerelateerd aan een overlevingsvoordeel. Hierdoor kan de ontwikkeling van niet of onvol-
doende werkzame medicijnen al in een vroeg stadium worden gestaakt zodat de ontwikkelingskosten 
kunnen worden beperkt en zo min mogelijk patiënten worden blootgesteld aan niet of onvoldoende 
werkzame medicijnen. 
In dit proefschrift hebben we PET en MRI parameters gevalideerd als surrogaat eindpunt biomarkers 
die correleren met de progressie-vrije overleving. Deze biomarkers correleerden beter met de PFS dan 
de huidige standaard, CT. De PET of MRI uitslag werd echter niet gebruikt om de behandeling wel of 
niet te continueren. De beslissing hiervoor werd genomen op basis van de CT scan uitslag. Omdat veel 
patiënten na drie weken nog een stabiele tumor diameter hebben, kan op basis van het CT resultaat 
hierover geen goede beslissing worden genomen. Daarom zijn nieuwe studies nodig die PET of MRI 
gebruiken ter evaluatie van het wel of niet continueren van behandeling, zodat duidelijk wordt of het 
gebruik van deze biomarkers leidt tot een betere behandeling van patiënten, resulterend in een lan-
gere overleving en minder bijwerkingen. Daarnaast zijn er veel nieuwe beeldvormende onderzoeken 
in ontwikkeling die momenteel getest worden op hun voorspellende waarde. Het is de hoop dat dit 
onderzoek leidt tot een betere behandeling van toekomstige patiënten. 
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Hoe vreemd is het om “mijn boekje” na al die jaren af te ronden!? Het is toch een beetje mijn kindje 
geworden en ik heb nu het gevoel er afstand van te moeten nemen. De afgelopen jaren hebben we 
een haat-liefde verhouding met elkaar gehad. We hebben veel in elkaar geïnvesteerd. Vaak elkaar 
vervloekt, maar ook mooie tijden met elkaar beleefd. Als ik denk aan de congresbezoeken in Amerika, 
mijn groeiproces als wetenschapper en arts, het bericht van de editor van een wetenschappelijk tijd-
schrift dat een artikel was geaccepteerd en de boeiende besprekingen met mijn inspirerende promo-
toren, dan blijven toch vooral de positieve herinneringen hangen.
Ik heb “mijn boekje” echter niet kunnen maken zonder de steun van velen in mijn omgeving. Misschien 
kan ik het daarom ook beter “ons boekje” noemen. Een aantal personen wil ik graag in het bijzonder 
bedanken, waarbij ik mij besef dat ik mensen ga vergeten. If so, let me know, dan maak ik het goed.
Prof. dr. O.S. Hoekstra, beste Otto, jij bent van onschatbare waarde geweest en dat ben je nog steeds. 
Je hebt mij altijd gesteund, gestimuleerd en alle kansen gegeven. Het promotietraject, maar ook bi-
jvoorbeeld de congresbezoeken en cursussen met als hoogtepunt “FLIMS” waar ik een onderzoeks-
voorstel heb geschreven dat nu bij de METC ligt. Daarnaast kon ik altijd bij jou terecht als ik even de 
weg in het onderzoek kwijt was. Jij zag waar we heen moesten en als ik er aan twijfelde of de studies 
wel onder één noemer in een boekje kon worden gebracht, sprak jij bemoedigende woorden. Je hebt 
gelijk gekregen ;). Daarnaast kunnen we het ook op persoonlijk vlak goed met elkaar vinden en spreek 
je me soms vaderlijk toe. Als ik het me goed herinner heb je zelfs een keer tegen me gezegd: ‘Doe je 
voorzichtig’. Ik hoop dat we elkaar nog vaak zullen zien, zowel als collega’s en als vrienden. 
Prof. dr. E.F. Smit, beste Egbert, jouw visie, durf, schoppen tegen dogma’s, lak aan bureaucratische 
regels, en je tomeloze energie stimuleren mij enorm. Van jou heb ik geleerd om onderzoek op een ef-
ficiënte en gestructureerde manier te doen. Bij elke stap in het onderzoek nadenken of die noodzake-
lijk is om de onderzoeksvraag te beantwoorden. Ik geniet van je directheid, eerlijkheid en inzicht. 
Daarnaast maak jij duidelijk dat een succesvolle academische carrière prima valt te combineren met 
een succesvol sociaal leven. Met jou praten over werk en privé, vaak onder het genot van een biertje, 
is voor mij waardevol. Ik kijk er naar uit om met jou een plan uit te stippelen voor een mooie (weten-
schappelijke) carrière in de longoncologie. 
Prof. dr. P.E. Postmus, beste Piet, Jij bent altijd geïnteresseerd geweest in mijn onderzoek en hebt het 
mij mogelijk gemaakt om dit te combineren met de opleiding tot longarts. Er was en is altijd ruimte om 
naar congressen en cursussen te gaan en je was altijd bereid om naar knelpunten te kijken als die zich 
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voordeden. Daarnaast was je altijd nieuwsgierig naar de vorderingen (‘wanneer is het klaar?’). Het is 
een voorrecht om onder jouw supervisie longarts te mogen worden.
Dr. M. Lubberink, beste Mark, als copromotor heb jij mij geholpen bij de meeste artikelen. Het re-
view stuk hebben wij goeddeels samen geschreven. Bij de water PET analyses met de parametrische 
plaatjes hebben we leuke en interessante discussies gehad en ook veel samen gewerkt. Daarnaast 
liep ik vaak even bij je binnen voor een kop koffie of om je op te halen voor lunch. Hier bewaar ik fijne 
herinneringen aan. Voor je het weet sta ik in Uppsala voor je deur met een lege mok. 
De leden van de leescommissie, prof. dr. S. Stroobants, prof. dr. P.E. Postmus, prof. dr. A.A. Lammerts-
ma, prof. dr. G.A.M.S. van Dongen en dr. A.M.C. Dingemans,  wil ik bedanken voor hun goedkeuring van 
het proefschrift en hun aanwezigheid bij de verdediging ervan.
Prof. dr. R. Boellaard, beste Ronald, zoals Otto stond ook jij altijd voor mij klaar en was je buitenge-
woon geïnteresseerd in wat ik deed. Inhoudelijk met jou discussiëren is een genot. Je SUV tool is een 
uitvinding, al heb ik ‘m ook wel eens vervloekt omdat je het programma maar bleef verbeteren en ik 
de oude ROIs niet meer kon openen in nieuwere versies van het programma. Je hebt je hoogleraarsc-
hap meer dan verdiend en er zullen in de (nabije) toekomst veel studenten met plezier promoveren 
onder jouw bezielende leiding. 
Prof. dr. A.A. Lammertsma, beste Adriaan, zoals vaak genoemd ben jij een autoriteit op het gebied 
van PET perfusie. Hoewel ik het meeste met Otto besprak, heb ik bij theoretische en methodologische 
vragen over perfusie metingen veel aan jouw kennis gehad. Daarnaast ben jij in staat de materie op 
het denkniveau van een klinische dokter uit te leggen. Best prettig!
Dr. J.M.A. Daniels, beste Hans, bij jou is het onderzoek allemaal begonnen. Ik weet nog dat ik had 
bedacht om chirurg te worden. Jij had een A4-tje op de geneeskunde faculteit opgehangen met de 
boodschap: student gezocht voor wetenschappelijke stage bij de afdeling thoraxchirurgie. Ik dacht 
bingo. Ik kwam bij jou op de kamer te zitten in het MCA en het klikte meteen. Je enthousiasmeerde mij 
in het onderzoek en gaf me een grote mate van zelfstandigheid. Dit is erg belangrijk geweest en heeft 
me deels gebracht tot waar ik nu sta. We hebben mooie plannen voor de behandelkamer en ik hoop 
dat we dat in de nabije toekomst waar kunnen maken. 
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Dr. P. Raijmakers, beste Pieter, dank voor jouw hulp bij het schrijven van de PET/CT meta-analyse. Het 
stuk is niet opgenomen in dit boekje, maar ik heb veel van je geleerd in deze periode op het gebied 
van statistiek en het analytisch ontleden van artikelen.
Dr. A.M.C. Dingemans, beste Anne-Marie, jij hebt de klinische studie getrokken die de basis vormt voor 
dit boekje. Jouw enthousiasme is aanstekelijk en het is plezierig om met jou samen te werken.
 
Vivian (van den Boogaart), wij hebben samen de data-analyses verricht op enige afstand van elkaar. 
Jij het MRI gedeelte in Maastricht en ik het PET gedeelte in Amsterdam. Altijd tijd tekort en te grote 
afstand waardoor het soms lastig was om samen te werken. Toch hebben we het samen voor elkaar 
gekregen. Ik hoop dat ook jij snel zal promoveren. Ik heb bewondering hoe je dat combineert met je 
gezinsleven en de opleiding tot longarts.
 
Prof. dr. E. Coomans, beste Emile, als ik twijfelde over een scan, waar houdt de tumor op en begint 
de rib, welk lymfklier station is dit? Je was en bent altijd bereid om mee te denken en een betrokken 
dokter in hart en nieren. Jouw kennis over de materie overstijgt je vakgebied ruimschoots. 
Andrew (Vincent) en Harm (van Tinteren), dank voor jullie hulp bij het analyseren van de data van veel 
van mijn stukken. De energie die jullie hebben gestoken in het FDG test-retest stuk is niet met deze pen 
te beschrijven. Dat het stuk maar veel geciteerd mag worden!
Dr. M.A. Paul, beste Rick, dank voor jouw begeleiding in het begin van mijn “onderzoekscarrière”.
Amanda (Kroonenberg-Kalwij), even bijkletsen met jou was altijd verhelderend en ontspannen. Je 
stond altijd klaar voor mij met raad, daad en koffie. Volgens mij weet jij beter waar Otto is dan hij zelf.
   
Wiebe (Douma), mede door jouw hulp heb ik überhaupt het VWO af kunnen ronden met een bèta 
pakket. De avonden dat jij mij op pro-deo basis hebt geholpen bij het vak wiskunde bleken later van 
onschatbare waarde te zijn. Hoewel ik het nu niet meer kan snappen dat ik het ooit niet heb gesnapt, 
moest het kwartje even vallen. Jij hebt het naar mij toe gegooid waarvoor ik je dank. 
Laboranten van de PET, analisten van het RNC en andere betrokkenen bij de PET, Rob, Suzette, Femke, Remi, 
Robert, Gert, Nikkie, Cemile: veel dank voor die situaties dat er toch kon worden geschoven als ik weer eens een 
patiënt door jullie strot probeerde te drukken. Dank voor het scannen van de patiënten en de bloedafnames. 
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Reina en Virginie, dank voor jullie hulp bij de data-analyses.
Beste Marthe, dank voor de lay-out van dit boekje en het ontwerp van de omslag.
Jasper, Bart, Jacco, Jan-Hein, Cees, Mark (Reisz), Marc (Bijvoet), Diederik en Lebohang. Heren, zonder 
de ontspanning met jullie zou dit boekje er niet liggen. Het heeft me natuurlijk ook veel tijd gekost 
door de vele brakke dagen in bed, maar ik heb het er graag voor over gehad. Dat er nog veel brakke 
dagen mogen volgen. De 28e zal er zeker één van zijn! 
Lieve collega AIOS van de longziekten, VUmc, dank voor jullie interesse in mijn onderzoek en het 
opvangen van klinische taken bij afwezigheid door congressen en studiereizen. 
Alle medewerkers van de afdeling, polikliniek en behandelkamer longziekten wil ik bedanken voor 
hun steun.
Atie (van Wijk), dank voor jouw hulp bij de behandeling en het begeleiden van de studie patiënten.
Gerard, Carla en Maurice, dank voor jullie steun en interesse in mijn onderzoek in de afgelopen jaren. 
Linda en Daan, mijn lieve zussen. Ik ben er trots op dat jullie mijn paranimfen zijn. We vormen een 
mooi trio! 
Rutger, Oliver en kids, dank voor jullie interesse de afgelopen jaren.
Lieve Iris, sometimes it lasts in love but sometimes it hurts instead. Jij stond gedurende het hele pro-
motietraject aan mijn zijde en hebt mij altijd gesteund. Ik heb je lief. 
Lieve papa en mama, dankzij jullie heb ik een onbezorgde jeugd gehad met alle mogelijkheden. 
Hiervoor ben ik jullie dankbaar. Ik was niet altijd even makkelijk, maar jullie brachten mij altijd weer 
op het juiste spoor als ik een zijsprongetje maakte. Jullie onvoorwaardelijke steun voel ik dagelijks. 
I love you!
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curriculum vitae
Adrianus Johannes (Joop) de Langen was born on the 7th of April 1978 in Alkmaar. He graduated 
secondary school in 1997 at the Petrus Canisius College in Alkmaar. That same year he started the 
study medical biology at the VU University Amsterdam in Amsterdam. In 2000 he was allowed to start 
with the study medicine. He finished these two studies in 2005 and 2007, respectively. During the last 
two years of his master, Joop followed two scientific internships. In 2004 he headed to North-Namibia, 
Africa, for six months to perform a field study on malaria. The results were published in the medical 
journal ‘Tropical Medicine & International Health’. In 2005 he performed research for five months at 
the departments of Pulmonary Surgery and Nuclear Medicine at the VU University Medical Center. 
The results of this work were published in the medical journal ‘European Journal of Cardio-Thoracic 
Surgery’. During this scientific internship, his interest was definitively raised for pulmonary oncology. 
During the last two years of his study medicine he continued his research activities. In 2007 he           com-
menced his specialist training in Pulmonology at the VU University Medical Center in Amsterdam and 
combined this work with his PhD. With the publication of his thesis, he finishes the latter. He hopes to 
finish his specialist training in pulmonology in August 2013. In the near future, Joop hopes that he can 
continue to combine patient care with scientific research. 
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Adrianus Johannes (roepnaam Joop) de Langen werd op 7 april 1978 geboren in Alkmaar. In 1997 
behaalde hij zijn Atheneum diploma aan het Petrus Canisius College te Alkmaar. In datzelfde jaar gaat 
hij medische biologie studeren aan de Vrije Universiteit in Amsterdam. Na drie keer te zijn uitgeloot 
voor de studie geneeskunde wordt hij in 2000 alsnog ingeloot. Deze studies rondt hij met succes 
af in respectievelijk 2005 en 2007. In de afstudeerfase liep Joop de Langen twee wetenschappelijke 
stages. In 2004 vertrok hij voor een half jaar naar het noorden van Namibië in Afrika om onderzoek 
te verrichten naar malaria. De resultaten werden gepubliceerd in het tijdschrift ‘Tropical Medicine & 
International Health’. In 2005 liep hij gedurende vijf maanden stage bij de afdelingen Longchirurgie 
en Nucleaire  Geneeskunde. De resultaten van dit onderzoek werden gepubliceerd in het tijdschrift 
‘European Journal of Cardio-Thoracic Surgery’. Tijdens deze wetenschappelijke stage werd zijn inter-
esse definitief gewekt voor de longoncologie. Tijdens de laatste twee jaar van zijn studie geneeskunde 
(de coschappen) zette Joop dit onderzoek voort. In 2007 startte hij met de opleiding tot longarts in 
combinatie met een promotietraject. Met de publicatie van dit proefschrift rondt hij de promotie af. 
De opleiding tot longarts hoopt hij in augustus 2013 af te ronden. In de toekomst hoopt Joop patiën-
tenzorg te kunnen blijven combineren met wetenschappelijk onderzoek. 
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